

# THE NEUROLOGICAL ALLIANCE

England & Wales · Charity number 1039034

## Details

|                |                                                         |
|----------------|---------------------------------------------------------|
| Other names    | THE NEUROLOGICAL CHARITIES                              |
| Status         | Registered                                              |
| Legal form     | Charitable company                                      |
| Company number | <a href="#">02939840</a>                                |
| Registered     | 1994-06-28                                              |
| Register       | <a href="#">View on the Charity Commission register</a> |

## Contact

|         |                                                            |
|---------|------------------------------------------------------------|
| Address | The Junction<br>Station Road<br>Watford<br>WD17 1EU        |
| Phone   | 01923 882590                                               |
| Email   | <a href="mailto:info@neural.org.uk">info@neural.org.uk</a> |
| Website | <a href="http://www.neural.org.uk">www.neural.org.uk</a>   |

## Activities

**Objects:** TO ADVANCE THE EDUCATION OF THE PUBLIC IN ALL MATTERS CONCERNING NEUROLOGICAL DISORDERS BY CARRYING OUT RESEARCH AND INVESTIGATION INTO PREVENTATIVE PROCEDURES, TREATMENT AND THE NEEDS AND CARE OF PERSONS AFFECTED BY NEUROLOGICAL CONDITIONS AND PUBLISHING THE USEFUL RESULTS THEREOF. 2.THE RELIEF OF THOSE PERSONS IN THE UNITED KINGDOM OF GREAT BRITAIN AND NORTHERN IRELAND WHO ARE RECEIVING OR HAVE RECEIVED TREATMENT FOR NEUROLOGICAL CONDITIONS.

**Activities:** We are a coalition of more than 100 organisations working together to transform quality of life for people with neurological conditions in England. We raise awareness and understanding of neurological conditions to ensure that every person diagnosed has access to high quality, joined up services and information from their first symptoms, and throughout their life.

### Classification

- **How:** Provides Advocacy/advice/information, Acts As An Umbrella Or Resource Body
- **What:** General Charitable Purposes, The Advancement Of Health Or Saving Of Lives
- **Who:** People With Disabilities, Other Charities Or Voluntary Bodies

### Geography

- **Area of benefit:** UNITED KINGDOM AND NORTHERN IRELAND
- Throughout England

### Finances

| Period end | Income   | Expenditure | Assets | Employees |
|------------|----------|-------------|--------|-----------|
| 2025-06-30 | £297,119 | £348,013    | -      | -         |
| 2024-06-30 | £268,818 | £258,349    | -      | -         |
| 2023-06-30 | £304,659 | £266,775    | -      | -         |
| 2022-06-30 | £217,671 | £281,869    | -      | -         |
| 2021-06-30 | £223,839 | £193,431    | -      | -         |

## Trustees

| Name                    | Role | Appointed  |
|-------------------------|------|------------|
| Adine Adonis            |      | 2024-05-16 |
| Alison Fuller           |      | 2022-11-15 |
| Aneeta Prem MBE JP      |      | 2023-11-22 |
| Anthony Lloyd           |      | 2024-11-28 |
| Catherine Anne Stanley  |      | 2020-11-18 |
| Dr Michael Dilley       |      | 2024-05-16 |
| Gideon Schulman         |      | 2024-05-16 |
| Kripen Vasantlal Dhrona |      | 2021-11-17 |
| Lucy Taylor             |      | 2023-11-22 |
| Rob Music               |      | 2022-11-15 |
| Sarah Bunting           |      | 2020-11-18 |
| Susan Jane Millman      |      | 2025-11-20 |

---

# Accounts

---



THE  
NEUROLOGICAL  
ALLIANCE

# Annual report

and financial statements for  
the year ended 30 June 2025



## Contents

|                                                                 |    |
|-----------------------------------------------------------------|----|
| A welcome from the Chair of Trustees .....                      | 3  |
| The Neurological Alliance annual report and accounts .....      | 5  |
| 1. Our objects.....                                             | 6  |
| 2. What we set out to do in 2024-2025.....                      | 7  |
| 3. What we are setting out to do in 2025-26.....                | 15 |
| 4. Our structure, governance and management.....                | 18 |
| 5. Public benefit.....                                          | 24 |
| 6. Reference and administrative details .....                   | 25 |
| 7. Finances.....                                                | 26 |
| 8. Independent examiner's report and financial statements ..... | 30 |

## A welcome from the Chair of Trustees

This year we marked The Neurological Alliance's 30th birthday, and it felt fitting that we celebrated with our biggest parliamentary event to date. More MPs and representatives joined us than ever before, hearing directly from people affected by neurological conditions and our members about the changes that are needed. It was a proud moment for the Alliance and a reminder of how far we have come together.

We reached this milestone in a year that has not been easy. The NHS in England continues to face immense pressures, with people waiting far too long for the treatment, care and support they need. Fundraising and cashflow remain a challenge for us and for many of our members, who are working harder than ever to meet rising demand with limited resources. These pressures are real and deeply felt.

And yet, against this backdrop, together we have delivered meaningful impact. The fifth iteration of My Neuro Survey gathered more than 10,000 experiences, including carers for the first time. It is the largest survey of its kind and is already influencing national plans, strengthening the case for investment in services, and giving decision-makers a clear picture of the realities of living with a neurological condition in England.

We also welcomed the launch of the UK Neuro Forum, the first governmental advisory body dedicated to neuro. The forum operates UK-wide, and we have ensured that the voices of people in England are heard and priorities reflected. Alongside this, our contributions to the 10-Year Health Plan for England, our leadership in the One Brain conference and our work on rare disease policy have ensured that neuro is firmly on the national agenda.

This year we also took stock. Right now, the health policy landscape is shifting faster than ever. NHS England is being abolished, responsibilities are moving to local Integrated Care Boards, and the Department of Health and Social Care is taking on more control – all against a backdrop of staff changes and shrinking budgets. Members, healthcare professionals, and people with neurological conditions often tell us it isn't clear who holds responsibility for services or how we can hold decision-makers to account. In this climate, clarity, coordination and a strong, united voice are essential. That is why the Alliance is focused on turning our collective influence, evidence and expertise into tangible results, ensuring neuro remains firmly on the national agenda.

Through a strategic review, the Board and team have sharpened our focus, ensuring our work is directed to where it will have the greatest impact. Our vision remains clear: that every person affected by a neurological condition in England can access the right treatment, care and support at the right time.

In 2025/26 we will build on the progress of recent years by focusing on three priorities: securing a strong national voice for neuro, deepening connections across our community, and generating evidence that changes minds. We will influence implementation of the NHS 10-Year Plan so it delivers for people with neurological conditions, press for investment and support for the neuro workforce, and ensure the UK Neuro Forum reflects our members' priorities. We will expand opportunities for collaboration and involvement, including a new platform for members and people with lived experience, and publish fresh evidence on mental health, children and

young people, and research. Above all, we will continue to make sure that together, as a united community, we can achieve change no organisation could deliver alone.

Thank you to everyone who has stood with us in our 30th year. Together, we have celebrated our achievements and laid strong foundations for the future.

**Cath Stanley, Chair, The Neurological Alliance**

# The Neurological Alliance annual report and accounts

Year ended June 2025

| Reference and administrative details |                                                                                                                                                                      |                                                                    |
|--------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------|
| <b>Registered charity name</b>       | <b>The Neurological Alliance</b>                                                                                                                                     |                                                                    |
| <b>Charity registration number</b>   | 1039034                                                                                                                                                              |                                                                    |
| <b>Company registration number</b>   | 02939840                                                                                                                                                             |                                                                    |
| <b>Registered office</b>             | The Junction<br>Station Road<br>Watford<br>Hertfordshire<br>WD17 1EU                                                                                                 |                                                                    |
| <b>Independent Examiner</b>          | <b>Martin Bailey FCA</b><br>Goodman Jones LLP<br>Chartered Accountants<br>1 <sup>st</sup> Floor, Arthur Stanley House<br>40-50 Tottenham Street<br>London<br>W1T 4RN |                                                                    |
| <b>Accountants</b>                   | <b>Godfrey Wilson</b><br>5th Floor, Mariner House<br>62 Prince Street<br>Bristol<br>BS1 4QD                                                                          |                                                                    |
| <b>Bankers</b>                       | <b>CAF Bank Ltd</b><br>25 Kings Hill Avenue<br><br>Kings Hill<br>West Malling<br>Kent<br>ME19 4JQ                                                                    | <b>Metro Bank PLC</b><br>One Southampton Row<br>London<br>WC1B 5HA |

The trustees present their report and independently examined financial statements for The Neurological Alliance for the year 1 July 2024 to 30 June 2025. The report and financial statements have been prepared in accordance with the Companies Act 2006 and the Charities Act 2011. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) in preparing the report and financial statements. The report and financial statements will be laid before the members of the charity at the Annual General Meeting to be held on 20 November 2025. In preparation of this report, the trustees had regard for the Charity Commission guidance on public benefit.

## 1. Our objects

Our principal objectives, as derived from the objects set out in our Articles of Association, are to advance the education of the public in all matters concerning neurological disorders by carrying out research and investigation into preventative procedures, treatment and the needs and care of persons affected by neurological conditions, and publishing the useful results thereof, and the relief of those persons in the United Kingdom of Great Britain and Northern Ireland who are receiving or have received treatment for neurological conditions.

We are the only collective voice for over 100 national charities, professional bodies, regional organisations and corporate organisations working together to transform treatment, care and support for people affected by neurological conditions.

## 2. What we set out to do in 2024-2025

Our vision, mission and strategic goals are as follows:

- Vision: Every person affected by a neurological condition can access the right treatment, care and support at the right time.
- Mission: To harness the energy and passion of the neurological community to ensure public policy in health reflects the realities of living with a neurological condition, so that everyone can access treatment, care and support whenever they need it.

### Our goals

1. Public policy and practice reflects and supports the realities of living with a neurological condition.
2. People affected by neurological conditions and our members are heard and have influence.
3. We are a strong, diverse organisation that delivers change.

### Our values

- **Bold:** We will not hesitate to speak truth to power, rooted in the experiences of people with neurological conditions.
- **United:** We unleash the power of our collective community.
- **Inclusive:** We listen to and celebrate the diversity of the neurological community. We work with anyone who shares our vision.
- **Leading:** We are the voice on issues relating to access and experience of healthcare for people with neurological conditions.
- **Expert:** We deliver evidence that changes minds and policy.

**The Annual Report of the Trustees for 2024/25 is set out under our three strategic goals:**

**Goal 1: Public policy and practice reflects and supports the realities of living with a neurological condition**

This year, The Neurological Alliance has worked across government, NHS England and wider health system partners to influence national policy and deliver real change with and for the 1 in 6 people living with a neurological condition. At our Annual General Meeting (AGM) in November, we welcomed Andrew Gwynne MP, then Under-Secretary of State for Health and Social Care, who announced the launch of the UK Neuro Forum. This is the first UK-wide government advisory body focused solely on improving services and support for people affected by neurological conditions, and represents a landmark outcome of our #BackThe1in6 campaign.

In line with our commitment to ensure the voices of people with neurological conditions are at the heart of decision-making, we coordinated the first UK Alliances all-member meeting ahead of the forum's inaugural session. Working alongside other Alliances across the UK, we convened members to shape collective priorities and ways of working. Insights gathered from members directly informed contributions at the forum and set the tone for future engagement. We are committed to continuing this model ahead of each forum meeting to ensure our community's expertise and lived experience remain central to national discussions.

We have continued to generate and shape evidence to drive improvements in care. A key piece of work this year has been our collaboration with the Association of British Neurologists (ABN) on a new neurology workforce report, due for publication in late 2025. For the first time, this report will model the neurology workforce required per 100,000 population and provide policymakers, commissioners and service leaders with the data they need to understand gaps and plan for sustainable, high-quality services.

Our leadership role extended to the Royal College of Psychiatry, where we continued as a co-opted member of the Neuropsychiatry Faculty Executive Committee. We also joined the newly established Neuro Quality Improvement Network Advisory Group, working to benchmark and drive improvements across neuropsychiatry services nationwide. This cross-sector collaboration is essential to tackling long-standing inequalities in access to mental health support for people with neurological conditions.

In June, we partnered with the Faculty of Neuropsychiatry and the British Psychological Society's Division of Neuropsychology to deliver the One Brain conference on integrating neurological and mental health services. The conference, held at the Royal College of Psychiatrists, was attended by more than 100 clinicians, commissioners, system leaders and voluntary organisations. The event showcased practical examples of service integration, while also enabling stakeholders to shape recommendations for change. These insights will feed into a forthcoming consensus statement, setting out how health and care systems can deliver truly joined-up care for people living with neurological conditions.

The government's decision in October 2024 to launch a national conversation on the future of the NHS presented an important opportunity to embed neuro in long-term health policy. We worked closely with members and people affected by neurological conditions to develop our consultation response, underpinned by three "tests" to

ensure the new NHS 10-Year Plan delivers for our community. To strengthen this, we collaborated with the Department of Health and Social Care to convene a roundtable of adults and carers affected by neurological conditions. Their contributions provided direct evidence of lived experience to shape the government's thinking.

Alongside this, our Chief Executive was invited to join the 10-Year Plan Partners Council, sitting alongside senior leaders from professional bodies, healthcare providers and the wider charity sector. This provided an important platform to ensure neuro remained a central part of national discussions during the development of the plan.

We supported the development of new optimal clinical pathways for MS and mental health. These pathways, originally developed through the National Neuro Advisory Group, set out what good treatment, care and support looks like and have directly informed commissioning policy.

Our membership of the NHS England Adult Neurology Clinical Reference Group (CRG) enabled us to play a direct role in shaping the new adult neurology service specification, published in August 2025. For the first time, this specification establishes minimum standards of care for people with neurological conditions, ensuring a benchmark for quality and access across the country. We supported members to participate in a dedicated session with NHS England and Dr Niran Nirmalananthan, National Clinical Director for Neurology, to inform the draft specification. The final document sets out a networked model of care and an integrated, population-based approach that marks a significant improvement on previous policy.

Throughout the year and in collaboration with our members, we have supported people with lived experience of neurological conditions to share their experiences with the group and shape national policy directly.

Beyond policy, we worked with the NHS England neuroscience transformation team to develop and roll out practical resources to support service improvement. This included shaping a new data dashboard on health inequalities in adult neurology, enabling Integrated Care Boards (ICBs) to understand variation in their areas and plan targeted action. We also led the development of a new resource exploring the benefits and common pitfalls of collaboration between the voluntary sector and NHS neurology services. Drawing on interviews with people affected by neurological conditions, clinicians and service managers, the resource provides real-world insights to strengthen partnership working.

The announcement that NHS England would be abolished, with responsibilities transferred to the Department of Health and Social Care and ICBs, created huge uncertainty for our community. We worked hard to analyse what these reforms could mean in practice and campaigned for positive elements of the current system to be preserved. Alongside Genetic Alliance UK and the Specialised Healthcare Alliance, we wrote to the Secretary of State for Health and Social Care, Wes Streeting, and NHS England leadership, to seek urgent clarification. Our letter highlighted concerns about the future of commissioning expertise, the stability of nationally commissioned specialised services, and the retention of vital clinical leadership roles.

We also called for a continued commitment to the UK Rare Diseases Framework, warning that budget cuts to ICBs and reduced capacity in the Department of Health and Social Care must not undermine progress. Together, we urged government to work collaboratively with the sector to safeguard services and ensure people with rare, genetic and neurological conditions are not left behind.

We were pleased to maintain our role on the England Rare Disease Action Plan Patient Advisory Group, supporting development of the penultimate England Rare Disease Action Plan. Through our rare conditions subgroup, we provided substantive feedback on draft versions of the plan, calling for a stronger focus on mental health support and the role of care coordinators. Both priorities were reflected in the final version of the plan, demonstrating the power of collaborative advocacy.

## **Goal 2: People affected by neurological conditions and our members are heard and have influence**

We believe change is only possible if people affected by neurological conditions and our members shape it. This year, thousands of people shared their experiences and insights through our programmes, influencing both government policy and public debate.

In April, we supported eight people living with neurological conditions to meet senior Department of Health and Social Care officials shaping the 10-Year Plan.

---

“Thank you for the invitation to join the session. It was good to be able to contribute and reassuring to hear that many of the points and themes raised are already being addressed in the plan. I will continue to follow the progress of the plan with interest.” – Attendee.

---

---

“Many thanks to you and Georgina for all of your help organising yesterday’s event, we all thought it was a really great discussion with lots of insights that will help us going forwards.” – Department of Health and Social Care.

---

We also trialled new ways of engaging people, including online polling, to gather views on what good care looks like. These methods, alongside our more established programmes, helped us to reach even more people and ensure their voices shaped our priorities.

Our flagship My Neuro Survey 2024 gathered the experiences from more than 10,000 adults, children, and carers across the UK, creating our largest ever evidence base of lived experience. It was delivered in collaboration with Neurological Alliances across the UK and Republic of Ireland – Wales Neurological Alliance, Neurological Alliance of Scotland, Northern Ireland Neurological Charities Alliance (niNCA) and The Neurological Alliance of Ireland. There were a couple of important firsts for

2024: opening it up to people in the Republic of Ireland and delivering a version of the survey specifically for carers.

We worked closely with members, people affected by neurological conditions and clinicians to design and deliver the survey, in partnership with research company Revealing Reality. Special thanks go to everyone who contributed – as respondents, as advisors shaping the survey questions, and as partners supporting its roll-out. As one participant told us:

---

“...Thank you, Neurological Alliance, for putting the 2024 Survey together to give us a voice.” – survey respondent.

---

My Neuro Survey 2024 has created a [strong, evidence-based case for change](#), revealing that only one in three respondents felt their care met their needs. Access to mental health support was especially poor, with many people turned away from services because of their neurological diagnosis. Despite these challenges, the survey also highlighted the positive impact of good care when it is available. Using these findings, we launched an open letter to the Secretary of State for Health and Social Care, calling for urgent action on workforce shortages, mental health access, and a dedicated implementation plan for neuro services. More than 3,000 people signed the open letter which we shared with the Secretary of State in July 2025. We will continue to use the data and experiences shared throughout 2025 and 2026.

At the same time, the survey revealed important gaps. 95% of respondents identified as White, a figure not reflective of the UK population. We recognise this as a significant shortcoming and are committed to strengthening our approach to reach and listen to underrepresented communities.

This year, we also worked with our UK Alliance partners to campaign for greater investment in neurological research. Led by the Neurological Alliance of Scotland, the #InvestInNeuroResearch campaign ran during Brain Awareness Week and showcased the experiences of people affected by neurological conditions alongside researchers.

---

“The government could help by providing funding for more research into neurological conditions, why they happen and how to treat them. Especially some of the rarer conditions like mine that have so little known about them. It makes it hard to know how to improve your quality of life when there is no evidence or information to tell you why the condition happens, what causes it and how to manage the symptoms. It also makes it really difficult to find and stay in work because your employer doesn’t know how they can help you. Eventually they give up and let you go when there could be an easy fix...” – survey respondent.

---

---

“Care for neurological patients is obviously lacking in all areas. It is important that research studies can be accessed as how else will progression be made to improve conditions for patients?” – person with a neurological condition.

---

Together, we shared the experiences and insights of people affected by neurological conditions and researchers from across the UK through social media videos, and [sent an open letter to the Secretary of State for Science, Innovation and Technology](#) calling for increased investment into neurological conditions research. The letter was supported by 74 member organisations across the UK and the four UK Alliances.

The campaign had significant engagement online with the videos viewed more than 20,000 times and the #InvestInNeuroResearch hashtag reaching more than 500,000 users across Facebook, Instagram and X.

---

“...The limited availability of psychological support for those with [my condition], in my area there is no provision for counselling for [my condition]. NHS Talking Therapies are not available due to the national service model, the only psychological support available is private and has to be self funded.” – person with a neurological condition.

---

Mental health and rare conditions remain priority areas for our community. Our subgroup meetings in 2024/25 brought together members, clinicians and people with lived experience to share insights and influence national workstreams including the NHS 10-Year Plan, the England Rare Disease Action Plan and My Neuro Survey 2024.

---

“The medical profession does not acknowledge rare neurological conditions and the vital acceptance these patients need.” – person living with a neurological condition.

---

The rare conditions subgroup hosted sessions with leading experts including Nicole Symes, Head of Trauma Programme of Care at NHS England, and Louise Fish, Chair of NHS England’s Rare Disease Advisory Group. The mental health subgroup welcomed Debra Moore, Head of Quality Transformation for Learning Disability and Autism at NHS England, and Dr Phil Yates, from the British Psychological Society’s Division of Neuropsychology, who outlined new commissioning guidelines for NHS neuropsychological services.

The progression of the Terminally Ill Adults (End of Life) Bill in Parliament this year had profound implications for people affected by neurological conditions. Recognising the importance of shaping this debate, we convened a working group of members to share experiences and align approaches to the Bill. We also worked

closely with our colleagues in the Scottish Neurological Alliance to share learning, as a parallel Members' Bill advanced in Scotland.

We collaborated with our membership to develop a submission to the Commission on End of Life Care in March 2025, ensuring that the voices and needs of people affected by neurological conditions were represented. This work builds on our wider commitment to improving palliative and end of life care for our community, ensuring services provide dignity, compassion and the right support at every stage of life.

### **Goal 3: We are a strong, diverse organisation that delivers change**

This year has shown more clearly than ever that the strength of The Neurological Alliance lies in the diversity and commitment of our growing membership. From large national charities to small, volunteer-led organisations, together we represent the breadth of the neurological community – common and rare conditions alike. It is this collective power that enables us to deliver real change: influencing Parliament, shaping national policy, and ensuring that the voices of people with neurological conditions are heard at the highest levels.

On Thursday 16 January, we hosted the Parliamentary Neuro Reception, attended by 35 MPs or their representatives from across the UK. This was the largest number of parliamentarians to attend an Alliance event in our 30-year history, and a powerful demonstration of the influence we are building. The reception followed a public action encouraging people across the UK to write to their MPs and ask them to attend. The response was extraordinary: in just one week, more than 1,400 people contacted their MPs, meaning 548 MPs received at least one letter – the highest reach we have ever achieved through a single action. This mobilisation was a striking example of people power in action and showed how, when we come together, our community cannot be ignored.

At the reception itself, MPs heard directly from people with lived experience of neurological conditions. Their testimonies were powerful and deeply moving, leaving a lasting impression on attendees and sparking commitments to raise neurological conditions in Parliament. Many have since followed through by asking questions and engaging with national policy opportunities. As one speaker reflected afterwards:

---

“Thank you for including me in such a powerful and hand on heart event, I feel privileged to be part of it. I have received lots of positive feedback, even off a guy sat opposite me on the train who saw the video Tourette’s Action had posted on LinkedIn, amazing. Once more many thanks.” – Paul Stevenson, speaker at Parliamentary Neuro Reception.

---

This event underlined the Alliance’s ability to convene, influence and connect. It was not only a milestone in terms of parliamentary engagement but also a clear signal of the trust people place in us to carry their voices to decision-makers. Learn more about the event and watch a short video of lived experience volunteer Paul speaking on the day [here](#).

Alongside our influencing work, we continued to grow our membership and strengthen our collective voice. Between July 2024 and June 2025, the Board

approved six new applications for membership: CHAMP1 UK, FND Friends, the MEF2C Foundation supporting people with MEF2C Haploinsufficiency Syndrome (MCHS), the Medcan Family Foundation, Muscular Dystrophy UK and the Nystagmus Network. Each of these organisations brings fresh perspectives, expertise and energy to our community. Together they reflect the breadth of the neurological community – from more common conditions to the rarest – and reinforce the Alliance’s position as the home of a united and diverse movement.

Listening to our members and responding to their views remains at the heart of our work. Each spring, we invite members to share feedback on our activities and how we can improve. In 2025, 29 organisations responded, and the findings were strongly positive: 89% said they were very satisfied or satisfied with their membership and all members reported that they considered their membership to be excellent or good value.

Comments from members highlighted the Alliance’s ability to advocate nationally and bring people together around shared goals. As members reflected:

---

“There seems to be so much happening in the neuro world and the Alliance are managing to be a voice whenever one is needed.” –  
Member organisation of The Neurological Alliance.

---

---

“Raising awareness, campaigning and influencing. Establishing strong relationships at a national level – e.g. Minister coming to NA AGM to announce launch of Neuro Forum is evidence of this.” –  
Member organisation of The Neurological Alliance.

---

While 39% of respondents did not suggest any changes, several raised valuable points about how we can continue to improve. Priorities identified by members include ensuring smaller charities feel included and supported, developing new ways of engaging such as online channels, continuing to provide clear explainer materials as the health system evolves, and revitalising and communicating our Equality, Diversity and Inclusion strategy. Members also emphasised the importance of continuing to develop the Involvement Network to include people affected by neurological conditions, organisational members and other stakeholders, making sure it is promoted widely and accessible to all, and considering how best to engage regionally as part of our wider strategic review and continue to provide a powerful, united voice at national level.

We remain committed to embedding equity, diversity and inclusion (EDI) across every aspect of our work. Over the past year, we have reviewed and updated our recruitment practices to ensure fairer processes and wider reach, introduced training and support for our team to strengthen knowledge and confidence around EDI, and begun revising our approach to involving people affected by neurological conditions so that barriers to participation are reduced. This means being more flexible, offering

different ways to engage, and recognising the diverse needs of those who want to share their experiences. By taking these steps, we are working to make sure that both our organisation and the wider neurological community we represent are more inclusive, representative and equitable, but recognise much more work needs to be done.

### 3. What we are setting out to do in 2025-26

As we enter 2025-26, The Neurological Alliance stands at a pivotal moment, both for the organisation and for the wider neurological community.

In light of the significant shifts in the external landscape and new evidence from My Neuro Survey, we have developed a refreshed strategic framework for 2025 - 2027 that recognises the scale of the challenge ahead and our unique role in driving system change.

Our revised vision is a world where everyone affected by a neurological condition is supported to live life to the fullest. Our mission is to unite and empower people affected by neurological conditions and our members to influence health and care policy in England, so it reflects real-life experiences – ensuring everyone can access the support they need.

We will do this by:

- Providing a leading collective, national voice to improve health and care.
- Developing a strong, connected community that strives for the collective good.
- Generating compelling evidence about what matters most to people affected by neurological conditions.

This work is underpinned by the values we live by:

- **Inclusive:** We listen deeply, value every voice, and celebrate the full diversity of those affected by neurological conditions.
- **Bold:** We speak truth to power, driven by lived experience and our members' insight.
- **Together:** We harness collective strength to achieve more.
- **Leading:** We shape the debate and influence the agenda.
- **Insightful:** We bring clarity, connect patterns and data, and guide smarter decisions.

We are preparing for the most significant changes to NHS structures in a decade. The proposed dissolution of NHS England, new commissioning responsibilities, and the roll-out of the NHS 10-Year Plan all represent high-stakes opportunities and risks. We will engage with decision-makers across Parliament and government to ensure that the needs of people with neurological conditions are not overlooked. As a core member of the UK Neuro Forum, we will work with national leaders, our members and people affected by neurological conditions to shape the delivery of these reforms.

We will also respond to major developments in workforce and mental health policy. Building on the work of our members, we will highlight the needs of the neuro workforce now and in the future, and seek to influence national workforce policy.

Alongside this and using insight from our members and My Neuro Survey, we will publish new evidence on access to mental health services, support for children and young people, and seek to grow our ability to listen and hear from seldom heard communities.

Strengthening the neurological voice is about more than influencing Westminster. We will deepen our support for members through a refreshed membership event programme and new resources to support members and people affected by neurological conditions to influence service improvement and policy change.

We will also build our capacity to listen. By July 2026, we aim to establish a network of lived experience leaders, people who will shape our campaigns, inform our communications and represent our work nationally. Their voices will help ensure everything we do is grounded in real life.

But ambition requires focus. We know that resources, across the system and within the Alliance, are finite. That's why we're taking steps to improve our digital infrastructure, streamline our internal processes, better evidence our impact and diversify our income streams.

We are proud of the work achieved over the past year. But we know there is still plenty to achieve together. As we enter 2025-26, we do so with a renewed sense of purpose and resolve. Together with our members, supporters, and people affected by neurological conditions, we will make this coming year one of real and lasting progress.

## 4. Our structure, governance and management

### 4.1 Trustee selection

We are governed by a Board of Trustees, made up of a minimum of three and a maximum of 14 people nominated by our members, recommended by our trustees and then elected by our members.

In advance of each AGM, all members are invited to send in their nominations for the Board for available elected trustee posts. Details of the trustee candidates are then circulated to all members and votes are made by ballot at the AGM or sent in advance to the Chair using a proxy form; each member organisation is entitled to one vote, placed at the AGM.

After completing a three-year term, each trustee will stand down from the Board. Trustees who have completed only one term may stand for re-election; those who have served two consecutive terms must stand down for one year before they may stand again for the Board.

On joining the Alliance Board, all new trustees undertake a tailored induction programme. The trustees, who are also directors for the purpose of the Companies Act, who served during the year are listed in [section 6.1](#).

### 4.2 Structure

We are a company limited by guarantee (no 02939840) and a registered charity (no 1039034). We are governed by Articles of Association and Byelaws. Our main activity is to secure the highest standards of care and treatment for every person affected by a neurological condition.

Our Board of Trustees is responsible for our governance and strategy and meets every quarter. Our Chief Executive is responsible for implementing the strategy and reports on its progress at the Board meetings. The Chief Executive reports directly to and is supervised by the Chair. They speak and meet regularly to discuss Alliance business.

Communication, both formal and informal, between trustees and staff is frequent and effective.

#### 4.2.1 Staff

| Name            | Role                                                                  |
|-----------------|-----------------------------------------------------------------------|
| Caroline Davies | Administration and Membership Officer (From September 2019 – present) |
| Georgina Carr   | Chief Executive and Company Secretary (from January 2020 – present)   |
| Jessica Mansel  | Involvement Lead (February 2022 – July 2024, May 2025 – present)      |
| Miranda Lloyd   | Communications and External Affairs Officer (March 2021 – present)    |
| Sam Mountney    | Policy and External Affairs Manager (June 2021 – present)             |

#### **4.2.2 Members**

Full membership is open to national voluntary (non-statutory, non-profit) organisations who represent people affected by neurological conditions, including friends, families and carers organisations, who, in addition to the full benefits of membership, will have a right to vote at the AGM, have the right to nominate a trustee and an opportunity to influence our strategic direction. Subscriptions are income assessed.

Full affiliate membership is open to Regional Neurological Alliances operating on a non-statutory, non-profit basis. Affiliate members will pay a subscription rate which is not income assessed.

Associate status is open to professional associations and statutory authorities, who will play an active part in the Alliance but do not have the right to nominate a trustee or vote at the AGM. Subscriptions are income assessed. Regional Associations of Neurological Organisations can also be associates. They are staff-led groups and will pay a subscription rate which is not income assessed.

Corporate supporter status is open to for-profit organisations, who cannot vote at the AGM or nominate a trustee.

Reciprocal partners are normally umbrella organisations whose aims and objectives match well with those of the Alliance. They cannot vote or influence our strategic direction.

## Members 2024 - 2025

| Organisation                                     | Website                                                                              |
|--------------------------------------------------|--------------------------------------------------------------------------------------|
| 3 Million Steps                                  | <a href="http://www.3millionsteps.org">www.3millionsteps.org</a>                     |
| Ataxia UK                                        | <a href="http://www.ataxia.org.uk">www.ataxia.org.uk</a>                             |
| Batten Disease Family Association                | <a href="http://www.bdfa-uk.org.uk">www.bdfa-uk.org.uk</a>                           |
| Behcets UK                                       | <a href="http://www.behcetsuk.org">www.behcetsuk.org</a>                             |
| The Brain and Spine Foundation                   | <a href="http://www.brainandspine.org.uk">www.brainandspine.org.uk</a>               |
| The Brain Charity                                | <a href="http://www.thebraincharity.org.uk">www.thebraincharity.org.uk</a>           |
| Brain Research UK                                | <a href="http://www.brainresearchuk.org.uk">www.brainresearchuk.org.uk</a>           |
| British Polio Fellowship                         | <a href="http://www.britishpolio.org.uk">www.britishpolio.org.uk</a>                 |
| Cavernoma Alliance UK                            | <a href="http://www.cavernoma.org.uk">www.cavernoma.org.uk</a>                       |
| CASK Research Foundation                         | <a href="http://www.caskresearch.org">www.caskresearch.org</a>                       |
| Childhood Tumour Trust                           | <a href="http://www.childhoodtumourtrust.org.uk">www.childhoodtumourtrust.org.uk</a> |
| CMT United Kingdom                               | <a href="http://www.cmt.org.uk">www.cmt.org.uk</a>                                   |
| CSF Leak                                         | <a href="http://www.csfleak.uk">www.csfleak.uk</a>                                   |
| Cure Parkinson's Trust <sup>1</sup>              | <a href="http://www.cureparkinsons.org.uk">www.cureparkinsons.org.uk</a>             |
| The Daisy Garland                                | <a href="http://www.thedaisygarland.org.uk">www.thedaisygarland.org.uk</a>           |
| Different Strokes                                | <a href="http://www.differentstrokes.co.uk">www.differentstrokes.co.uk</a>           |
| Downs Syndrome Research (DSRF)                   | <a href="http://www.dsrf-uk.org">www.dsrf-uk.org</a>                                 |
| Dravet Syndrome UK                               | <a href="http://www.www.dravet.org.uk">www.www.dravet.org.uk</a>                     |
| Dystonia UK                                      | <a href="http://www.dystonia.org.uk">www.dystonia.org.uk</a>                         |
| Epilepsy Action                                  | <a href="http://www.epilepsy.org.uk">www.epilepsy.org.uk</a>                         |
| Epilepsy Research Institute UK                   | <a href="http://www.epilepsyresearch.org.uk">www.epilepsyresearch.org.uk</a>         |
| Face Blind <sup>1</sup>                          | <a href="http://www.faceblind.org.uk">www.faceblind.org.uk</a>                       |
| FD UK                                            | <a href="http://www.familialdysautonomia.co.uk">www.familialdysautonomia.co.uk</a>   |
| FND Action                                       | <a href="http://www.fndaction.org.uk">www.fndaction.org.uk</a>                       |
| FND Dimensions                                   | <a href="http://fnddimensions.org">http://fnddimensions.org</a>                      |
| FND Hope                                         | <a href="http://www.fndhope.org">www.fndhope.org</a>                                 |
| Inflammatory Neuropathies UK (previously GAIN)   | <a href="http://www.inflammatoryneuropathies.uk">www.inflammatoryneuropathies.uk</a> |
| Glut1 Deficiency UK                              | <a href="http://www.glut1deficiency.org.uk">www.glut1deficiency.org.uk</a>           |
| Harry's Hat                                      | <a href="http://www.harrys-hat.org">www.harrys-hat.org</a>                           |
| Headway <sup>1</sup>                             | <a href="http://www.headway.org.uk">www.headway.org.uk</a>                           |
| Hereditary Brain Aneurysms Support (HBA Support) | <a href="http://www.hbasupport.org">www.hbasupport.org</a>                           |
| Hereditary Spastic Paraplegia Support Group      | <a href="http://www.hspgroup.org">www.hspgroup.org</a>                               |
| Huntington's Disease Association                 | <a href="http://www.hda.org.uk">www.hda.org.uk</a>                                   |
| IIH UK                                           | <a href="http://www.www.iih.org.uk">www.www.iih.org.uk</a>                           |
| Intractable Epilepsy                             | <a href="http://www.www.intractable.org.uk">www.www.intractable.org.uk</a>           |
| Matthew's Friends                                | <a href="http://www.www.matthewsfriends.org">www.www.matthewsfriends.org</a>         |
| Migraine Trust                                   | <a href="http://www.migrainetrust.org">www.migrainetrust.org</a>                     |
| Motor Neurone Disease Association                | <a href="http://www.mndassociation.org">www.mndassociation.org</a>                   |
| MS Together <sup>1</sup>                         | <a href="http://www.mstogether.org">www.mstogether.org</a>                           |
| Multiple Sclerosis Society                       | <a href="http://www.mssociety.org.uk">www.mssociety.org.uk</a>                       |

|                                                                             |                                                                                                                            |
|-----------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| Multiple Sclerosis Trust                                                    | <a href="http://www.mstrust.org.uk">www.mstrust.org.uk</a>                                                                 |
| Multiple System Atrophy Trust                                               | <a href="http://www.msatrust.org.uk">www.msatrust.org.uk</a>                                                               |
| Myaware                                                                     | <a href="http://www.myaware.org">www.myaware.org</a>                                                                       |
| Myelopathy.org <sup>2</sup>                                                 | <a href="http://www.myelopathy.org">www.myelopathy.org</a>                                                                 |
| Narcolepsy UK                                                               | <a href="http://www.narcolepsy.org.uk">www.narcolepsy.org.uk</a>                                                           |
| Naseems Manx Brain Tumour Charity <sup>1</sup>                              | <a href="http://www.naseemsmanxbraintumourcharity.co.uk">www.naseemsmanxbraintumourcharity.co.uk</a>                       |
| The National Hospital for Neurology and Neurosurgery Development Foundation | <a href="http://www.nationalbrainappeal.org">www.nationalbrainappeal.org</a>                                               |
| National Tremor Foundation                                                  | <a href="http://www.tremor.org.uk">www.tremor.org.uk</a>                                                                   |
| Nerve of My MS                                                              | <a href="http://www.thenerveofmys.org.uk">www.thenerveofmys.org.uk</a>                                                     |
| Nerve Tumours UK                                                            | <a href="http://www.nervetumours.org.uk">www.nervetumours.org.uk</a>                                                       |
| Neuro Therapy Network                                                       | <a href="http://www.neurotherapynetwork.org.uk">www.neurotherapynetwork.org.uk</a>                                         |
| NF2 Biosolutions <sup>1</sup>                                               | <a href="http://www.nf2biosolutions.org/nf2-biosolutions-uk-europe">www.nf2biosolutions.org/nf2-biosolutions-uk-europe</a> |
| Overcoming MS                                                               | <a href="http://www.overcomingms.org">www.overcomingms.org</a>                                                             |
| Pans Pandas UK                                                              | <a href="http://www.panspandasuk.org">www.panspandasuk.org</a>                                                             |
| Parkinson's UK                                                              | <a href="http://www.parkinsons.org.uk">www.parkinsons.org.uk</a>                                                           |
| Pernicious Anaemia Society (PAS)                                            | <a href="http://www.pernicious-anaemia-society.org">www.pernicious-anaemia-society.org</a>                                 |
| Polio Survivors Network                                                     | <a href="http://www.poliosurvivorsnetwork.org.uk">www.poliosurvivorsnetwork.org.uk</a>                                     |
| PSP Association                                                             | <a href="http://www.pspassociation.org.uk">www.pspassociation.org.uk</a>                                                   |
| Restless Legs Syndrome UK <sup>1</sup>                                      | <a href="http://www.rls-uk.org">www.rls-uk.org</a>                                                                         |
| Ring 20 Research and Support UK CIO                                         | <a href="http://www.ring20researchsupport.co.uk">www.ring20researchsupport.co.uk</a>                                       |
| Spotlight YOPD                                                              | <a href="https://spotlightyopd.org">https://spotlightyopd.org</a>                                                          |
| SUDEP Action                                                                | <a href="http://www.sudep.org">www.sudep.org</a>                                                                           |
| Timothy Syndrome Alliance                                                   | <a href="http://www.timothysyndrome.org">www.timothysyndrome.org</a>                                                       |
| Tourettes Action                                                            | <a href="http://www.tourettes-action.org.uk">www.tourettes-action.org.uk</a>                                               |
| Transverse Myelitis Society                                                 | <a href="http://www.myelitis.org.uk">www.myelitis.org.uk</a>                                                               |
| Trigeminal Neuralgia Association UK                                         | <a href="http://www.tna.org.uk">www.tna.org.uk</a>                                                                         |
| UK Acquired Brain Injury Forum                                              | <a href="http://www.ukabif.org.uk">www.ukabif.org.uk</a>                                                                   |

## Associates

| Organisation                                                    | Website                                                                                                                                                                                  |
|-----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Association of British Neurologists (ABN)                       | <a href="http://www.theabn.org">www.theabn.org</a>                                                                                                                                       |
| Association of Chartered Physiotherapists in Neurology (ACPIN)  | <a href="http://www.acpin.net">www.acpin.net</a>                                                                                                                                         |
| British Paediatric Neurology Association (BPNA)                 | <a href="http://www.bpna.org.uk">www.bpna.org.uk</a>                                                                                                                                     |
| British Society of Physical and Rehabilitation Medicine (BSPRM) | <a href="http://www.bsprm.org.uk">www.bsprm.org.uk</a>                                                                                                                                   |
| Division of Neuropsychology (British Psychological Society)     | <a href="http://www.bps.org.uk/networks-and-communities/member-microsite/division-neuropsychology">www.bps.org.uk/networks-and-communities/member-microsite/division-neuropsychology</a> |
| The British and Irish Association of Stroke Physicians (BIASP)  | <a href="http://www.biasp.org">www.biasp.org</a>                                                                                                                                         |
| Neurology Academy                                               | <a href="http://www.neurologyacademy.org">www.neurologyacademy.org</a>                                                                                                                   |
| Independent Neurorehabilitation Providers Alliance (INPA)       | <a href="http://www.in-pa.org.uk">www.in-pa.org.uk</a>                                                                                                                                   |

## Corporate supporters

| Organisation                   | Website                                                                                                  |
|--------------------------------|----------------------------------------------------------------------------------------------------------|
| AbbVie                         | <a href="http://www.abbvie.co.uk">www.abbvie.co.uk</a>                                                   |
| Angelini Pharma                | <a href="http://www.angelinipharma.com">www.angelinipharma.com</a>                                       |
| Biogen                         | <a href="http://www.biogen.uk.com">www.biogen.uk.com</a>                                                 |
| Boston Scientific <sup>2</sup> | <a href="http://www.bostonscientific.com">www.bostonscientific.com</a>                                   |
| Sanofi Genzyme                 | <a href="http://www.genzyme.co.uk">www.genzyme.co.uk</a>                                                 |
| Lundbeck <sup>2</sup>          | <a href="http://www.lundbeck.com/uk">www.lundbeck.com/uk</a>                                             |
| Merck Serono                   | <a href="http://www.merckserono.co.uk">www.merckserono.co.uk</a>                                         |
| Novartis                       | <a href="http://www.novartis.co.uk">www.novartis.co.uk</a>                                               |
| Pfizer                         | <a href="http://www.pfizer.co.uk/science/pfizer-in-the-uk">www.pfizer.co.uk/science/pfizer-in-the-uk</a> |
| PTC Therapeutics <sup>2</sup>  | <a href="http://www.ptcbio.com">www.ptcbio.com</a>                                                       |
| Roche                          | <a href="http://www.roche.com">www.roche.com</a>                                                         |
| Sandoz                         | <a href="http://www.sandoz.com">www.sandoz.com</a>                                                       |
| Teva UK Limited                | <a href="http://www.tevauk.com">www.tevauk.com</a>                                                       |
| UCB Pharma Ltd                 | <a href="http://www.ucb.co.uk">www.ucb.co.uk</a>                                                         |

## Affiliates

| Organisation                                  | Website                                                                                                                        |
|-----------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
| Bolton Neuro Voices                           | <a href="http://www.boltoncvs.org.uk">www.boltoncvs.org.uk</a>                                                                 |
| Essex Neurology Network <sup>1</sup>          | <a href="http://www.community360.org.uk/blog/essex-neurology-network">www.community360.org.uk/blog/essex-neurology-network</a> |
| Hampshire Neurological Alliance               | <a href="https://www.hampshireneural.org.uk/index.html">https://www.hampshireneural.org.uk/index.html</a>                      |
| Merseyside and Cheshire Neurological Alliance | <a href="http://www.neurosupport.org.uk">www.neurosupport.org.uk</a>                                                           |
| West Berkshire Neurological Alliance          | <a href="http://www.wbna.org.uk">www.wbna.org.uk</a>                                                                           |

## Reciprocal members

| Organisation                                     | Website                                                                                        |
|--------------------------------------------------|------------------------------------------------------------------------------------------------|
| Genetic Alliance UK                              | <a href="https://geneticalliance.org.uk">https://geneticalliance.org.uk</a>                    |
| National Voices                                  | <a href="http://www.nationalvoices.org.uk">www.nationalvoices.org.uk</a>                       |
| Neurological Alliance of Ireland                 | <a href="http://www.nai.ie">www.nai.ie</a>                                                     |
| Neurological Alliance of Scotland                | <a href="http://www.scottishneurological.org.uk">www.scottishneurological.org.uk</a>           |
| Neurological Alliance of Wales                   | <a href="http://www.walesneurologicalalliance.org.uk">www.walesneurologicalalliance.org.uk</a> |
| Northern Ireland Neurological Charities Alliance | <a href="http://www.ninca.org.uk">www.ninca.org.uk</a>                                         |

<sup>1</sup>. New members in 2024 – 25.    <sup>2</sup>. Ceased members in 2024 – 25.

### 4.2.3 The way we work

As a membership organisation, our whole ethos is to work in partnership. We work across the neurological community to identify common priorities for people affected by neurological conditions and then seek to influence, shape and support policy development to reduce inequalities, enhance their outcomes and, where possible, help them live for longer and in better health. Our activities are therefore based on a

clear and shared sense of purpose. We work with our trustees, the policy group and policy steering group to determine our strategy and plans.

#### 4.2.4 The policy group

Any member of the Alliance can be part of the policy group. The group's purpose is to:

- make recommendations on Alliance policy and activity, ensuring that these reflect the needs and objectives of its member organisations;
- build collective ownership of the Alliance beyond staff and trustees and to promote team-working across the member organisations;
- provide a forum for policy and campaigns staff of member organisations to share information and provide mutual support;
- ensure alignment between member organisations' priorities and the collective needs of the Alliance; and
- ensure that all member organisations, large and small, can contribute to the work of the Alliance;
- help to devise and oversee the Alliance's outputs, including policy statements, the Alliance's workplan; campaign activities, and any Alliance manifestos.

#### 4.2.5. Policy group leads

| Name           | Role & organisation                                                                       |
|----------------|-------------------------------------------------------------------------------------------|
| Frankie Bowyer | Senior Policy Officer, MS Society, Chair (November 2023 – June 2024)                      |
| Sam Mountney   | Policy & External Affairs Manager, The Neurological Alliance, Chair (June 2024 – present) |

#### 4.3 Risk management

The trustees have assessed the major risks to which the charity is exposed and are satisfied that systems are in place to mitigate exposure to major risks. A risk management framework, reviewed annually, is in place. We also have a risk-based reserves policy which mitigates our main financial risks.

### 5. Public benefit

Our work benefits people affected by a neurological condition and those who represent them. Sections 1 and 2 of this report set out our objectives, report on our activities and successes, and set out our plans for the current financial year.

The trustees consider that they have complied with their duty in s4 of the Charities Act 2011 to have due regard to the guidance on public benefit published by the Charity Commission. The trustees have considered this matter and concluded:

- That the aims of the organisation continue to be charitable;
- That the aims and the work done give identifiable benefits to the charitable sector and both indirectly and directly to individuals in need;
- That the benefits are for the public, are not unreasonably restricted in any way and certainly not by ability to pay;
- That there is no detriment or harm arising from the aims or activities.

## 6. Reference and administrative details

The Alliance is a registered charity (1039034) and company limited by guarantee (02939840) registered in England. The Alliance's registered office was, from 21<sup>st</sup> September 2019, The Junction, Station Road, Watford, WD17 1ET.

### 6.1 Trustees and the nominating organisation

| Name             | Nominating organisation                                                            |
|------------------|------------------------------------------------------------------------------------|
| Aneeta Prem      | TNA UK (appointed Nov 2024)                                                        |
| Alison Fuller    | Epilepsy Action                                                                    |
| Lucy Taylor      | MS Trust (appointed Nov 2024)                                                      |
| Cath Stanley     | Huntington's Disease Association                                                   |
| Alex Massey      | Motor Neurone Disease Association (Appointed May 2025)                             |
| Kripen Dhrona    | British Polio Fellowship (Treasurer)                                               |
| Tony Lloyd       | West Berkshire Regional Neurological Alliance (appointed Nov 2024)                 |
| Richard Evans    | Motor Neurone Disease Association (Appointed November 2024, stepped down May 2025) |
| Rob Music        | Migraine Trust                                                                     |
| Sarah Rawlings   | MS Society (re-appointed Nov 2024) (Vice-chair)                                    |
| Victoria Wareham | Dystonia UK (trustee with responsibility for safeguarding)                         |

During the year the Board, again, co-opted three independent trustees with the aim of achieving greater diversity on the Board in terms of the professional backgrounds of members. The co-opted trustees are:

| Name            | Date appointed     |
|-----------------|--------------------|
| Adine Adonis    | Appointed May 2025 |
| Gideon Schulman | Appointed May 2025 |
| Mike Dilley     | Appointed May 2025 |

## 6.2 Professional advisors

| Supplier              | Address                                                                      |
|-----------------------|------------------------------------------------------------------------------|
| Banks                 | CAF Bank Ltd, PO Box 289, West Malling, Kent, ME19 4TA                       |
|                       | Metro Bank PLC, One Southampton Row, London, WC1B 5HA                        |
| Accountants           | Godfrey Wilson, 5th Floor, Mariner House, 62 Prince Street, Bristol, BS1 4QD |
| Independent Examiners | Goodman Jones LLP, 29-30 Fitzroy Square, London W1T 6LQ                      |

## 6.3 Advisors

In February 2025 the Board agreed to appoint four advisors to provide the Board with clinical and health industry experience and expertise:

| Name                  | Date appointed          |
|-----------------------|-------------------------|
| Dr. Paul Cooper       | Appointed February 2025 |
| David Garmon-Jones    | Appointed February 2025 |
| Nadia Jefferies       | Appointed February 2025 |
| Prof. Adrian Williams | Appointed February 2025 |

## 7. Finances

### 7.1 Investment

Article 5.1.23 empowers the Alliance, with advice from a financial expert, to invest the funds of the Alliance as it sees fit, with consideration of the suitability of investments and the need for diversification.

### 7.2 Subscriptions

Subscription rates are determined by the organisational income of each member and associate. Subscriptions for affiliate members are at a fixed rate.

### 7.3 Reserves policy

A reserves policy was agreed by trustees during 2024. This policy is a risk-based policy, to reflect the reality that any reduction in income or increasing in costs would take place over a period of time.

Having considered the risks, trustees consider it prudent that reserves should be maintained in order to cover the loss of income from one third of the significant income sources. This equates to approximately £68,000.

At the end of the year reserves of £55,495 were held, of which £21,069 were restricted. This is £12,505 below the level of reserves the trustees calculate are required. The shortfall reflects our decision to invest in My Neuro Survey, alongside delays in anticipated payments from funders. Trustees are confident that the position will be recovered in 25/26 and have approved a conservative budget.

## 7.4 Financial position

Income from membership subscriptions increased by 14% in the year to £109,705 (23/24: £95,885). In parallel, unrestricted corporate funding increased by 6% to £158,314 (23/24 £149,225).

Overall, there is a deficit of £52,888 (before transfers) on the unrestricted funds (23/24 deficit of £4,365) and a surplus of £1,994 (before transfers) on restricted funds (23/24: surplus of £14,834). This leaves an overall deficit of £50,894 (23/24 surplus of £10,469) for the year.

Our focus for 2025/26 will be to return to a surplus and begin rebuilding our reserves to a sustainable level.

## 7.5 Trustees' responsibilities statement

The trustees (who are also directors of The Neurological Alliance for the purposes of company law) are responsible for preparing the trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2015 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant information of which the charitable company's independent examiner is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the independent examiner is aware of that information.

## 7.6 Independent examiners

At the AGM in November 2024, members agreed to delegate responsibility for selecting The Neurological Alliance's Independent Examiners for the forthcoming year and 2024-2025 accounts to the Board of Trustees.

The Board decided to appoint Goodman Jones LLP to be our independent examiner for 2024-25.

## 7.7 Small company provisions

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the Board of Trustees,

Cath Stanley *Cath Stanley*

Chair, Board of Trustees      Date: 24-11-25

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**INDEPENDENT EXAMINER'S REPORT**  
**FOR THE YEAR ENDED 30 JUNE 2025**

---

**Independent Examiner's Report to the Trustees of The Neurological Alliance ('the Charity')**

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 30 June 2025.

**Responsibilities and Basis of Report**

As the Trustees of the Charity (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

**Independent Examiner's Statement**

Since the Charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of (enter body here), which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Charity as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**INDEPENDENT EXAMINER'S REPORT (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2025**

---

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed: *Martin Bailey*

Dated: 25-11-25

Martin Bailey

FCA

**Martin Bailey FCA**  
Goodman Jones LLP  
1st Floor, Arthur Stanley House  
40-50 Tottenham Street  
London  
W1T 4RN

**THE NEUROLOGICAL ALLIANCE**  
(A Company Limited by Guarantee)

**STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)  
FOR THE YEAR ENDED 30 JUNE 2025**

|                                    | Note | Unrestricted<br>funds<br>2025<br>£ | Restricted<br>funds<br>2025<br>£ | Total<br>funds<br>2025<br>£ | Total<br>funds<br>2024<br>£ |
|------------------------------------|------|------------------------------------|----------------------------------|-----------------------------|-----------------------------|
| <b>Income from:</b>                |      |                                    |                                  |                             |                             |
| Donations and legacies             | 4    | 2,242                              | -                                | 2,242                       | 301                         |
| Charitable activities              | 5    | 277,942                            | 13,994                           | 291,936                     | 266,770                     |
| Investments                        | 6    | 2,941                              | -                                | 2,941                       | 1,747                       |
| <b>Total income</b>                |      | <b>283,125</b>                     | <b>13,994</b>                    | <b>297,119</b>              | <b>268,818</b>              |
| <b>Expenditure on:</b>             |      |                                    |                                  |                             |                             |
| Raising funds                      |      | 690                                | -                                | 690                         | 5,635                       |
| Charitable activities              | 7    | 335,323                            | 12,000                           | 347,323                     | 252,714                     |
| <b>Total expenditure</b>           |      | <b>336,013</b>                     | <b>12,000</b>                    | <b>348,013</b>              | <b>258,349</b>              |
| <b>Net movement in funds</b>       |      | <b>(52,888)</b>                    | <b>1,994</b>                     | <b>(50,894)</b>             | <b>10,469</b>               |
| <b>Reconciliation of funds:</b>    |      |                                    |                                  |                             |                             |
| Total funds brought forward        |      | 87,314                             | 19,075                           | 106,389                     | 95,920                      |
| Net movement in funds              |      | (52,888)                           | 1,994                            | (50,894)                    | 10,469                      |
| <b>Total funds carried forward</b> |      | <b>34,426</b>                      | <b>21,069</b>                    | <b>55,495</b>               | <b>106,389</b>              |

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 10 to 20 form part of these financial statements.

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**  
**REGISTERED NUMBER: 02939840**

**BALANCE SHEET**  
**AS AT 30 JUNE 2025**

|                                                | Note | 2025<br>£ | 2024<br>£ |
|------------------------------------------------|------|-----------|-----------|
| <b>Fixed assets</b>                            |      |           |           |
|                                                |      | -         | -         |
| <b>Current assets</b>                          |      |           |           |
| Debtors                                        | 11   | 60,617    | 53,258    |
| Cash at bank and in hand                       |      | 41,222    | 64,306    |
|                                                |      | 101,839   | 117,564   |
| <b>Current liabilities</b>                     |      |           |           |
| Creditors: amounts falling due within one year | 12   | (46,344)  | (11,175)  |
| <b>Net current assets</b>                      |      | 55,495    | 106,389   |
| <b>Total net assets</b>                        |      | 55,495    | 106,389   |
| <b>Charity funds</b>                           |      |           |           |
| Restricted funds                               | 13   | 21,069    | 19,075    |
| Unrestricted funds                             | 13   | 34,426    | 87,314    |
| <b>Total funds</b>                             |      | 55,495    | 106,389   |

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

*Cath Stanley*  
 .....  
**Cath Stanley**  
 Chair of Trustees

Date: 24-11-25

The notes on pages 10 to 20 form part of these financial statements.

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025**

---

**1. General information**

The Neurological Alliance is a registered charity and company limited by guarantee. Its charitable objects are set out in the Trustees' Report. Its registered office address is The Junction, Station Road, Watford, WD17 1EU.

**2. Accounting policies**

**2.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The financial statements are prepared on the going concern basis under the historical cost convention, modified to include certain items at fair value. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are presented in Sterling which is the functional currency of the Charity and monetary amounts are rounded to the nearest £.

The Neurological Alliance meets the definition of a public benefit entity under FRS 102.

**2.2 Company status**

The Charity is a company limited by guarantee. The members of the company are the Trustees named in the Trustee report section 5.1. In the event of the Charity being wound up, the liability in respect of the guarantee is limited to £10 per member of the Charity.

**2.3 Going concern**

The Trustees have assessed whether the use of the going concern assumption is appropriate in preparing these accounts and are of the opinion that the Charity will have sufficient resources to meet its liabilities as they fall due. The Trustees have made this assessment in respect of a period of one year from the date of approval of these accounts. The Trustees of the Charity have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the Charity to continue as a going concern.

**2.4 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025**

---

**2. Accounting policies (continued)**

**2.5 Income**

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received, and the amount of income receivable can be measured reliably.

The following specific policies are applied to particular categories of income:

Subscription income is invoiced in line with the financial year and recognised in the period to which it relates.

Corporate support represents amounts invoiced in the year.

Donated services or facilities are recognised when the Charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the Charity of the item is probable and that economic benefit can be measured reliably. On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the Charity which is the amount the Charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

**2.6 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the Bank.

**2.7 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Support costs are those costs incurred directly in support of expenditure on the objects of the Charity. Governance costs are those incurred in connection with administration of the Charity and compliance with constitutional and statutory requirements.

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025**

---

**2. Accounting policies (continued)**

**2.7 Expenditure (continued)**

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds. All expenditure is inclusive of irrecoverable VAT.

**2.8 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**2.9 Cash at Bank and in hand**

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

**2.10 Liabilities and Provision**

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

**2.11 Operating Leases**

Rentals under operating leases are charged to the Statement of Financial Activities incorporating Income and Expenditure Account on a straight-line basis over the lease term.

**2.12 Pensions**

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2025

3. Critical accounting estimates and areas of judgement

In the application of the Charity’s accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The Charity makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Critical areas of judgement:

Income recognition - the Charity receives grant income. These agreements may include quantitative and qualitative milestones, performance conditions, and /or donor imposed time conditions which must be met in order for the Charity to have entitlement to the funds

4. Income from donations and legacies

|            | Unrestricted<br>funds<br>2025<br>£ | Total<br>funds<br>2025<br>£ | Total<br>funds<br>2024<br>£ |
|------------|------------------------------------|-----------------------------|-----------------------------|
| Donations  | 2,110                              | 2,110                       | 301                         |
| Legacies   | 132                                | 132                         | -                           |
|            | <u>2,242</u>                       | <u>2,242</u>                | <u>301</u>                  |
| Total 2024 | <u>301</u>                         | <u>301</u>                  |                             |

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025**

---

**5. Income from charitable activities**

|                   | <b>Unrestricted<br/>funds<br/>2025<br/>£</b> | <b>Restricted<br/>funds<br/>2025<br/>£</b> | <b>Total<br/>funds<br/>2025<br/>£</b> | <i>Total<br/>funds<br/>2024<br/>£</i> |
|-------------------|----------------------------------------------|--------------------------------------------|---------------------------------------|---------------------------------------|
| Corporate support | 158,314                                      | -                                          | <b>158,314</b>                        | 133,319                               |
| Subscriptions     | 113,336                                      | -                                          | <b>113,336</b>                        | 95,885                                |
| Projects          | 6,292                                        | 13,994                                     | <b>20,286</b>                         | 37,566                                |
|                   | <u>277,942</u>                               | <u>13,994</u>                              | <u><b>291,936</b></u>                 | <u>266,770</u>                        |
| <i>Total 2024</i> | <u>241,910</u>                               | <u>24,860</u>                              | <u>266,770</u>                        |                                       |

**6. Investment income**

|                   | <b>Unrestricted<br/>funds<br/>2025<br/>£</b> | <b>Total<br/>funds<br/>2025<br/>£</b> | <i>Total<br/>funds<br/>2024<br/>£</i> |
|-------------------|----------------------------------------------|---------------------------------------|---------------------------------------|
| Interest income   | 2,941                                        | <b>2,941</b>                          | 1,747                                 |
|                   | <u>1,747</u>                                 | <u>1,747</u>                          |                                       |
| <i>Total 2024</i> | <u>1,747</u>                                 | <u>1,747</u>                          |                                       |

**THE NEUROLOGICAL ALLIANCE**  
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025**

**7. Analysis of expenditure on charitable activities**

**Summary by fund type**

|                    | <b>Unrestricted<br/>funds<br/>2025<br/>£</b> | <b>Restricted<br/>funds<br/>2025<br/>£</b> | <b>Total<br/>2025<br/>£</b> | <b>Total<br/>2024<br/>£</b> |
|--------------------|----------------------------------------------|--------------------------------------------|-----------------------------|-----------------------------|
| Policy Development | 124,887                                      | -                                          | <b>124,887</b>              | 61,031                      |
| Members Activities | 210,436                                      | 12,000                                     | <b>222,436</b>              | 191,683                     |
|                    | <u>335,323</u>                               | <u>12,000</u>                              | <u><b>347,323</b></u>       | <u>252,714</u>              |
| <i>Total 2024</i>  | <u>242,688</u>                               | <u>10,026</u>                              | <u>252,714</u>              |                             |

**8. Analysis of expenditure by activities**

|                    | <b>Activities<br/>undertaken<br/>directly<br/>2025<br/>£</b> | <b>Support<br/>costs<br/>2025<br/>£</b> | <b>Total<br/>funds<br/>2025<br/>£</b> | <b>Total<br/>funds<br/>2024<br/>£</b> |
|--------------------|--------------------------------------------------------------|-----------------------------------------|---------------------------------------|---------------------------------------|
| Policy Development | 95,415                                                       | 29,472                                  | <b>124,887</b>                        | 61,031                                |
| Members Activities | 218,513                                                      | 3,923                                   | <b>222,436</b>                        | 191,683                               |
|                    | <u>313,928</u>                                               | <u>33,395</u>                           | <u><b>347,323</b></u>                 | <u>252,714</u>                        |
| <i>Total 2024</i>  | <u>220,513</u>                                               | <u>32,201</u>                           | <u>252,714</u>                        |                                       |

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025**

---

**9. Staff costs**

|                                                      | <b>2025</b><br>£ | <b>2024</b><br>£ |
|------------------------------------------------------|------------------|------------------|
| Wages and salaries                                   | <b>173,694</b>   | 151,982          |
| Social security costs                                | <b>11,443</b>    | 9,932            |
| Contribution to defined contribution pension schemes | <b>9,872</b>     | 9,052            |
|                                                      | <b>195,009</b>   | 170,966          |

The average number of persons employed by the Charity during the year was as follows:

|           | <b>2025</b><br>No. | <b>2024</b><br>No. |
|-----------|--------------------|--------------------|
| Employees | <b>5</b>           | 4                  |

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

|                               | <b>2025</b><br>No. | <b>2024</b><br>No. |
|-------------------------------|--------------------|--------------------|
| In the band £60,001 - £70,000 | -                  | 1                  |
| In the band £70,001 - £80,000 | <b>1</b>           | -                  |

Key management personnel remuneration, including employer's NIC and pension contributions, incurred by the Charity in the year totalled £80,898 (2024: £79,996).

**10. Trustees' remuneration and expenses**

During the year, no Trustees received any remuneration or other benefits (2024 - £NIL).

During both the current and prior years, no expenses were reimbursed or paid directly to any trustee.

**11. Debtors**

|                                | <b>2025</b><br>£ | <b>2024</b><br>£ |
|--------------------------------|------------------|------------------|
| <b>Due within one year</b>     |                  |                  |
| Other debtors                  | <b>23,675</b>    | 18,443           |
| Prepayments and accrued income | <b>36,942</b>    | 34,815           |
|                                | <b>60,617</b>    | 53,258           |

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025**

---

**12. Creditors: Amounts falling due within one year**

|                                    | <b>2025</b>   | <b>2024</b> |
|------------------------------------|---------------|-------------|
|                                    | <b>£</b>      | <b>£</b>    |
| Trade creditors                    | <b>28,457</b> | 6,890       |
| Other taxation and social security | <b>2,907</b>  | 2,763       |
| Other creditors                    | -             | 1,172       |
| Accruals and deferred income       | <b>14,980</b> | 350         |
|                                    | <b>46,344</b> | 11,175      |

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025**

---

**13. Statement of funds**

**Statement of funds - current year**

|                           | Balance at 1<br>July 2024<br>£ | Income<br>£    | Expenditure<br>£ | Balance at<br>30 June<br>2025<br>£ |
|---------------------------|--------------------------------|----------------|------------------|------------------------------------|
| <b>Unrestricted funds</b> |                                |                |                  |                                    |
| General Funds - all funds | 87,314                         | 283,125        | (336,013)        | 34,426                             |
|                           | <hr/>                          | <hr/>          | <hr/>            | <hr/>                              |
| <b>Restricted funds</b>   |                                |                |                  |                                    |
| NNAG Events               | 719                            | -              | -                | 719                                |
| Epilepsy Tool             | 16,020                         | 1,994          | -                | 18,014                             |
| Neurolifenow              | 2,334                          | 12,000         | (12,000)         | 2,334                              |
| Outpatient Transformation | 2                              | -              | -                | 2                                  |
|                           | <hr/>                          | <hr/>          | <hr/>            | <hr/>                              |
|                           | 19,075                         | 13,994         | (12,000)         | 21,069                             |
|                           | <hr/>                          | <hr/>          | <hr/>            | <hr/>                              |
| <b>Total funds</b>        | <b>106,389</b>                 | <b>297,119</b> | <b>(348,013)</b> | <b>55,495</b>                      |
|                           | <hr/> <hr/>                    | <hr/> <hr/>    | <hr/> <hr/>      | <hr/> <hr/>                        |

**THE NEUROLOGICAL ALLIANCE**  
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2025**

**13. Statement of funds (continued)**

**Statement of funds - prior year**

|                           | <i>Balance at<br/>1 July 2023<br/>£</i> | <i>Income<br/>£</i> | <i>Expenditure<br/>£</i> | <i>Balance at<br/>30 June<br/>2024<br/>£</i> |
|---------------------------|-----------------------------------------|---------------------|--------------------------|----------------------------------------------|
| <b>Unrestricted funds</b> |                                         |                     |                          |                                              |
| General Funds - all funds | 91,679                                  | 243,958             | (248,323)                | 87,314                                       |
| <b>Restricted funds</b>   |                                         |                     |                          |                                              |
| NNAG Pathways             | 719                                     | -                   | -                        | 719                                          |
| Epilepsy Tool             | 1,020                                   | 15,000              | -                        | 16,020                                       |
| Neurolifenow              | 2,500                                   | 9,860               | (10,026)                 | 2,334                                        |
| Outpatient Transformation | 2                                       | -                   | -                        | 2                                            |
|                           | 4,241                                   | 24,860              | (10,026)                 | 19,075                                       |
| <b>Total funds</b>        | 95,920                                  | 268,818             | (258,349)                | 106,389                                      |

Restricted funds represent the following:

NNAG Pathways - events and activities to support the development of an epilepsy pathway.

Neurolifenow - funds received for a real-time survey which aims to provide routine patient experience data to support service improvement and positive public policy change.

Epilepsy Navigator Tool - a tool developed to provide a range of resources to support service development.

Outpatient Transformation - funds to provide improvements to outpatient services and resources.

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025**

---

**14. Analysis of net assets between funds**

**Analysis of net assets between funds - current year**

|                               | <b>Unrestricted<br/>funds<br/>2025<br/>£</b> | <b>Restricted<br/>funds<br/>2025<br/>£</b> | <b>Total<br/>funds<br/>2025<br/>£</b> |
|-------------------------------|----------------------------------------------|--------------------------------------------|---------------------------------------|
| Current assets                | 80,770                                       | 21,069                                     | <b>101,839</b>                        |
| Creditors due within one year | (46,344)                                     | -                                          | <b>(46,344)</b>                       |
| <b>Total</b>                  | <b>34,426</b>                                | <b>21,069</b>                              | <b>55,495</b>                         |

**Analysis of net assets between funds - prior year**

|                               | <i>Unrestricted<br/>funds<br/>2024<br/>£</i> | <i>Restricted<br/>funds<br/>2024<br/>£</i> | <i>Total<br/>funds<br/>2024<br/>£</i> |
|-------------------------------|----------------------------------------------|--------------------------------------------|---------------------------------------|
| Current assets                | 98,489                                       | 19,075                                     | 117,564                               |
| Creditors due within one year | (11,175)                                     | -                                          | (11,175)                              |
| <b>Total</b>                  | <b>87,314</b>                                | <b>19,075</b>                              | <b>106,389</b>                        |

**15. Pension commitments**

The Charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Charity in an independently administered fund. The pension cost charge represents contributions payable by the Charity to the fund and amounted to £9,872 (2024: £9,052).

Contributions totalling £218 were receivable from (2024: £1,172 payable to) the fund at the balance sheet date.

**16. Related party transactions**

Other than disclosed elsewhere in these financial statements, there were no related party transactions requiring disclosure during the current or previous year

# Together we are stronger.

The Neurological Alliance  
The Junction  
Station Rd  
Watford  
WD17 1EU

01923 882590  
[www.neural.org.uk](http://www.neural.org.uk)  
[info@neural.org.uk](mailto:info@neural.org.uk)

## Connect with us.

 [www.linkedin.com/company/neurological-alliance](http://www.linkedin.com/company/neurological-alliance)

 @neurologicalalliance

 @neurological\_alliance

 @NeuroAlliance

Company limited by guarantee registered in  
England 2939840. Registered charity 1039034.



---

# Accounts

---

**COMPANY REGISTRATION NUMBER 02939840**



**THE NEUROLOGICAL ALLIANCE**  
**(LIMITED BY GUARANTEE)**  
**FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED**  
**30 JUNE 2024**

**Charity Number 103903**

**THE NEUROLOGICAL ALLIANCE**  
**TRUSTEE ANNUAL REPORT**  
**LETTER FROM THE CHAIR**

As I conclude my first year as Chair of The Neurological Alliance, I'm filled with both gratitude and optimism for the future. The past year has been one of collaboration, learning, and advocacy. I have been inspired by the strength and dedication of our members, whose passion for improving the lives of people with neurological conditions is truly remarkable. Through your support, we've been able to make significant strides in raising the profile of neurological conditions within the political sphere.

Prior to the general election being called, we supported members and people affected by neurological conditions to engage in the development of key government initiatives, such as the NHS England Neuroscience Transformation Programme, the Major Conditions Strategy and the revitalised Rare Conditions Strategy for England.

Crucially, many members have told us that they are finding it increasingly difficult to influence local decision makers (such as Integrated Care Boards). In response, we have developed new tools and information to support members to campaign locally, and sought to encourage ICBs to prioritise services for people affected by neurological conditions. Nationally, we have encouraged and challenged NHS England to ensure that ICBs have the resources they need to understand care for people affected by neurological conditions in their patch, and how the sector can help them improve.

One of the highlights of the year was our #NeuroChampion campaign for the UK general election. It was an impressive collective effort, mobilizing nearly 1,000 people across the UK to reach out to over 2,200 parliamentary candidates and call on them to improve workforce and services for people affected by neurological conditions. We ensured that neurological conditions were a part of the election discourse, helping prospective MPs understand the critical importance of improving services for the one in six people in the UK living with neurological conditions. The election of 12 Neuro Champion MPs stands as a testament to our work, and they will be vital allies as we push for further change.

Looking ahead, I'm excited to work with these MPs and continue advocating for the much-needed improvements in care, support, and services for our community. Our call for a UK-wide Neuro Taskforce remains a priority.

A key focus for the coming year is the expansion of My Neuro Survey, our national neurological patient experience survey. This initiative continues to inform vital service improvements and policy changes. This year's survey will be our most ambitious yet, with an expanded focus on carers and a roll-out in the Republic of Ireland for the first time. We hope to capture an even broader range of voices, ensuring our data reflects the true diversity of our community and strengthens our advocacy efforts.

The Trustee Board has gone through more change this year. I'd like in particular to thank our departing trustees Marc Smith (Brain and Spine Foundation), and Chris James (MNDA), Dr Ralph Gregory (Independent Trustees) and, David Garmon-Jones (Independent Trustee), who have dedicated so much time and wisdom during their time on the board. A particular thanks, of course, to my predecessor, David Martin (MS Trust), who made it so easy to pick up the role as Chair, leaving a strong, collegiate board and executive.

In closing, I am deeply grateful for the warm welcome and invaluable insights I've gained from our members during this first year. Together, we have made significant progress, and I am confident that the year ahead will bring even greater achievements. Thank you for your ongoing support; we are stronger together, and I am excited about all we will accomplish in the coming months.

**Cath Stanley, Chair, The Neurological Alliance**

**THE NEUROLOGICAL ALLIANCE**  
**ANNUAL REPORT AND ACCOUNTS**  
**YEAR ENDED JUNE 2024**

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Registered charity name**                      The Neurological Alliance

**Charity registration number**                1039034

**Company registration number**               02939840

**Registered office**                              The Junction  
Station Road  
Watford  
WD17 1EU

**Independent Examiner**                      Martin Bailey FCA  
Goodman Jones LLP  
Chartered Accountants  
1<sup>st</sup> Floor, Arthur Stanley House  
40 – 50 Tottenham Street  
London  
W1T 4RN

**Accountants**                                    Godfrey Wilson  
5th Floor, Mariner House  
62 Prince Street  
Bristol  
BS1 4QD

---

**Bankers**

CAF Bank Ltd

25 Kings Hill Avenue

Kings Hill

West Malling

Kent

ME19 4JQ

Metro Bank PLC

One Southampton Row

London

WC1B 5HA

The trustees present their report and independently examined financial statements for The Neurological Alliance for the year 1 July 2023 to 30 June 2024. The report and financial statements have been prepared in accordance with the Companies Act 2006 and the Charities Act 2011. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) in preparing the report and financial statements. The report and financial statements will be laid before the members of the charity at the Annual General Meeting (AGM) to be held on 28 November 2024. In preparation of this report, the trustees had regard for the Charity Commission guidance on public benefit.

## **1. Our objects**

Our principal objectives, as derived from the objects set out in our Articles of Association, are to advance the education of the public in all matters concerning neurological disorders by carrying out research and investigation into preventative procedures, treatment and the needs and care of persons affected by neurological conditions, and publishing the useful results thereof, and the relief of those persons in the United Kingdom of Great Britain and Northern Ireland who are receiving or have received treatment for neurological conditions.

We are the only collective voice for over 100 national charities, professional bodies, regional organisations and corporate organisations working together to transform treatment, care and support for people affected by neurological conditions.

"The Neurological Alliance brings communities together. Symptoms often cross over and people find themselves battling the same issues within different neurological conditions. Why fight it alone when we can fight it together? A collective voice is a much louder voice."

**Rhys, co-production group member living with superficial siderosis and hydrocephalus.**

## **2. What we set out to do in 2023-2024**

Our vision, mission and strategic goals are as follows:

- Vision: Every person affected by a neurological condition can access the right treatment, care and support at the right time.
- Mission: To harness the energy and passion of the neurological community to ensure public policy in health reflects the realities of living with a neurological condition, so that everyone can access treatment, care and support whenever they need it.

Our goals:

1. Public policy and practice reflects and supports the realities of living with a neurological condition.
2. People affected by neurological conditions and our members are heard and have influence.
3. We are a strong, diverse organisation that delivers change.

Our values:

- **Bold:** We will not hesitate to speak truth to power, rooted in the experiences of people with neurological conditions.
- **United:** We unleash the power of our collective community.

- **Inclusive:** We listen to and celebrate the diversity of the neurological community. We work with anyone who shares our vision.
- **Leading:** We are the voice on issues relating to access and experience of healthcare for people with neurological conditions.
- **Expert:** We deliver evidence that changes minds and policy.

The Annual Report of the Trustees for 2023/24 is set out under our three strategic goals:

**Goal 1: Public policy and practice reflects and supports the realities of living with a neurological condition**

“The alliance has helped me to make a difference to people's lives and the way in which neurological conditions are addressed in the UK, not just for people living with the neurological condition that I have but for people who live with lots of different neurological conditions. I'm part of the change that I want to see happen.”

**Trishna, co-production group member living with multiple sclerosis.**

We have continued to take every opportunity available to secure much needed health service improvement for people affected by neurological conditions.

In particular, we have continued to engage with the NHS England neuroscience transformation programme, which is setting out a range of new resources for Integrated Care Boards to effectively commission adult neurology and neurosurgery services. As a member of the programme board, we have sought to ensure these resources reflect the experiences of people affected by neurological conditions and provide a comprehensive model of care. Through this programme, new resources have been developed to improve the data available to commissioners and providers about their neurosurgery and neurology service, as well as new evidence on health inequity in access to services.

We also played an active part in planning and delivering the first ‘National Neurology Transformation Meeting’ organised by the Neurology Academy. The meeting had representation from all but seven of the country's integrated care boards (ICBs), and many were managers and commissioners interested in improving services. Our CEO, Georgina Carr, presented findings from My Neuro Survey 2021/22 at the meeting, and another National Neurology Transformation Meeting is planned for 2025.

We continued our engagement around the Major Conditions Strategy in 2023/24, supported by ongoing dialogue with relevant officials in the Department for Health and Social Care. In September 2023 we used our Q3 Policy Group meeting to facilitate member engagement with Department of Health and Social Care (DHSC) officials working on the strategy, including the policy lead, providing a forum for members to share their views and insights with senior civil servants.

The alliance also supported the department in setting up two listening and engagement sessions directly with people affected by neurological conditions. 13 adults, children, young people and parents/carers participated across two sessions in October 2023. We played a leading role in ensuring our members and wider community were heard and influenced the development of the previous government's flagship health policy, ensuring it reflected the realities of living with a neurological condition.

We were invited to join the Rare Disease Strategy Patient Advisory Group for the first time, playing a central role in the development of the 2024 England Rare Disease Strategy.

Working with members of our Rare Conditions Subgroup we provided feedback on two drafts of the strategy and were involved in three meetings with colleagues and key DHSC officials. Our feedback on the need to ensure people affected by neurological conditions are not denied access to mental health support was included in the strategy and advice was circulated to all NHS England systems.

We have continued to play an active role in the Association of British Neurologists (ABN) Services Committee. The Committee includes regional representation from across the UK. The committee has focussed on updating job planning guidance, identifying areas of best practice neurology care and developing a new report on workforce need and provision. We have been particularly active in the latter piece of work, with a new report on this anticipated in 24/25.

We received restricted funding to develop a new MS service improvement tool, which follows the success of our epilepsy tool (published in 2023). The tool provides support to commissioners and providers to identify key pieces of evidence to plan their service, drawing on resources from our membership and beyond. The tool will be published in 2024.

We continued to support the publication of new clinical optimal pathways this year. In January, we published new optimal clinical pathways of care for epilepsy and neurological autoimmune diseases, and crosscutting pathways for neurogenetics and rehabilitation for adults with neurological conditions. These now sit alongside other clinical pathways for Functional Neurological Disorder (FND), headache and facial pain, movement disorders, Motor Neurone Disease (MND) and Traumatic Brain Injury (TBI). Pathways for mental health, neuromuscular conditions and Multiple Sclerosis (MS) will be published in 2024.

Many members told us how difficult they were finding it to navigate health and care reforms, in particular the development of Integrated Care Systems (ICSs). As a result, we developed a suite of new 'explainers' on health and care reforms. These include information on ICBs, Integrated Care Partnerships (ICPs) and ICSs and information about how neuroscience services will be commissioned in the future. Members have found these tools particularly useful, and we will continue to keep these resources updated as the health and care system changes in England.

Collaboration as part of the informal long term conditions mental health coalition continued – ensuring neurological conditions are represented alongside other specialties. We supported a successful backbench business debate application, securing a [Westminster Hall debate](#) on mental health and long term conditions in May 2024. My Neuro Survey data was included in the briefing for parliamentarians and referenced by the debate lead, Peter Dowd MP.

Our Policy and External Affairs Manager, Sam Mountney, retained his position as a co-opted member of the RCPsych Neuropsychiatry Faculty Executive. Alongside contributing to quarterly meetings, we attended an in-person strategy day, informing future priorities of the faculty and providing vital community and social enterprise sector (VCSE) and patient perspectives.

## **Goal 2: People affected by neurological conditions and our members are heard and have influence**

“The alliance is someone in your corner fighting for and with those who have neurological conditions, an opportunity to have your voice heard and acted upon.”

**Jeanette, co-production group member living with FND.**

We launched our #NeuroChampion campaign to coincide with the 2024 UK General Election, asking people affected by neurological conditions and members of the public to write to their prospective parliamentary candidates using an e-action before the general election on 4 July, and ask them to commit to improving workforce and services for people affected by neurological conditions in the next Parliament.

The overall aim of the #NeuroChampion campaign was to secure the support necessary from MPs elected at the election and the next government to deliver a Neuro Taskforce during the next Parliament. Almost 1,000 people took the e-action, reaching 2,222 candidates in 451 constituencies, putting neurological conditions firmly on the agenda in Parliament, ensuring MPs understand the impact of these conditions and the need for action to improve treatment, care and support for the one in six people in the UK who have a neurological condition.

In total, 12 Neuro Champions were elected, providing a solid basis for our future campaigning and continued calls for a Neuro Taskforce.

Many thanks to the neurological community and our member organisations for backing the campaign. Particular thanks go to the MS Society for hosting the e-action and providing the Engaging Networks platform to make the e-action possible.

Alongside the e-action, we wrote to the leaders of the three main political parties in England ahead of the general election setting out the case for a Neuro Taskforce and calling on them to support establishing a taskforce if they were to form the next government.

Ahead of launching the latest iteration of My Neuro Survey in July 2024, we secured £11,000 of restricted funding to develop and deliver a series of listening and engagement exercises to better understand the current and potential role of patient experience data and insights in service improvement.

During March and April 2024, we carried out a series of three roundtable discussions and four semi-structured interviews with voluntary community and social enterprise (VCSE) colleagues, NHS stakeholders (including commissioners, managers and system leaders) and healthcare professionals. Alongside being used to inform various phases of My Neuro Survey, key findings will be published in a summary report in September 2024 along with a focussed literature review carried out by the Patient Experience Library.

We'd like to thank all those who contributed their time and insights, along with our sponsors who together made this project possible.

Alongside this timely project, we developed the next iteration of My Neuro Survey. For the first time ever, we are partnering with The Neurological Alliance of Ireland to conduct the survey. We are thrilled to be able to expand the survey again, and of course to work again with the Northern Ireland Neurological Charities Alliance (NINCA), Neurological Alliance of Scotland and Wales Neurological Alliance on this important initiative. Another first – we have developed a new survey for friends and family of people affected by neurological conditions (also known as 'carers').

Our huge thanks to every person affected by a neurological condition, healthcare professional and charity colleague who took the time to review questionnaires and promotional materials ahead of launch on 22 July 2024. Results will be launched in spring/summer 2025.

We have continued to work closely with the Brain and Spine Foundation to deliver NeuroLifeNow, a real-time survey which aims to provide routine patient experience data to

support service improvement and positive public policy change. To date, more than 8,000 people have shared their experiences through the platform. We worked with the Brain and Spine Foundation to give new resources to our membership to promote the platform. Together, the NeuroLifeNow team published four new reports in 2023-24.

An important part of our work is to provide opportunities for members to discuss relevant topics and to engage with issues affecting the sector. During the past year Policy Group has considered the Major Conditions Strategy with representatives of DHSC, received an update from Geraint Fuller on progress with the Get It Right First Time (GIRFT) programme, and in the early summer the group heard from Rich Watts, Deputy Director of Policy, Strategy and Innovation at NHS England about the Outpatient Recovery & Transformation Programme. We were pleased to welcome Frankie Bowyer, of the MS Society, who joined as co-chair alongside Charlotte Gerada, who has been on maternity leave.

The Rare Conditions Subgroup continued to meet, and to discuss the England Rare Conditions Action Plan, responding quickly to the consultation on the 2024 plan. The group also heard from Lucy McKay of Medics 4 Rare Diseases and Sue Farrington who is leading the work on the development of quality standards. Two members of the group, Sue Millman of Ataxia UK and Andy Barrick of the MSA Trust led a session looking at how best to tackle the isolation experienced by people with rare conditions and sharing members experiences.

We are implementing a communications strategy that supports our wider goals, creating opportunities for representatives of member organisations and people affected by neurological conditions to work together, be heard and ensure public policy reflects the realities of living with a neurological condition. We continue to work towards fully embedding co-production into all aspects of our work, from recruitment to campaigning.

As part of this, people affected by neurological conditions and now actively involved in producing communications and providing direction, focus and feedback on our activities and campaigning in a way they have not previously been. As well as supporting the continuation of the #BackThe1in6 campaign, members of our co-production group have had a key role in both shaping the call to action behind the #NeuroChampion campaign in the run-up to the general election as well as sharing their experiences and creating resources to support the campaign itself, including emails to supporters and videos that have become some of our most viewed content on YouTube. To further embed co-production and support the roll-out of My Neuro Survey 2024, a communications action group comprised of representatives of member organisations, people affected by neurological conditions and representatives of organisations beyond the alliance is also being recruited.

Our audiences continue to grow slowly across all social media platforms upon which we are active (LinkedIn, Facebook, X (formerly Twitter) and Instagram), and the number of people who subscribe to receive our newsletter is steadily increasing. Uncertainty remains over the ongoing stability of X, as some organisations and individuals move away from the platform. X remains our largest audience in total with approximately 7,000 followers, while LinkedIn is our fastest growing audience.

This year the confidence and knowledge of our team around co-production has grown and our culture has shifted. Colleagues describe how “co-production activities feel very different from last year because everyone is thinking about co-production from the get-go now.” and how “our members have increased confidence in co-production and in the alliance as a whole, I feel, because of our greater understanding of co-production.”

The foundations for this were laid in 2021/2022 which saw the positive impact co-production had on the #BackThe1in6 campaign, and has continued to have a positive impact on all our

activities since. Our commitment to embedding involvement and genuine co-production is felt by the people we're involving too. As one member of the Back The 1 in 6 co-production group said, "We thought this would be a week or two of consultation and that would be that: we didn't expect to still be going 18 months later."

In May, we appointed an Involvement Lead who joins us two days a week as part of a joint role with member organisation MND Association. This role provides a strategic focus and helps shape our approach to involvement and deliver our involvement road map 2023-2024 to further embed lived experience and the involvement of our community in shaping our work.

Six members of our Back The 1 in 6 co-production group have continued to support our work in a number of different ways, including supporting our #NeuroChampion e-action, developing our approaches to equity, diversity and inclusion, advising on the accessibility of My Neuro Survey 2024 and planning our communications around the survey roll-out.

Alongside broadening the types of activities that have involved people with lived experience, we have also broadened the pool of people we are involving. In May we introduced an interim co-production payment policy, which has supported the involvement of people across our work, including the participation of 17 people with lived experience who had not previously engaged with us in this way. Alongside this, we are actively working to refine this policy and understand how it can be applied to its greatest effect in helping to remove barriers to participation, addressing power imbalances and valuing the diversity of knowledge and experience of the people involved in co-production.

One member of the Back The 1 in 6 co-production group said:

"I suffered a traumatic brain injury. Many neurological conditions like this are hidden. Hidden disabilities can cause the biggest problems and every day is a challenge. It's only when you start working with other people that you realise there are people with other neurological conditions, often hidden or invisible, living all over the UK and facing the same challenges as me. The Neurological Alliance is tackling these issues on a national level. Supporting them is therapeutic as you are able to put your personal, unfortunate, experiences to good use."

As we move forward, a key focus is to proactively improve the experiences of the people taking part in co-production, while measuring and evaluating the benefits to them as individuals, which might include increased knowledge, confidence and skills, an improved sense of wellbeing and a reduction in isolation, or a stronger sense of community connection.

Work has commenced (and is due to complete this year) to co-develop an involvement network, or community of people with lived experience which will allow us to listen to, engage and involve our wider community as well as provide opportunities for them to connect. Alongside this we'll refine our approach and model for involvement to make sure the lived experiences, knowledge and skills of our community are embedded meaningfully and impactfully throughout our work.

### **Goal 3: We are a strong, diverse organisation that delivers change**

"Often living with a neurological condition can make you feel you are a lone voice. It's only when you meet others in the same situation that you realise that you are not alone. Working

together makes you feel stronger. Together we are stronger and by being stronger we can bring about change.”

**Jeanie, co-production group member living with hereditary spastic paraplegia.**

We continue to recruit new members. From July 2024 to June 2024 the board approved ten applications for membership. These include British Home, CASK Research, Cure Parkinsons, Essex Neuro Network, FaceBlind, Harry’s Hydrocephalus Awareness Trust (Harry’s Hat), Headway, MS Together, NF2 Biosolutions, and Naseem’s Manx Brain Tumour Charity.

Our annual membership survey provides the chance for members to comment formally on the strengths of the alliance and to give us suggestions about what we can improve. It was notable in March 2024 that 23% of the responses came from charities representing rare conditions. As always all of our membership was represented in the survey including professional bodies (associate members), and industry supports. 84% said they felt engaged with the alliance and 94% were satisfied or very satisfied with their membership.

This year, we adjusted the question about value of membership to include the option of a neutral response following feedback on the previous year’s survey (excellent value/good value/neutral/poor). The majority of respondents (24) said the alliance represents excellent or good value (77%). Six chose the neutral option, including a reciprocal member (reciprocal members do not pay a fee).

Members say we are good at ‘representing the neuro sector and raising awareness’ and at ‘providing expertise in policy, campaigning and influencing’. Among the suggestions for improvement were people wanting more collaborations and an even greater sense of community. The last point related to the usefulness of our in-person AGM.

We continue to roll out new practices and support a working culture that embraces and celebrates equity, diversity and inclusion. In particular, we are now signed up to the Disability Confident Scheme, and have reviewed our trustee and staff recruitment practices to promote greater inclusivity.

We have sought to improve the diversification of our income, recognising pressures on both the voluntary sector and our corporate sponsors. This included recruitment of a consultant fundraiser to support this work, and this will be a continued focus in 2024/25.

“The alliance is where people affected by neurological conditions and member organisations come together to influence change for the neuro community and make a positive change towards a better future supporting their realities. I feel it is important that policies and practices support, with as much information on people’s day-to-day-experience to ensure they are getting the right care. Being a part of the co-production group allows me to influence these changes for the better, with people with neurological conditions at the heart of it.”

**Rebecca – co-production group member living with MS.**

### **3. Our structure, governance and management**

#### **3.1 Trustee selection**

We are governed by a Board of Trustees, made up of a minimum of three and a maximum of 14 people nominated by our members, recommended by our trustees and then elected by our members.

In advance of each AGM, all members are invited to send in their nominations to the board for available elected trustee posts. Details of the trustee candidates are then circulated to all members and votes are made by ballot at the AGM or sent in advance to the Chair using a proxy form; each member organisation is entitled to one vote, placed at the AGM.

After completing a three-year term, each trustee will stand down from the board. Trustees who have completed only one term may stand for re-election; those who have served two consecutive terms must stand down for one year before they may stand again for the board.

On joining the alliance board, all new trustees undertake a tailored induction programme. The trustees, who are also directors for the purpose of the Companies Act, who served during the year, are listed in section 5.1.

### **3.2 Structure**

We are a company limited by guarantee (no 02939840) and a registered charity (no 1039034). We are governed by Articles of Association and Byelaws. Our main activity is to secure the highest standards of care and treatment for every person affected by a neurological condition.

Our Board of Trustees is responsible for our governance and strategy and meets every quarter. Our Chief Executive is responsible for implementing the strategy and reports on its progress at the board meetings. The Chief Executive reports directly to and is supervised by the Chair. They speak and meet regularly to discuss alliance business.

Communication, both formal and informal, between trustees and staff is frequent and effective.

#### **3.2.1 Staff**

| <b>Name</b>     | <b>Role</b>                                                         |
|-----------------|---------------------------------------------------------------------|
| Caroline Davies | Administration and Membership Officer (From October 2019 – present) |
| Georgina Carr   | Chief Executive and Company Secretary (from January 2020 – present) |
| Jessica Mansel  | Involvement Lead (February 2022 – July 2023, May 2024 – present)    |
| Miranda Lloyd   | Communications and External Affairs Officer (March 2021 – present)  |
| Sam Mountney    | Policy and External Affairs Manager (June 2021 – present)           |

#### **3.2.2 Members**

##### **Full membership**

Full membership is open to national voluntary (non-statutory, non-profit) organisations who represent people affected by neurological conditions, including friends, families and carers. In addition to the full benefits of membership, these organisations have a right to vote at the AGM, have the right to nominate a trustee and an opportunity to influence our strategic direction. Subscriptions are income assessed.

##### **Affiliate membership**

Full affiliate membership is open to Regional Neurological Alliances operating on a non-statutory, non-profit basis. Affiliate members pay a subscription rate which is not income assessed.

### Associate membership

Associate status is open to professional associations and statutory authorities. Associate members play an active part in the alliance but do not have the right to nominate a trustee or vote at the AGM. Subscriptions are income assessed. Regional Associations of Neurological Organisations can also be associates. They are staff led groups and will pay a subscription rate which is not income assessed.

### Corporate supporter status

Corporate supporter status is open to for-profit organisations. Corporate supporters cannot vote at the AGM or nominate a trustee.

### Reciprocal membership

Reciprocal partners are normally umbrella organisations whose aims and objectives match well with those of the alliance. They cannot vote or influence our strategic direction.

### Members 2023 – 2024

| Members                             |                                                                                        |
|-------------------------------------|----------------------------------------------------------------------------------------|
| 3 Million Steps                     | <a href="http://www.3millionsteps.org">www.3millionsteps.org</a>                       |
| Alex TLC                            | <a href="http://www.alextlc.org">www.alextlc.org</a>                                   |
| Ataxia UK                           | <a href="http://www.ataxia.org.uk">www.ataxia.org.uk</a>                               |
| Autistica <sup>2</sup>              | <a href="http://www.autistica.org.uk">www.autistica.org.uk</a>                         |
| Batten Disease Family Association   | <a href="http://www.bdfa-uk.org.uk">www.bdfa-uk.org.uk</a>                             |
| Behcets UK                          | <a href="http://www.behcetsuk.org">www.behcetsuk.org</a>                               |
| The Brain and Spine Foundation      | <a href="http://www.brainandspine.org.uk">www.brainandspine.org.uk</a>                 |
| The Brain Charity                   | <a href="http://www.thebraincharity.org.uk">www.thebraincharity.org.uk</a>             |
| Brain Research UK                   | <a href="http://www.brainresearchuk.org.uk">www.brainresearchuk.org.uk</a>             |
| British Polio Fellowship            | <a href="http://www.britishpolio.org.uk">www.britishpolio.org.uk</a>                   |
| Cavernoma Alliance UK               | <a href="http://www.cavernoma.org.uk">www.cavernoma.org.uk</a>                         |
| CASK Research Foundation            | <a href="http://www.caskresearch.org">www.caskresearch.org</a>                         |
| Childhood Tumour Trust              | <a href="http://www.childhoodtumourtrust.org.uk/">www.childhoodtumourtrust.org.uk/</a> |
| Covid Aid <sup>3</sup>              | <a href="http://www.covidaidcharity.org">www.covidaidcharity.org</a>                   |
| CMT United Kingdom                  | <a href="http://www.cmt.org.uk">www.cmt.org.uk</a>                                     |
| CSF Leak                            | <a href="http://www.csfleak.uk">www.csfleak.uk</a>                                     |
| Cure Parkinson's Trust <sup>1</sup> | <a href="http://www.cureparkinsons.org.uk">www.cureparkinsons.org.uk</a>               |
| The Daisy Garland                   | <a href="http://www.thedaisygarland.org.uk">www.thedaisygarland.org.uk</a>             |
| Different Strokes                   | <a href="http://www.differentstrokes.co.uk">www.differentstrokes.co.uk</a>             |
| Downs Syndrome Research (DSRF)      | <a href="http://www.dsrf-uk.org">www.dsrf-uk.org</a>                                   |
| Dravet Syndrome UK                  | <a href="http://www.dravet.org.uk">www.dravet.org.uk</a>                               |
| Dystonia UK                         | <a href="http://www.dystonia.org.uk">www.dystonia.org.uk</a>                           |
| Epilepsy Action                     | <a href="http://www.epilepsy.org.uk">www.epilepsy.org.uk</a>                           |
| Epilepsy Research Institute UK      | <a href="https://epilepsy-institute.org.uk">https://epilepsy-institute.org.uk</a>      |
| Face Blind <sup>1</sup>             | <a href="http://www.faceblind.org.uk">www.faceblind.org.uk</a>                         |
| FD UK                               | <a href="http://www.familialdysautonomia.co.uk">www.familialdysautonomia.co.uk</a>     |
| FND Action                          | <a href="http://www.fndaction.org.uk">www.fndaction.org.uk</a>                         |
| FND Dimensions                      | <a href="http://fnddimensions.org">http://fnddimensions.org</a>                        |
| FND Hope                            | <a href="http://www.fndhope.org">www.fndhope.org</a>                                   |

|                                                                             |                                                                                                                            |
|-----------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| GAIN (Guillain-Barré and Associated Inflammatory Neuropathies)              | <a href="http://www.gaincharity.org.uk">www.gaincharity.org.uk</a>                                                         |
| Global Brain Injury Awareness                                               |                                                                                                                            |
| Glut1 Deficiency UK                                                         | <a href="http://www.glut1deficiency.org.uk">www.glut1deficiency.org.uk</a>                                                 |
| Harry's Hat <sup>1</sup>                                                    | <a href="http://www.harrys-hat.org">www.harrys-hat.org</a>                                                                 |
| Headway <sup>1</sup>                                                        | <a href="http://www.headway.org.uk">www.headway.org.uk</a>                                                                 |
| Hereditary Brain Aneurysms Support (HBA Support)                            | <a href="http://www.hbasupport.org">www.hbasupport.org</a>                                                                 |
| Hereditary Spastic Paraplegia Support Group                                 | <a href="http://www.hspgroup.org">www.hspgroup.org</a>                                                                     |
| Huntington's Disease Association                                            | <a href="http://www.hda.org.uk">www.hda.org.uk</a>                                                                         |
| IIH UK                                                                      | <a href="http://www.iih.org.uk">www.iih.org.uk</a>                                                                         |
| Intractable Epilepsy                                                        | <a href="http://www.intractable.org.uk">www.intractable.org.uk</a>                                                         |
| Matthew's Friends                                                           | <a href="http://www.matthewsfriends.org">www.matthewsfriends.org</a>                                                       |
| Migraine Trust                                                              | <a href="http://www.migrainetrust.org">www.migrainetrust.org</a>                                                           |
| Motor Neurone Disease Association                                           | <a href="http://www.mndassociation.org">www.mndassociation.org</a>                                                         |
| MS Together <sup>1</sup>                                                    | <a href="http://www.ms2gether.org">www.ms2gether.org</a>                                                                   |
| Multiple Sclerosis Society                                                  | <a href="http://www.mssociety.org.uk">www.mssociety.org.uk</a>                                                             |
| Multiple Sclerosis Trust                                                    | <a href="http://www.ms2rust.org.uk">www.ms2rust.org.uk</a>                                                                 |
| Multiple System Atrophy Trust                                               | <a href="http://www.msatrust.org.uk">www.msatrust.org.uk</a>                                                               |
| Myaware                                                                     | <a href="http://www.myaware.org">www.myaware.org</a>                                                                       |
| Myelopathy.org <sup>2</sup>                                                 | <a href="http://www.myelopathy.org">www.myelopathy.org</a>                                                                 |
| Narcolepsy UK                                                               | <a href="http://www.narcolepsy.org.uk">www.narcolepsy.org.uk</a>                                                           |
| Naseems Manx Brain Tumour Charity <sup>1</sup>                              | <a href="http://www.naseemsmanxbraintumourcharity.co.uk">www.naseemsmanxbraintumourcharity.co.uk</a>                       |
| The National Hospital for Neurology and Neurosurgery Development Foundation | <a href="http://www.nationalbrainappeal.org">www.nationalbrainappeal.org</a>                                               |
| National Tremor Foundation                                                  | <a href="http://www.tremor.org.uk">www.tremor.org.uk</a>                                                                   |
| Nerve of My MS                                                              | <a href="http://www.thenerveofmymms.org.uk">www.thenerveofmymms.org.uk</a>                                                 |
| Nerve Tumours UK                                                            | <a href="http://www.nervetumours.org.uk">www.nervetumours.org.uk</a>                                                       |
| Neuro Therapy Network                                                       | <a href="http://www.neurotherapynetwork.org.uk">www.neurotherapynetwork.org.uk</a>                                         |
| NF2 Biosolutions <sup>1</sup>                                               | <a href="http://www.nf2biosolutions.org/nf2-biosolutions-uk-europe">www.nf2biosolutions.org/nf2-biosolutions-uk-europe</a> |
| Overcoming MS                                                               | <a href="http://www.overcomingms.org">www.overcomingms.org</a>                                                             |
| Pans Pandas UK                                                              | <a href="http://www.panspandasuk.org">www.panspandasuk.org</a>                                                             |
| Parkinson's UK                                                              | <a href="http://www.parkinsons.org.uk">www.parkinsons.org.uk</a>                                                           |
| Pernicious Anaemia Society (PAS)                                            | <a href="http://www.pernicious-anaemia-society.org">www.pernicious-anaemia-society.org</a>                                 |
| Polio Survivors Network                                                     | <a href="http://www.poliosurvivorsnetwork.org.uk">www.poliosurvivorsnetwork.org.uk</a>                                     |
| PSP Association                                                             | <a href="http://www.pspassociation.org.uk">www.pspassociation.org.uk</a>                                                   |
| Restless Legs Syndrome UK <sup>1</sup>                                      | <a href="http://www.rls-uk.org">www.rls-uk.org</a>                                                                         |
| Ring 20 Research and Support UK CIO                                         | <a href="http://www.ring20researchsupport.co.uk">www.ring20researchsupport.co.uk</a>                                       |
| Shift.MS                                                                    | <a href="http://www.shift.ms">www.shift.ms</a>                                                                             |
| Spotlight YOPD                                                              | <a href="http://spotlightyopd.org">spotlightyopd.org</a>                                                                   |
| SUDEP Action                                                                | <a href="http://www.sudep.org">www.sudep.org</a>                                                                           |
| Sue Ryder <sup>2</sup>                                                      | <a href="http://www.sueryder.org">www.sueryder.org</a>                                                                     |
| Timothy Syndrome Alliance                                                   | <a href="http://www.timothysyndrome.org">www.timothysyndrome.org</a>                                                       |

|                                                                 |                                                                                                                                                                                          |
|-----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Tourettes Action                                                | <a href="http://www.tourettes-action.org.uk">www.tourettes-action.org.uk</a>                                                                                                             |
| Transverse Myelitis Society                                     | <a href="http://www.myelitis.org.uk">www.myelitis.org.uk</a>                                                                                                                             |
| Trigeminal Neuralgia Association UK                             | <a href="http://www.tna.org.uk">www.tna.org.uk</a>                                                                                                                                       |
| UK Acquired Brain Injury Forum                                  | <a href="http://www.ukabif.org.uk">www.ukabif.org.uk</a>                                                                                                                                 |
| The World-Wide Fellowship of Polio Warriors                     |                                                                                                                                                                                          |
| <b>Associates</b>                                               |                                                                                                                                                                                          |
| Association of British Neurologists (ABN)                       | <a href="http://www.theabn.org">www.theabn.org</a>                                                                                                                                       |
| Association of Chartered Physiotherapists in Neurology (ACPIN)  | <a href="http://www.acpin.net">www.acpin.net</a>                                                                                                                                         |
| British Paediatric Neurology Association (BPNA)                 | <a href="http://www.biasp.org">www.biasp.org</a>                                                                                                                                         |
| British Society of Physical and Rehabilitation Medicine (BSPRM) | <a href="http://www.bpna.org.uk">www.bpna.org.uk</a>                                                                                                                                     |
| Division of Neuropsychology (British Psychological Society)     | <a href="http://www.bps.org.uk/networks-and-communities/member-microsite/division-neuropsychology">www.bps.org.uk/networks-and-communities/member-microsite/division-neuropsychology</a> |
| The British and Irish Association of Stroke Physicians (BIASP)  | <a href="http://www.biasp.org">www.biasp.org</a>                                                                                                                                         |
| Neurology Academy                                               | <a href="http://www.in-pa.org.uk">www.in-pa.org.uk</a>                                                                                                                                   |
| Independent Neurorehabilitation Providers Alliance (INPA)       | <a href="http://www.neurologyacademy.org">www.neurologyacademy.org</a>                                                                                                                   |
| <b>Corporate supporters</b>                                     |                                                                                                                                                                                          |
| AbbVie                                                          | <a href="http://www.abbvie.co.uk">www.abbvie.co.uk</a>                                                                                                                                   |
| Angelini Pharma                                                 | <a href="http://www.angelinipharma.com">www.angelinipharma.com</a>                                                                                                                       |
| Biogen                                                          | <a href="http://www.biogen.uk.com">www.biogen.uk.com</a>                                                                                                                                 |
| Boston Scientific <sup>2</sup>                                  | <a href="http://www.bostonscientific.com">www.bostonscientific.com</a>                                                                                                                   |
| Sanofi Genzyme                                                  | <a href="http://www.genzyme.co.uk">www.genzyme.co.uk</a>                                                                                                                                 |
| Lundbeck <sup>2</sup>                                           | <a href="http://www.lundbeck.com/uk">www.lundbeck.com/uk</a>                                                                                                                             |
| Merck Serono                                                    | <a href="http://www.merckserono.co.uk">www.merckserono.co.uk</a>                                                                                                                         |
| Novartis                                                        | <a href="http://www.novartis.co.uk">www.novartis.co.uk</a>                                                                                                                               |
| Pfizer                                                          | <a href="http://www.pfizer.co.uk/science/pfizer-in-the-uk">www.pfizer.co.uk/science/pfizer-in-the-uk</a>                                                                                 |
| PTC Therapeutics <sup>2</sup>                                   | <a href="http://www.ptcbio.com">www.ptcbio.com</a>                                                                                                                                       |
| Roche                                                           | <a href="http://www.roche.com">www.roche.com</a>                                                                                                                                         |
| Sandoz                                                          | <a href="http://www.sandoz.com">www.sandoz.com</a>                                                                                                                                       |
| Teva UK Limited                                                 | <a href="http://www.tevauk.com">www.tevauk.com</a>                                                                                                                                       |
| UCB Pharma Ltd                                                  | <a href="http://www.ucb.co.uk">www.ucb.co.uk</a>                                                                                                                                         |
| <b>Affiliates</b>                                               |                                                                                                                                                                                          |
| Bolton Neuro Voices                                             | <a href="http://www.boltoncvs.org.uk">www.boltoncvs.org.uk</a>                                                                                                                           |
| Essex Neurology Network <sup>1</sup>                            | <a href="http://www.community360.org.uk/blog/essex-neurology-network">www.community360.org.uk/blog/essex-neurology-network</a>                                                           |
| Hampshire Neurological Alliance                                 | <a href="http://www.hampshireneural.org.uk/index.html">www.hampshireneural.org.uk/index.html</a>                                                                                         |

|                                                                                                  |                                                                                                |
|--------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------|
| Merseyside and Cheshire Neurological Alliance                                                    | <a href="http://www.neurosupport.org.uk">www.neurosupport.org.uk</a>                           |
| Neuro Key (formerly Tees Valley, Durham, and North Yorkshire Neurological Alliance) <sup>2</sup> | <a href="http://www.na-tvdny.org.uk">www.na-tvdny.org.uk</a>                                   |
| West Berkshire Neurological Alliance                                                             | <a href="http://www.wbna.co.uk">www.wbna.co.uk</a>                                             |
| <b>Reciprocal members</b>                                                                        |                                                                                                |
| Genetic Alliance UK                                                                              | <a href="https://geneticalliance.org.uk">https://geneticalliance.org.uk</a>                    |
| National Voices                                                                                  | <a href="https://www.nationalvoices.org.uk">https://www.nationalvoices.org.uk</a>              |
| Neurological Alliance of Ireland                                                                 | <a href="http://www.nai.ie">www.nai.ie</a>                                                     |
| Neurological Alliance of Scotland                                                                | <a href="http://www.scottishneurological.org.uk">www.scottishneurological.org.uk</a>           |
| Neurological Alliance of Wales                                                                   | <a href="http://www.walesneurologicalalliance.org.uk">www.walesneurologicalalliance.org.uk</a> |
| Northern Ireland Neurological Charities Alliance                                                 |                                                                                                |

<sup>1</sup>. New members in 2023 – 24

<sup>2</sup>. Ceased members in 2023 – 24

<sup>3</sup>. Organisation closed in 2023 – 24

### 3.2.3 The way we work

As a membership organisation, our whole ethos is to work in partnership. We work across the neurological community to identify common priorities for people affected by neurological conditions and then seek to influence, shape and support policy development to reduce inequalities, enhance their outcomes and, where possible, help them live for longer and in better health. Our activities are therefore based on a clear and shared sense of purpose. We work with the trustees, the Policy Group and Policy Steering Group to determine our strategy and plans.

### 3.2.4 The Policy Group

Any member of the alliance can be part of the Policy Group. The group's purpose is to:

- Build collective ownership of the alliance beyond staff and trustees and to promote team-working across the member organisations
- Provide a forum for policy, campaigns and public affairs staff of member organisations to share information and provide mutual support
- Feed into The Neurological Alliance policy development process
- More closely align member organisations' priorities with the collective needs of the alliance; and
- Ensure that all member organisations, large and small, can contribute to the work of the alliance.

### 3.2.5. Policy Group Leads

Charlotte Gerada

Policy and Public Affairs Manager, Huntington's Disease UK,  
Co-Chair (May 2023 – present)

Frankie Bowyer

Senior Policy Officer, MS Society, Co-Chair (November 2023 – July 2024)

### 3.3 Risk management

The trustees have assessed the major risks to which the charity is exposed and are satisfied that systems are in place to mitigate exposure to major risks. A risk management strategy, reviewed annually, is in place. We also have a risk-based reserves policy which mitigates one of our main financial risks. Accordingly, the trustees seek to ensure a minimum reserve equating to one third of the income from the highest band members and one third of the income from corporate supporters to enable them to manage and mitigate such a loss over a reasonable time period.

### 4. Public benefit

Our work benefits people affected by a neurological condition and those who represent them. Sections 1 and 2 of this report set out our objectives, report on our activities and successes, and set out our plans for the current financial year.

The trustees consider that they have complied with their duty in section 4 of the Charities Act 2011 to have due regard to the guidance on public benefit published by the Charity Commission. The trustees have considered this matter and concluded:

- That the aims of the organisation continue to be charitable
- That the aims and the work done give identifiable benefits to the charitable sector and both indirectly and directly to individuals in need
- That the benefits are for the public, are not unreasonably restricted in any way and certainly not by ability to pay
- That there is no detriment or harm arising from the aims or activities.

### 5. Reference and administrative details

The alliance is a registered charity (1039034) and company limited by guarantee (02939840) registered in England. The alliance's registered office was, from 21<sup>st</sup> September 2019, The Junction, Station Road, Watford, WD17 1ET.

#### 5.1 Trustees and the nominating organisation

|                  |                                                           |
|------------------|-----------------------------------------------------------|
| Aneeta Prem      | TNA UK (appointed Nov 2023)                               |
| Alison Fuller    | Epilepsy Action                                           |
| Amanda Swain     | UK Acquired Brain Injury Forum                            |
| Lucy Taylor      | MS Trust (appointed Nov 2023)                             |
| Cath Stanley     | Huntington's Disease Association                          |
| Chris James      | Motor Neurone Disease Association (stepped down May 2024) |
| David Martin     | MS Trust (stepped down November 2023)                     |
| Richard Evans    | Motor Neurone Disease Association (appointed May 2024)    |
| Kripen Dhrona    | British Polio Fellowship (Treasurer)                      |
| Marc Smith       | Brain and Spine Foundation (Vice-Chair)                   |
| Rob Music        | Migraine Trust                                            |
| Sarah Rawlings   | MS Society (re-appointed Nov 2023)                        |
| Victoria Wareham | Dystonia UK                                               |

During the year the board, again, co-opted three independent trustees with the aim of achieving greater diversity on the board in terms of the professional backgrounds of members. The co-opted trustees are:

|                    |                                                                             |
|--------------------|-----------------------------------------------------------------------------|
| David Garmon-Jones | Appointed February 2018, re-appointed February 2021. Stepped down May 2024  |
| Ralph Gregory      | Appointed February 2018, re-appointed February 2021. Stepped down May 2024. |
| Adine Adonis       | Appointed May 2024                                                          |
| Gideon Schulman    | Appointed May 2024                                                          |
| Mike Dilley        | Appointed May 2024                                                          |

## 5.2 Professional advisors

|                       |                                                                                                                 |
|-----------------------|-----------------------------------------------------------------------------------------------------------------|
| Bankers               | CAF Bank Ltd, PO Box 289, West Malling, Kent, ME19 4TA<br>Metro Bank PLC, One Southampton Row, London, WC1B 5HA |
| Accountants           | Godfrey Wilson, 5th Floor, Mariner House, 62 Prince Street, Bristol, BS1 4QD                                    |
| Independent Examiners | Goodman Jones LLP, 1 <sup>st</sup> Floor Arthur Stanley House, 40-50 Tottenham Street, London W1T 4RN           |

## 6. Finances

### 6.1 Investment

Article 5.1.23 empowers the Alliance, with advice from a financial expert, to invest the funds of the Alliance as it sees fit, with consideration of the the suitability of investments and the need for diversification.

### 6.2 Subscriptions

Subscription rates are determined by the organisational income of each member and associate. Subscriptions for affiliate members are at a fixed rate.

### 6.3 Reserves policy

A reserves policy was agreed by trustees during 2024. This policy is a risk-based policy, to reflect the reality that any reduction in income or increase in costs would take place over a period of time.

Having considered the risks, trustees consider it prudent that reserves should be maintained in order to cover the loss of income from one third of the significant income sources. This equates to approximately £66,000.

At the end of the year cash reserves of £106,389 were held, of which £19,075 (22/23: £4,241) were restricted. This is £40,389 above the level of reserves the trustees calculate are required.

### 6.4 Financial position

Income from membership subscriptions decreased slightly in the year to £95,885 (22/23: £95,952). In parallel, unrestricted corporate funding from Industry Reference Group members decreased from £149,225 to £132,486.

We also received generous support from Novartis, Merck, Roche, Biogen, the MS Trust and MS Society to develop a new MS Service Improvement Navigator Tool, totalling £15,000.

Overall, there is a deficit of £4,365 (before transfers) on the unrestricted funds (22/23: surplus of £38,877) and a surplus of £14,834 (before transfers) on restricted funds (22/23: deficit of £993). This leaves an overall surplus of £10,469 (22/23 surplus of £37,884) for the year.

## **6.5 Trustees' responsibilities statement**

The trustees (who are also directors of The Neurological Alliance for the purposes of company law) are responsible for preparing the trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2015 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant information of which the charitable company's independent examiner is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the independent examiner is aware of that information.

## **6.6 Independent examiners**

At the AGM in November 2023, members agreed to delegate responsibility for selecting The Neurological Alliance's Independent Examiners for the forthcoming year and 2023-2024 accounts to the Board of Trustees.

The board decided to appoint Goodman Jones LLP to be our independent examiner for 2023-24.

## **6.7 Small company provisions**

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the Board of Trustees,

*Cath Stanley*

**Cath Stanley**

**Chair, Board of Trustees      Date:** 02-12-24

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**INDEPENDENT EXAMINER'S REPORT**  
**FOR THE YEAR ENDED 30 JUNE 2024**

---

**Independent Examiner's Report to the Trustees of The Neurological Alliance ('the Charity')**

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 30 June 2024.

**Responsibilities and Basis of Report**

As the Trustees of the Charity (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

**Independent Examiner's Statement**

Since the Charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of (enter body here), which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Charity as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**INDEPENDENT EXAMINER'S REPORT (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2024**

---

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed: *Martin Bailey*

Dated: 02-12-24

**Martin Bailey FCA**  
Goodman Jones LLP  
1st Floor, Arthur Stanley House  
40-50 Tottenham Street  
London  
W1T 4RN

**THE NEUROLOGICAL ALLIANCE**  
(A Company Limited by Guarantee)

**STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)  
FOR THE YEAR ENDED 30 JUNE 2024**

|                                    | Note | Unrestricted<br>funds<br>2024<br>£ | Restricted<br>funds<br>2024<br>£ | Total<br>funds<br>2024<br>£ | Total<br>funds<br>2023<br>£ |
|------------------------------------|------|------------------------------------|----------------------------------|-----------------------------|-----------------------------|
| <b>Income from:</b>                |      |                                    |                                  |                             |                             |
| Donations and legacies             | 4    | 301                                | -                                | 301                         | 1,166                       |
| Charitable activities              | 5    | 241,910                            | 24,860                           | 266,770                     | 302,723                     |
| Investments                        | 6    | 1,747                              | -                                | 1,747                       | 770                         |
| <b>Total income</b>                |      | <b>243,958</b>                     | <b>24,860</b>                    | <b>268,818</b>              | <b>304,659</b>              |
| <b>Expenditure on:</b>             |      |                                    |                                  |                             |                             |
| Raising funds                      |      | 5,635                              | -                                | 5,635                       | -                           |
| Charitable activities              | 7    | 242,688                            | 10,026                           | 252,714                     | 266,775                     |
| <b>Total expenditure</b>           |      | <b>248,323</b>                     | <b>10,026</b>                    | <b>258,349</b>              | <b>266,775</b>              |
| <b>Net movement in funds</b>       |      | <b>(4,365)</b>                     | <b>14,834</b>                    | <b>10,469</b>               | <b>37,884</b>               |
| <b>Reconciliation of funds:</b>    |      |                                    |                                  |                             |                             |
| Total funds brought forward        |      | 91,679                             | 4,241                            | 95,920                      | 58,036                      |
| Net movement in funds              |      | (4,365)                            | 14,834                           | 10,469                      | 37,884                      |
| <b>Total funds carried forward</b> |      | <b>87,314</b>                      | <b>19,075</b>                    | <b>106,389</b>              | <b>95,920</b>               |

The Statement of Financial Activities includes all gains and losses recognised in the year.

The notes on pages 23 to 33 form part of these financial statements.

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**  
**REGISTERED NUMBER: 02939840**

**BALANCE SHEET**  
**AS AT 30 JUNE 2024**

|                                                | Note | 2024<br>£             | 2023<br>£            |
|------------------------------------------------|------|-----------------------|----------------------|
| <b>Fixed assets</b>                            |      |                       |                      |
|                                                |      | -                     | -                    |
| <b>Current assets</b>                          |      |                       |                      |
| Debtors                                        | 11   | 53,258                | 27,040               |
| Cash at bank and in hand                       |      | 64,306                | 76,836               |
|                                                |      | <u>117,564</u>        | <u>103,876</u>       |
| Creditors: amounts falling due within one year | 12   | (11,175)              | (7,956)              |
| <b>Net current assets</b>                      |      | <u>106,389</u>        | <u>95,920</u>        |
| <b>Total net assets</b>                        |      | <u><u>106,389</u></u> | <u><u>95,920</u></u> |
| <b>Charity funds</b>                           |      |                       |                      |
| Restricted funds                               | 13   | 19,075                | 4,241                |
| Unrestricted funds                             | 13   | 87,314                | 91,679               |
| <b>Total funds</b>                             |      | <u><u>106,389</u></u> | <u><u>95,920</u></u> |

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

*Cath Stanley*  
 .....  
**Cath Stanley**  
 Chair of Trustees

Date: 02-12-24

The notes on pages 23 to 33 form part of these financial statements.

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2024**

---

**1. General information**

The Neurological Alliance is a registered charity and company limited by guarantee. Its charitable objects are set out in the Trustees' Report. Its registered office address is The Junction, Station Road, Watford, WD17 1EU.

**2. Accounting policies**

**2.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The financial statements are prepared on the going concern basis under the historical cost convention, modified to include certain items at fair value. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are presented in Sterling which is the functional currency of the Charity and monetary amounts are rounded to the nearest £.

The Neurological Alliance meets the definition of a public benefit entity under FRS 102.

**2.2 Company status**

The Charity is a company limited by guarantee. The members of the company are the Trustees named in the Trustee report section 5.1. In the event of the Charity being wound up, the liability in respect of the guarantee is limited to £10 per member of the Charity.

**2.3 Going concern**

The Trustees have assessed whether the use of the going concern assumption is appropriate in preparing these accounts and are of the opinion that the Charity will have sufficient resources to meet its liabilities as they fall due. The Trustees have made this assessment in respect of a period of one year from the date of approval of these accounts. The Trustees of the Charity have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the Charity to continue as a going concern.

**2.4 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2024**

---

**2. Accounting policies (continued)**

**2.5 Income**

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received, and the amount of income receivable can be measured reliably.

The following specific policies are applied to particular categories of income:

Subscription income is invoiced in line with the financial year and recognised in the period to which it relates.

Corporate support represents amounts invoiced in the year.

Donated services or facilities are recognised when the Charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the Charity of the item is probable and that economic benefit can be measured reliably. On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the Charity which is the amount the Charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

**2.6 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the Bank.

**2.7 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Expenditure on raising funds includes all expenditure incurred by the Charity to raise funds for its charitable purposes and includes costs of all fundraising activities events and non-charitable trading.

Support costs are those costs incurred directly in support of expenditure on the objects of the Charity. Governance costs are those incurred in connection with administration of the Charity and compliance with constitutional and statutory requirements.

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2024**

---

**2. Accounting policies (continued)**

**2.7 Expenditure (continued)**

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds. All expenditure is inclusive of irrecoverable VAT.

**2.8 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**2.9 Cash at Bank and in hand**

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

**2.10 Liabilities and Provision**

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

**2.11 Operating Leases**

Rentals under operating leases are charged to the Statement of Financial Activities incorporating Income and Expenditure Account on a straight-line basis over the lease term.

**2.12 Pensions**

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2024**

**3. Critical accounting estimates and areas of judgement**

In the application of the Charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

In the opinion of the Trustees, there are no significant areas of estimation, uncertainty and critical judgements in applying accounting policies that have significant effect on the amounts recognised in the financial statements.

**4. Income from donations and legacies**

|                   | <b>Unrestricted<br/>funds<br/>2024<br/>£</b> | <b>Total<br/>funds<br/>2024<br/>£</b> | <i>Total<br/>funds<br/>2023<br/>£</i> |
|-------------------|----------------------------------------------|---------------------------------------|---------------------------------------|
| Donations         | 301                                          | <b>301</b>                            | 1,166                                 |
|                   | <u>          </u>                            | <u>          </u>                     | <u>          </u>                     |
| <i>Total 2023</i> | <u>1,166</u>                                 | <u>1,166</u>                          |                                       |

**5. Income from charitable activities**

|                   | <b>Unrestricted<br/>funds<br/>2024<br/>£</b> | <b>Restricted<br/>funds<br/>2024<br/>£</b> | <b>Total<br/>funds<br/>2024<br/>£</b> | <i>Total<br/>funds<br/>2023<br/>£</i> |
|-------------------|----------------------------------------------|--------------------------------------------|---------------------------------------|---------------------------------------|
| Corporate support | 133,319                                      | -                                          | <b>133,319</b>                        | 171,226                               |
| Subscriptions     | 95,885                                       | -                                          | <b>95,885</b>                         | 95,952                                |
| Projects          | 12,706                                       | 24,860                                     | <b>37,566</b>                         | 35,545                                |
|                   | <u>241,910</u>                               | <u>24,860</u>                              | <u><b>266,770</b></u>                 | <u>302,723</u>                        |
| <i>Total 2023</i> | <u>267,178</u>                               | <u>35,545</u>                              | <u>302,723</u>                        |                                       |

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2024**

---

**6. Investment income**

|                   | <b>Unrestricted<br/>funds<br/>2024<br/>£</b> | <b>Total<br/>funds<br/>2024<br/>£</b> | <i>Total<br/>funds<br/>2023<br/>£</i> |
|-------------------|----------------------------------------------|---------------------------------------|---------------------------------------|
| Interest income   | 1,747                                        | <b>1,747</b>                          | 770                                   |
|                   |                                              |                                       |                                       |
| <i>Total 2023</i> | 770                                          | 770                                   |                                       |

**7. Analysis of expenditure on charitable activities**

**Summary by fund type**

|                    | <b>Unrestricted<br/>funds<br/>2024<br/>£</b> | <b>Restricted<br/>funds<br/>2024<br/>£</b> | <b>Total<br/>2024<br/>£</b> | <i>Total<br/>2023<br/>£</i> |
|--------------------|----------------------------------------------|--------------------------------------------|-----------------------------|-----------------------------|
| Policy Development | 59,857                                       | 1,174                                      | <b>61,031</b>               | 78,278                      |
| Members Activities | 182,831                                      | 8,852                                      | <b>191,683</b>              | 188,497                     |
|                    |                                              |                                            |                             |                             |
|                    | 242,688                                      | 10,026                                     | <b>252,714</b>              | 266,775                     |
|                    |                                              |                                            |                             |                             |
| <i>Total 2023</i>  | 230,237                                      | 36,538                                     | 266,775                     |                             |

**THE NEUROLOGICAL ALLIANCE**  
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2024**

**8. Analysis of expenditure by activities**

|                    | <b>Activities<br/>undertaken<br/>directly<br/>2024<br/>£</b> | <b>Support<br/>costs<br/>2024<br/>£</b> | <b>Total<br/>funds<br/>2024<br/>£</b> | <i>Total<br/>funds<br/>2023<br/>£</i> |
|--------------------|--------------------------------------------------------------|-----------------------------------------|---------------------------------------|---------------------------------------|
| Policy Development | 32,479                                                       | 28,552                                  | <b>61,031</b>                         | 78,278                                |
| Members Activities | 188,034                                                      | 3,649                                   | <b>191,683</b>                        | 188,497                               |
|                    | <u>220,513</u>                                               | <u>32,201</u>                           | <u><b>252,714</b></u>                 | <u>266,775</u>                        |
| <i>Total 2023</i>  | <u><u>238,411</u></u>                                        | <u><u>28,364</u></u>                    | <u><u>266,775</u></u>                 |                                       |

**9. Staff costs**

|                                                      | <b>2024<br/>£</b>     | <i>2023<br/>£</i> |
|------------------------------------------------------|-----------------------|-------------------|
| Wages and salaries                                   | <b>151,982</b>        | 156,847           |
| Social security costs                                | <b>9,932</b>          | 10,725            |
| Contribution to defined contribution pension schemes | <b>9,052</b>          | 8,847             |
|                                                      | <u><b>170,966</b></u> | <u>176,419</u>    |

The average number of persons employed by the Charity during the year was as follows:

|           | <b>2024<br/>No.</b> | <i>2023<br/>No.</i> |
|-----------|---------------------|---------------------|
| Employees | <u><b>4</b></u>     | <u>5</u>            |

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

|                               | <b>2024<br/>No.</b> | <i>2023<br/>No.</i> |
|-------------------------------|---------------------|---------------------|
| In the band £60,001 - £70,000 | <b>1</b>            | 1                   |

Key management personnel remuneration, including employer's NIC and pension contributions, incurred by the Charity in the year totalled £79,996 (2023: £77,193).

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2024**

---

**10. Trustees' remuneration and expenses**

During the year, no Trustees received any remuneration or other benefits (2023 - £NIL).

During the year ended 30 June 2024, expenses totalling £NIL were reimbursed or paid directly to Trustee (2023 - £NIL to Trustee).

**11. Debtors**

|                                | 2024<br>£     | 2023<br>£     |
|--------------------------------|---------------|---------------|
| <b>Due within one year</b>     |               |               |
| Other debtors                  | 18,443        | 11,661        |
| Prepayments and accrued income | 34,815        | 15,379        |
|                                | <u>53,258</u> | <u>27,040</u> |

**12. Creditors: Amounts falling due within one year**

|                                    | 2024<br>£     | 2023<br>£    |
|------------------------------------|---------------|--------------|
| Trade creditors                    | 6,890         | 3,430        |
| Other taxation and social security | 2,763         | -            |
| Other creditors                    | 1,172         | 456          |
| Accruals and deferred income       | 350           | 4,070        |
|                                    | <u>11,175</u> | <u>7,956</u> |

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2024**

---

**13. Statement of funds**

**Statement of funds - current year**

|                           | Balance at 1<br>July 2023<br>£ | Income<br>£    | Expenditure<br>£ | Balance at<br>30 June<br>2024<br>£ |
|---------------------------|--------------------------------|----------------|------------------|------------------------------------|
| <b>Unrestricted funds</b> |                                |                |                  |                                    |
| General Funds - all funds | 91,679                         | 243,958        | (248,323)        | 87,314                             |
|                           |                                |                |                  |                                    |
| <b>Restricted funds</b>   |                                |                |                  |                                    |
| NNAG Pathways             | 719                            | -              | -                | 719                                |
| Epilepsy Tool             | 1,020                          | 15,000         | -                | 16,020                             |
| Neurolifenow              | 2,500                          | 9,860          | (10,026)         | 2,334                              |
| Outpatient Transformation | 2                              | -              | -                | 2                                  |
|                           | 4,241                          | 24,860         | (10,026)         | 19,075                             |
|                           |                                |                |                  |                                    |
| <b>Total funds</b>        | <b>95,920</b>                  | <b>268,818</b> | <b>(258,349)</b> | <b>106,389</b>                     |

**THE NEUROLOGICAL ALLIANCE**  
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2024**

**13. Statement of funds (continued)**

**Statement of funds - prior year**

|                           | <i>Balance at<br/>1 July 2022<br/>£</i> | <i>Income<br/>£</i> | <i>Expenditure<br/>£</i> | <i>Balance at<br/>30 June<br/>2023<br/>£</i> |
|---------------------------|-----------------------------------------|---------------------|--------------------------|----------------------------------------------|
| <b>Unrestricted funds</b> |                                         |                     |                          |                                              |
| General Funds - all funds | 52,802                                  | 269,114             | (230,237)                | 91,679                                       |
| <b>Restricted funds</b>   |                                         |                     |                          |                                              |
| NNAG Pathways             | 5,234                                   | -                   | (4,515)                  | 719                                          |
| Epilepsy Tool             | -                                       | 9,015               | (7,995)                  | 1,020                                        |
| Neurolifenow              | -                                       | 12,500              | (10,000)                 | 2,500                                        |
| Outpatient Transformation | -                                       | 14,030              | (14,028)                 | 2                                            |
|                           | 5,234                                   | 35,545              | (36,538)                 | 4,241                                        |
| <b>Total funds</b>        | 58,036                                  | 304,659             | (266,775)                | 95,920                                       |

Restricted funds represent the following:

NNAG Pathways - events and activities to support the development of an epilepsy pathway.

Neurolifenow - funds received for a real-time survey which aims to provide routine patient experience data to support service improvement and positive public policy change.

Epilepsy Navigator Tool - a tool developed to provide a range of resources to support service development.

Outpatient Transformation - funds to provide improvements to outpatient services and resources.

**THE NEUROLOGICAL ALLIANCE**  
(A Company Limited by Guarantee)

**NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2024**

**14. Analysis of net assets between funds**

**Analysis of net assets between funds - current period**

|                               | <b>Unrestricted<br/>funds<br/>2024<br/>£</b> | <b>Restricted<br/>funds<br/>2024<br/>£</b> | <b>Total<br/>funds<br/>2024<br/>£</b> |
|-------------------------------|----------------------------------------------|--------------------------------------------|---------------------------------------|
| Current assets                | 98,489                                       | 19,075                                     | <b>117,564</b>                        |
| Creditors due within one year | (11,175)                                     | -                                          | <b>(11,175)</b>                       |
| <b>Total</b>                  | <b>87,314</b>                                | <b>19,075</b>                              | <b>106,389</b>                        |

**Analysis of net assets between funds - prior period**

|                               | <i>Unrestricted<br/>funds<br/>2023<br/>£</i> | <i>Restricted<br/>funds<br/>2023<br/>£</i> | <i>Total<br/>funds<br/>2023<br/>£</i> |
|-------------------------------|----------------------------------------------|--------------------------------------------|---------------------------------------|
| Current assets                | 99,635                                       | 4,241                                      | 103,876                               |
| Creditors due within one year | (7,956)                                      | -                                          | (7,956)                               |
| <b>Total</b>                  | <b>91,679</b>                                | <b>4,241</b>                               | <b>95,920</b>                         |

**15. Pension commitments**

The Charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Charity in an independently administered fund. The pension cost charge represents contributions payable by the Charity to the fund and amounted to £9,052 (2023 - £8,847).

Contributions totalling £1,172 (2023 - £456) were payable to the fund at the balance sheet date and are included in creditors.

**16. Operating lease commitments**

At 30 June 2024 the Charity had commitments to make future minimum lease payments under non-cancellable operating leases as follows:

|                       | <b>2024<br/>£</b> | <b>2023<br/>£</b> |
|-----------------------|-------------------|-------------------|
| Not later than 1 year | -                 | 9,000             |

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2024**

---

**17. Related party transactions**

Other than disclosed elsewhere in these financial statements, there were no related party transactions requiring disclosure during the current or previous year

---

# Accounts

---

**COMPANY REGISTRATION NUMBER 02939840**



**THE  
NEUROLOGICAL  
ALLIANCE**

**THE NEUROLOGICAL ALLIANCE**

**(LIMITED BY GUARANTEE)**

**FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED**

**30 JUNE 2023**

**Charity Number 103903**

---

**THE NEUROLOGICAL ALLIANCE**  
**TRUSTEE ANNUAL REPORT**  
**LETTER FROM THE CHAIR**

This annual report bears witness to the big strides we have taken that have shaped our path this past year.

Against the backdrop of a world that continues to grapple with uncertainties, the spirit and resilience of our community has shone brighter than ever. At the core of this lies a fundamental shift – the increased involvement of people affected by neurological conditions in our endeavours. This transformation has enriched our work and made us more effective and influential in advocating for the change our community deserves.

We now have more than 100 members. Over a dozen organisations joined us in 2022-23. This is the biggest increase in membership in our near 30-year history and stands as a testament to the resonance of our mission and the trust placed in us by individuals and organisations alike.

The increase in the number of people on NHS waiting lists in England, continued pressures on our health and care workforce and increases in the cost of living serve as a stark reminder of the urgency of our mission. The commitment we make today is not merely to challenge numbers or statistics, but to highlight the lives that lie behind them. It is a commitment to transform pathways of access, to seek out and highlight timely interventions, and to replace uncertainty with hope.

More than 100 organisations and 19,000 people have come together this year to call for urgent action to support the 1 in 6 across the country who live with a neurological condition. Despite a hugely challenging external environment, we have generated much needed momentum for positive change. As a general election looms, we must capitalise on this and ensure the neurological community is heard by candidates and political parties alike.

Our compass remains guided by the principle that each individual's journey is unique and deserving of dignity and support. Through collaboration with like-minded organisations, we are determined to increase our impact and to ensure that the voices of those affected by neurological conditions resonate far and wide.

This annual report is a snapshot of our collective efforts. As you delve into its pages, I invite you not only to see the numbers and achievements but to feel the pulse of a community bound by compassion, united by purpose, and driven by the shared vision of a brighter, more inclusive future.

**David Martin, Chair, The Neurological Alliance**

**THE NEUROLOGICAL ALLIANCE**  
**ANNUAL REPORT AND ACCOUNTS**  
**YEAR ENDED JUNE 2023**

**REFERENCE AND ADMINISTRATIVE DETAILS**

|                                    |                           |
|------------------------------------|---------------------------|
| <b>Registered charity name</b>     | The Neurological Alliance |
| <b>Charity registration number</b> | 1039034                   |
| <b>Company registration number</b> | 02939840                  |

|                          |                                                                                 |
|--------------------------|---------------------------------------------------------------------------------|
| <b>Registered office</b> | The Junction<br>Station Road<br>Watford<br>Hertfordshire<br>WD17 1EU<br>Watford |
|--------------------------|---------------------------------------------------------------------------------|

|                             |                                                                                                              |
|-----------------------------|--------------------------------------------------------------------------------------------------------------|
| <b>Independent Examiner</b> | Martin Bailey FCA<br>Goodman Jones LLP<br>Chartered Accountants<br>29-30 Fitzroy Square<br>London<br>W1T 6LQ |
|-----------------------------|--------------------------------------------------------------------------------------------------------------|

|                    |                                                                                      |
|--------------------|--------------------------------------------------------------------------------------|
| <b>Accountants</b> | Godfrey Wilson<br>5th Floor, Mariner House<br>62 Prince Street<br>Bristol<br>BS1 4QD |
|--------------------|--------------------------------------------------------------------------------------|

---

**Bankers**

CAF Bank Ltd

25 Kings Hill Avenue

Kings Hill

West Malling

Kent

ME19 4JQ

Metro Bank PLC

One Southampton Row

London

WC1B 5HA

The trustees present their report and independently examined financial statements for The Neurological Alliance for the year 1 July 2022 to 30 June 2023. The report and financial statements have been prepared in accordance with the Companies Act 2006 and the Charities Act 2011. The trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) effective January 2019 in preparing the report and financial statements. The report and financial statements will be laid before the members of the charity at the Annual General Meeting to be held on 22 November 2023. In preparation of this report, the trustees had regard for the Charity Commission guidance on public benefit.

## **1. Our objects**

Our principal objectives, as derived from the objects set out in our Articles of Association, are to advance the education of the public in all matters concerning neurological disorders by carrying out research and investigation into preventative procedures, treatment and the needs and care of persons affected by neurological conditions, and publishing the useful results thereof, and the relief of those persons in the United Kingdom of Great Britain and Northern Ireland who are receiving or have received treatment for neurological conditions.

We are the only collective voice for over 100 national charities, professional bodies, regional organisations and corporate organisations working together to transform treatment, care and support for people affected by neurological conditions.

## **2. What we set out to do in 2022-23**

Our mission is to raise awareness and understanding of neurological conditions to ensure that every person diagnosed with a neurological condition has access to high quality, joined up services and information from their first symptoms, throughout their life.

We conducted a thorough review of our organisational strategy in 2022. Our new strategy, "Together for the 1 in 6: Our strategy to deliver change 2022 - 2027" was developed using insight from people affected by neurological conditions, our membership and the wider external environment. It was clear that our direction of travel was broadly correct. However, we needed to be more bold in our ambition, and deepen the involvement of people affected by neurological conditions throughout our work.

Our revised vision, mission and strategic goals are as follows:

- Vision: Every person affected by a neurological condition can access the right treatment, care and support at the right time.
- Mission: To harness the energy and passion of the neurological community to ensure public policy in health reflects the realities of living with a neurological condition, so that everyone can access treatment, care and support whenever they need it.

Our goals:

1. Public policy and practice reflects and supports the realities of living with a neurological condition
2. People affected by neurological conditions and our members are heard and have influence
3. We are a strong, diverse organisation that delivers change

Our values:

- **Bold:** We will not hesitate to speak truth to power, rooted in the experiences of people with neurological conditions.
- **United:** We unleash the power of our collective community.
- **Inclusive:** We listen to and celebrate the diversity of the neurological community. We work with anyone who shares our vision.
- **Leading:** We are the voice on issues relating to access and experience of healthcare for people with neurological conditions.
- **Expert:** We deliver evidence that changes minds and policy.

The Annual Report of the Trustees for 2022/23 is set out under our three strategic goals:

### **Goal 1: Public policy and practice reflects and supports the realities of living with a neurological condition**

In an incredibly changeable and challenging external environment, we have managed to secure much needed momentum to improve services for people affected by neurological conditions.

We successfully co-ordinated a [joint letter](#) to the Secretary of State for Health and Social Care, Steve Barclay, supported by 44 member organisations, calling for the inclusion of neurological conditions in the scope of the proposed Major Conditions Strategy. Influencing activities around the strategy continued with a [news piece](#) on the announcement of the call for evidence, and our [response](#). We also met with the Major Conditions Strategy team from the Department of Health and Social Care, sharing a briefing paper and securing engagement events with members and people affected by neurological conditions. These are going ahead in Autumn 2023.

We responded to the call for evidence for the Hewitt Review and separately, the Health and Social Care Committee inquiry on Integrated Care Systems. Our Chief Executive was invited to join the Hewitt Review workstreams into data and digital. Upon publication of the two reports, we summarised our responses, report outcomes and next steps in an online news story.

We have worked with NHS England to help steer the neuroscience transformation review. The review recognises two areas of neuroscience (neurology and neurosurgery) as two specialties in need of improvement, particularly given the forthcoming delegation of specialised commissioning responsibilities to a local level. The transformation programme will set out a new model of commissioning (within and between Integrated Care Systems and the national NHS England specialised commissioning team), with a view to providing improved, co-ordinated care. The National Clinical Directors for neurosurgery and spinal surgery, and neurology, are leading the review. Our Chief Executive is a member of the NHS England Neuroscience Transformation Programme Board.

In parallel, we have continued to hold a national role on the NHS England Clinical Reference Group (CRG) for neurology. The group advises NHS England on clinical policy, commissioning policy and guidance and service specification development. As a member of this group, we have supported greater involvement of people affected by neurological

conditions within discussions and sought to ensure public policy reflects the realities of living with a neurological condition.

The Acquired Brain Injury (ABI) Strategy, which was successfully secured by charities and individuals from across the brain injury community, represents an important opportunity for change. The strategy applies across the UK, and we have played an active role in the Public and Patient Voice Group for the Strategy. The Strategy is likely to be published in 2024.

We continued to work closely with clinicians and members to develop optimal pathways for a range of neurological conditions. Five pathways (on functional neurological disorders, movement disorders, headache and facial pain, motor neurone disease and traumatic brain injury) have now been published and shared across the neurological community. They set out what good care should look and feel like and have been endorsed by a range of organisations. Our huge thanks to every clinician, person affected by a neurological condition and organisation, who has taken the time to provide input into the pathways and share them with their networks.

We also developed a new 'Service Improvement Navigator' tool for epilepsy. The tool, which was developed following interviews with people affected by epilepsy, Regional Neurological Alliances and clinicians, includes a range of resources to support service development. The tool has been warmly received by commissioners and providers, and we intend to develop new tools for a range of conditions in the future. Our thanks to UCB for sponsoring this project.

Finally, we have been working with our Mental Health Group and mental health specialists to develop research into the contractual barriers to mental health support for people affected by neurological conditions. This work will form an important basis of the Mental Health Group's agenda in 23/24.

## **Goal 2: People affected by neurological conditions and our members are heard and have influence**

The #BackThe1in6 campaign, calling for a UK-wide Neuro Taskforce, was supported by over 100 organisations and more than 19,000 people through our e-petition. It is our largest public facing campaign to date. The petition was handed into the Department of Health and Social Care on 5 June 2023 together with members of our Co-production Group. Its receipt was confirmed by the Minister of State, Helen Whately MP, in response to a [written Parliamentary Question](#).

To coincide with the petition hand-in, we organised a parliamentary drop-in event to engage with MPs on the campaign and calls for a UK Neuro Taskforce. A campaigner e-action was developed, leading to over 1,400 people inviting their MP to attend the drop-in. 22 MPs were represented at the event including members from all main political parties – the highest number of MPs to attend a Neurological Alliance event to date.

The #BackThe1in6 campaign has been shaped and steered by The Neurological Alliance co-production group. Members of the group live with one or more neurological conditions and live in different parts of the UK. The group brings together people of different ages, backgrounds and ethnicities. All have personal experiences of the daily challenges of living with different neurological conditions. Members of the group have been meeting weekly online since its inception in March 2022, and all are passionate about ensuring that the governments of all four nations in the UK commit to forming a Neuro Taskforce to create a seamless, appropriate and adequate health and care service, for life, for the millions of people living with a neurological condition in the UK and their families.

The group have used their expertise and insight to create campaign messages and blogs, decide the look and feel of the hand-in and drop-in events, and work together to design a collective video artwork that was displayed in Parliament and T-shirts containing unique personal messages highlighting the need for a UK-wide Neuro Taskforce. The group have kindly pulled together a note on their experiences this past year, which is below.

### **A note from the Co-production Group**

Being involved in the Co-production Group has opened different doors.

It's been an opportunity to engage with some of the member organisations from the Alliance, it's opened doors in places I wouldn't have had the opportunity to go if I hadn't been involved in the Co-production Group. It's led to other opportunities around different aspects of my condition and the brain tumour.

We all became involved in the Co-production group in different ways – some of us can't remember how! Rhys and Jeanie became involved after completing My Neuro Survey and ticking the box that said we were happy to stay in contact. Jeanette was recruited through the Northern Ireland Neurological Charities Alliance. Rebecca came to the group through Alliance member charity, the MS Society, and Trishna saw an advert on The Neurological Alliance website. As part of the Co-production Group, we've all been involved in shaping the Back the 1 in 6 campaign and related activities, including the petition hand-in and campaign materials.

We all have varying levels of experience of co-production too. Debbie says she jumped at the chance to make a valuable contribution to the whole neurological community, as well as for acquired brain injury survivors like her. Some of us are quite surprised to still be involved 18 months later! We thought it would be a week or two project, which would be a bit of consultation on our opinion and then the Alliance would go away and do its own thing.

But this is what we like about the Co-production Group: it's a proactive group. It's not lipservice. It's not a tick box exercise. Often, people are just looking to tick the box that says "we must speak to people with lived experience" rather than actively engaging with them.

This is not the case with our Co-production Group – we've become part of the group and we've been able to influence the work of the Alliance, particularly the #BackThe1in6 campaign. That's been the big benefit. Co-production has meant co-production.

It was exciting to work together because it was a new way of working. We got to work together with other people with personal experience of a range of different neurological conditions. We learned new things. It's rewarding because the whole co-production group shared knowledge, ideas, tips and experience. We were flying high and combining the hard work and enthusiasm of people from across the UK. We are all quietly enthusiastic.

Putting this together we were all asked to pick one thing that was best about working in the co-production group and that's really hard because it's given us each a range of new experiences. We've enjoyed the friendships that have developed, even though we are sometimes hundreds of miles apart. You get to know each other and it's nice to see each other on Zoom.

The Co-production Group has highlighted how important it is to speak to people living with neurological conditions. It can't just be doctors and politicians trying to do their jobs: you need to have people with neurological conditions involved shaping campaigns, services and healthcare that is meant for them. It's been really beneficial to have conversations with other people with neurological conditions, even though our neurological conditions are different and are symptoms might be different there is a commonality with all of us, and we've learned about what different things might affect different parts of the neurological community and

established common ground between us. We all seem to have a struggle one way or another with health services. And often it's because they think they know what we want but often they've never asked, and they've not communicated. It's not patient-centred and this needs to change.

The Co-production Group has been really useful in helping us realise that you are not battling alone as a person with a neurological condition. You can be very isolated and on your own and because of that you think you're making a big deal of something, and perhaps you are the only one with the problem and perhaps you're being a bit over-the-top or paranoid, but in actual fact what working in the Co-production Group has shown is that we've all got a valid claim to have good, holistic and cohesive support.

We married everything together and came together as one voice. We all have different conditions, but as the Co-production Group, we were able to come together as one and say, "We all need this". We are being listened to. Co-production makes you feel more comfortable about talking about your experiences and sharing. So, then you get a little more clarity on how to explain it to others when you need to and how to say, "this is how I feel, this is what I need" and getting other people to listen to those things. Co-production has been about driving things in the direction you want to see them go in – for yourself and others, and the care they need – and having some change happen.

Over a dozen parliamentary questions discussing neurological conditions have been tabled since the #Backthe1in6 petition was handed in and further support has been garnered for a pan-neuro debate application.

Working with an external PR agency, we secured 26 pieces of media coverage for the campaign to coincide with the petition hand-in – 17 online articles, 8 print and 1 radio item. Coverage included BBC regional radio and leading regional titles including The Yorkshire Post and Express and Star.

The #BackThe1in6 petition link has been shared hundreds of times by member organisations, reaching thousands of people across Facebook, Twitter (X), LinkedIn, and Instagram. Over 300 people sent in their pictures to be part of the collective mosaic artwork that was displayed in Parliament on 5 June, which has been viewed over 5,000 times to date on Twitter (X) alone.

We delivered a varied and engaging series of member meetings this year. Policy Group highlights included a panel discussion on the needs of the neuroscience workforce with professional bodies and a session unpacking what NHS reform in England means for neuroscience services and those who use them.

We were delighted to welcome Charlotte Gerada, Policy and Public Affairs Manager at the Huntington's Disease Association as our incoming Policy Group Chair. Our thanks go to our former co-chairs Sam Freeman-Carney and Dawn Golder for their leadership and support of the group during their terms.

The Rare Conditions group continued to meet, discussing the England Rare Conditions Action Plan with colleagues from the Department of Health and Social Care and hearing from Rare Minds about mental health support for people affected by rare neurological conditions. Mental Health Group highlights included developing our response to the Government's 10-year Mental Health and Wellbeing Plan Consultation. We also welcomed Prof. Hugh Rickards, Neuropsychiatrist, to the group to discuss common barriers to mental health support for people affected by neurological conditions. More broadly, the Group have continued to engage with our joint research project on identifying contractual or commissioning barriers to accessing mental health services.

The Alliance hosted quarterly meetings for CEOs and Chairs of Regional Neurological Alliances to join together for peer support and to discuss their challenges and successes and to share experiences. Thanks to Kripen Dhrona, Alliance trustee and CEO of the British Polio Fellowship for chairing these meetings. Members of the group valued the peer support and in the evaluation. At the June 2023 meeting CEOs heard from the National Clinical Director for Neurology, Dr Niran Nirmalanathan, who reflected on six months in the role. He stressed that collaboration across condition areas was vital to avoid the fragmentation of our voices.

We have continued to work closely with the Brain and Spine Foundation to deliver NeuroLifeNow, a real-time survey which aims to provide routine patient experience data to support service improvement and positive public policy change. To date, more than 4,000 people have shared their experiences through the platform. We worked with the Brain and Spine Foundation to give new resources to our membership to promote the platform, including a webinar attended by a range of organisations, held in March 2023. Together, the NeuroLifeNow team published seven new reports in 2022-2023.

Finally, experiences shared through My Neuro Survey continue to have a significant impact. We have shared the data at no less than a dozen professional conferences and continue to receive requests for Integrated Care System level data from commissioners and providers alike. Our thoughts are now turning to the next iteration of the survey, which will be conducted in 2024.

### **Goal 3: We are a strong, diverse organisation that delivers change**

We are nothing without our members, and 2022/23 was a year of significant growth. More than 100 members from across the neurological community are now part of the Alliance network.

From July 2022-June 2023 the Board approved 17 applications for membership. Members who have joined the Alliance include Alex-The Leukodystrophy Charity, Behcets UK, the Brain Charity, CSF Leak, FND Dimensions, Hereditary Brain Aneurysms Support (HBA Support), Intractable Epilepsy, Pans Pandas UK, Shift MS, the Timothy Syndrome Alliance (TSA), and 3 Million Steps. We were pleased to welcome back the Pernicious Anaemia Society and to agree reciprocal arrangements with the Genetic Alliance and the Northern Ireland Neurological Charities Alliance (niNCA).

Our annual membership survey provides the chance for members to comment formally on the strengths of the Alliance and to give us critical comments on what can be improved. In 2023 97% of respondents said the Alliance represents good or excellent value for money. 93% agree we are a strong national voice and 87% said we provide effective forums for collaboration. Nearly three quarters felt that they were listened to by the Alliance – that's why we will focus on improving dialogue across our membership, to ensure that members, no matter their interest or size, are able to influence our work to an even greater extent in the coming year.

We were pleased to join the Disability Confident scheme this year, as part of our wider commitment to inclusivity and diversity within the Alliance. As part of this, we reviewed our recruitment and interview practices.

In recruiting to the co-production group, we placed a heavy emphasis on ensuring a diversity of voices were represented. We were relatively successful in this, although further work

needs to be undertaken to ensure we are inclusive of minoritised communities throughout our work (for example, via the next iteration of My Neuro Survey).

We worked with a group of clinicians to conduct a focussed literature review examining available evidence on the relationship between protected characteristics and experience and outcomes of care, as well as prevalence and incidence of neurological conditions. The review was a first of its kind, and clearly highlighted the need to improve evidence to understand health inequalities in neurological conditions. In addition, we submitted a letter to the Lancet Neurology calling for improvements to evidence. Our particular thanks to our former trustee Dr Arani Nitkunan, Dr James Mitchell, Dr Kit Wu and Micha Vidot, for their commitment and time dedicated to this project.

We commissioned the National Council of Voluntary Organisations (NCVO) to conduct a light touch governance review. This was as part of a continuous improvement exercise to support The Neurological Alliance in assuring that its governance is in-line with sector good practice and identifying areas for improvement to further increase the impact of the Trustee Board in fulfilling the Alliance's mission.

### **3. Our structure, governance and management**

#### **3.1 Trustees selection**

We are governed by a Board of Trustees, made up of a minimum of three and a maximum of 14 people nominated by our members, recommended by our trustees and then elected by our members.

In advance of each Annual General Meeting (AGM), all members are invited to send in their nominations for the Board for available elected trustee posts. Details of the trustee candidates are then circulated to all members and votes are made by ballot at the AGM or sent in advance to the Chair using a proxy form; each member organisation is entitled to one vote, placed at the AGM.

After completing a three-year term, each trustee will stand down from the Board. Trustees who have completed only one term may stand for re-election; those who have served two consecutive terms must stand down for one year before they may stand again for the Board.

On joining the Alliance Board, all new trustees undertake a tailored induction programme. The trustees, who are also directors for the purpose of the Companies Act, who served during the year are listed in section 5.1.

#### **3.2 Structure**

We are a company limited by guarantee (no 02939840) and a registered charity (no 1039034). We are governed by Articles of Association and Byelaws. Our main activity is to secure the highest standards of care and treatment for every person affected by a neurological condition.

Our Board of Trustees is responsible for our governance and strategy and meets every quarter. Our Chief Executive is responsible for implementing the strategy and reports on its progress at the Board meetings. The Chief Executive reports directly to and is supervised by the Chair. They speak and meet regularly to discuss Alliance business.

Communication, both formal and informal, between Trustees and staff is frequent and effective.

### 3.2.1 Staff

|                 |                                                                     |
|-----------------|---------------------------------------------------------------------|
| Georgina Carr   | Chief Executive and Company Secretary (from January 2020 – present) |
| Caroline Davies | Administration and Membership Officer (From October 2019 – present) |
| Miranda Lloyd   | Communications and External Affairs Officer (March 2021 – present)  |
| Jessica Mansel  | Co-production Co-ordinator (February 2022 – July 2023)              |
| Sam Mountney    | Policy and External Affairs Manager (June 2021 – present)           |

### 3.2.2 Members

Full membership is open to national voluntary (non-statutory, non-profit) organisations who represent people affected by neurological conditions, including friends, families and carers organisations, who, in addition to the full benefits of membership, will have a right to vote at the AGM, have the right to nominate a trustee and an opportunity to influence our strategic direction. Subscriptions are income assessed.

Full affiliate membership is open to Regional Neurological Alliances operating on a non-statutory, non-profit basis. Affiliate members will pay a subscription rate which is not income assessed.

Associate status is open to professional associations and statutory authorities, who will play an active part in the Alliance but do not have the right to nominate a trustee or vote at the AGM. Subscriptions are income assessed. Regional Associations of Neurological Organisations can also be associates. They are staff led groups and will pay a subscription rate which is not income assessed.

Corporate supporter status is open to for-profit organisations, who cannot vote at the AGM or nominate a trustee.

Reciprocal partners are normally umbrella organisations whose aims and objectives match well with those of the Alliance. They cannot vote or influence our strategic direction.

### Members 2022 – 23

|                                   |                                                                        |
|-----------------------------------|------------------------------------------------------------------------|
| 3 Million Steps <sup>1</sup>      | <a href="https://3millionsteps.org">https://3millionsteps.org</a>      |
| Alex TLC <sup>1</sup>             | <a href="https://alextlc.org">https://alextlc.org</a>                  |
| Ataxia UK                         | <a href="http://www.ataxia.org.uk">www.ataxia.org.uk</a>               |
| Autistica                         | <a href="http://www.autistica.org.uk">www.autistica.org.uk</a>         |
| Batten Disease Family Association | <a href="http://www.bdfa-uk.org.uk">www.bdfa-uk.org.uk</a>             |
| Behcets UK <sup>1</sup>           | <a href="https://behcetsuk.org">https://behcetsuk.org</a>              |
| The Brain and Spine Foundation    | <a href="http://www.brainandspine.org.uk">www.brainandspine.org.uk</a> |

|                                                                |                                                                                     |
|----------------------------------------------------------------|-------------------------------------------------------------------------------------|
| The Brain Charity <sup>1</sup>                                 | <a href="https://www.thebraincharity.org.uk">https://www.thebraincharity.org.uk</a> |
| Brain Research UK                                              | <a href="http://www.brainresearchuk.org.uk">www.brainresearchuk.org.uk</a>          |
| British Polio Fellowship                                       | <a href="http://www.britishpolio.org.uk">www.britishpolio.org.uk</a>                |
| Cavernoma Alliance UK                                          | <a href="http://www.cavernoma.org.uk">www.cavernoma.org.uk</a>                      |
| Covid Aid <sup>1</sup>                                         | <a href="http://www.covidaidcharity.org">www.covidaidcharity.org</a>                |
| CMT United Kingdom                                             | <a href="http://www.cmt.org.uk">www.cmt.org.uk</a>                                  |
| CSF Leak <sup>1</sup>                                          | <a href="https://csfleak.uk">https://csfleak.uk</a>                                 |
| Cure Parkinson's Trust                                         | <a href="http://www.cureparkinsons.org.uk">www.cureparkinsons.org.uk</a>            |
| The Daisy Garland                                              | <a href="http://www.thedaisygarland.org.uk">www.thedaisygarland.org.uk</a>          |
| Different Strokes                                              | <a href="http://www.differentstrokes.co.uk">www.differentstrokes.co.uk</a>          |
| Downs Syndrome Research (DSRF)                                 | <a href="http://www.dsrf-uk.org">www.dsrf-uk.org</a>                                |
| Dravet Syndrome UK                                             | <a href="https://www.dravet.org.uk">https://www.dravet.org.uk</a>                   |
| Dystonia Society                                               | <a href="http://www.dystonia.org.uk">www.dystonia.org.uk</a>                        |
| Epilepsy Action                                                | <a href="http://www.epilepsy.org.uk">www.epilepsy.org.uk</a>                        |
| Epilepsy Research Institute UK                                 | <a href="http://www.epilepsyresearch.org.uk">www.epilepsyresearch.org.uk</a>        |
| FD UK                                                          | <a href="http://www.familialdysautonomia.co.uk">www.familialdysautonomia.co.uk</a>  |
| FND Action                                                     | <a href="http://www.fndaction.org.uk">www.fndaction.org.uk</a>                      |
| FND Dimensions <sup>1</sup>                                    | <a href="http://fnddimensions.org">http://fnddimensions.org</a>                     |
| FND Hope                                                       | <a href="http://www.fndhope.org">www.fndhope.org</a>                                |
| GAIN (Guillain-Barré and Associated Inflammatory Neuropathies) | <a href="http://www.gaincharity.org.uk">www.gaincharity.org.uk</a>                  |
| Hereditary Brain Aneurysms Support (HBA Support) <sup>1</sup>  | <a href="https://www.hbasupport.org">https://www.hbasupport.org</a>                 |
| Huntington's Disease Association                               | <a href="http://www.hda.org.uk">www.hda.org.uk</a>                                  |
| IIH UK                                                         | <a href="https://www.iih.org.uk">https://www.iih.org.uk</a>                         |

|                                                                             |                                                                                            |
|-----------------------------------------------------------------------------|--------------------------------------------------------------------------------------------|
| Intractable Epilepsy <sup>1</sup>                                           | <a href="https://www.intractable.org.uk">https://www.intractable.org.uk</a>                |
| Matthew's Friends                                                           | <a href="https://www.matthewsfriends.org">https://www.matthewsfriends.org</a>              |
| Migraine Trust                                                              | <a href="http://www.migrainetrust.org">www.migrainetrust.org</a>                           |
| Motor Neurone Disease Association                                           | <a href="http://www.mndassociation.org">www.mndassociation.org</a>                         |
| Neuro Therapy Network (Was Multiple Sclerosis National Therapy Centres)     | <a href="http://www.neurotherapynetwork.org.uk">www.neurotherapynetwork.org.uk</a>         |
| Multiple Sclerosis Society                                                  | <a href="http://www.mssociety.org.uk">www.mssociety.org.uk</a>                             |
| Multiple Sclerosis Trust                                                    | <a href="http://www.mstrust.org.uk">www.mstrust.org.uk</a>                                 |
| Multiple System Atrophy Trust                                               | <a href="http://www.msatrust.org.uk">www.msatrust.org.uk</a>                               |
| Myaware                                                                     | <a href="http://www.myaware.org">www.myaware.org</a>                                       |
| Myelopathy.org                                                              | <a href="http://www.myelopathy.org">www.myelopathy.org</a>                                 |
| Narcolepsy UK                                                               | <a href="http://www.narcolepsy.org.uk">www.narcolepsy.org.uk</a>                           |
| The National Hospital for Neurology And Neurosurgery Development Foundation | <a href="http://www.nationalbrainappeal.org">www.nationalbrainappeal.org</a>               |
| National Tremor Foundation                                                  | <a href="http://www.tremor.org.uk">www.tremor.org.uk</a>                                   |
| Nerve of My MS <sup>1</sup>                                                 | <a href="https://thenerveofmymms.org.uk">https://thenerveofmymms.org.uk</a>                |
| Pans Pandas UK <sup>1</sup>                                                 | <a href="https://www.panspandasuk.org">https://www.panspandasuk.org</a>                    |
| Parkinson's UK                                                              | <a href="http://www.parkinsons.org.uk">www.parkinsons.org.uk</a>                           |
| Pernicious Anaemia Society (PAS)                                            | <a href="http://www.pernicious-anaemia-society.org">www.pernicious-anaemia-society.org</a> |
| Polio Survivors Network                                                     | <a href="http://www.poliosurvivorsnetwork.org.uk">www.poliosurvivorsnetwork.org.uk</a>     |
| PSP Association                                                             | <a href="https://www.pspassociation.org.uk">https://www.pspassociation.org.uk</a>          |
| Ring 20 Research and Support UK CIO                                         | <a href="http://ring20researchsupport.co.uk">ring20researchsupport.co.uk</a>               |
| Shift.MS <sup>1</sup>                                                       | <a href="https://shift.ms/">https://shift.ms/</a>                                          |
| Spotlight YOPD                                                              | <a href="http://spotlightyopd.org">spotlightyopd.org</a>                                   |
| SUDEP Action                                                                | <a href="http://www.sudep.org">www.sudep.org</a>                                           |

|                                                                |                                                                                                                                                                                          |
|----------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Sue Ryder                                                      | <a href="http://www.sueryder.org">www.sueryder.org</a>                                                                                                                                   |
| Timothy Syndrome Alliance <sup>1</sup>                         | <a href="https://timothysyndrome.org">https://timothysyndrome.org</a>                                                                                                                    |
| Tourettes Action                                               | <a href="http://www.tourettes-action.org.uk">www.tourettes-action.org.uk</a>                                                                                                             |
| Tranverse Myelitis Society                                     | <a href="http://www.myelitis.org.uk">www.myelitis.org.uk</a>                                                                                                                             |
| Trigeminal Neuralgia Association UK                            | <a href="http://www.tna.org.uk">www.tna.org.uk</a>                                                                                                                                       |
| UK Acquired Brain Injury Forum                                 | <a href="http://www.ukabif.org.uk">www.ukabif.org.uk</a>                                                                                                                                 |
| <b>Associates</b>                                              |                                                                                                                                                                                          |
| Association of British Neurologists                            | <a href="http://www.theabn.org">www.theabn.org</a>                                                                                                                                       |
| Association of Chartered Physiotherapists in Neurology (ACPIN) | <a href="https://www.acpin.net">https://www.acpin.net</a>                                                                                                                                |
| British and Irish Association of Stroke Physicians (BIASP)     | <a href="https://biasp.org">https://biasp.org</a>                                                                                                                                        |
| British Paediatric Neurology Association (BPNA)                | <a href="http://www.bpna.org.uk">www.bpna.org.uk</a>                                                                                                                                     |
| Division of Neuropsychology (British Psychological Society)    | <a href="http://www.bps.org.uk/networks-and-communities/member-microsite/division-neuropsychology">www.bps.org.uk/networks-and-communities/member-microsite/division-neuropsychology</a> |
| Independent Neurorehabilitation Providers Alliance (INPA)      | <a href="https://in-pa.org.uk">https://in-pa.org.uk</a>                                                                                                                                  |
| Neurology Academy                                              | <a href="https://neurologyacademy.org">https://neurologyacademy.org</a>                                                                                                                  |
| <b>Corporate supporters</b>                                    |                                                                                                                                                                                          |
| AbbVie                                                         | <a href="http://www.abbvie.co.uk">www.abbvie.co.uk</a>                                                                                                                                   |
| Biogen                                                         | <a href="http://www.biogen.uk.com">www.biogen.uk.com</a>                                                                                                                                 |
| Boston Scientific                                              | <a href="https://www.bostonscientific.com">https://www.bostonscientific.com</a>                                                                                                          |
| Sanofi Genzyme                                                 | <a href="http://www.genzyme.co.uk">www.genzyme.co.uk</a>                                                                                                                                 |
| Lundbeck                                                       | <a href="https://www.lundbeck.com/uk">https://www.lundbeck.com/uk</a>                                                                                                                    |
| Merck Serono                                                   | <a href="http://www.merckserono.co.uk">www.merckserono.co.uk</a>                                                                                                                         |

|                                                                                     |                                                                                                                   |
|-------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| Novartis                                                                            | <a href="http://www.novartis.co.uk">www.novartis.co.uk</a>                                                        |
| Pfizer <sup>1</sup>                                                                 | <a href="https://www.pfizer.co.uk/science/pfizer-in-the-uk">https://www.pfizer.co.uk/science/pfizer-in-the-uk</a> |
| PTC Therapeutics <sup>1</sup>                                                       | <a href="https://www.ptcbio.com/">https://www.ptcbio.com/</a>                                                     |
| Roche                                                                               | <a href="https://www.roche.com/">https://www.roche.com/</a>                                                       |
| Sandoz <sup>1</sup>                                                                 | <a href="https://www.sandoz.com/">https://www.sandoz.com/</a>                                                     |
| Teva UK Limited                                                                     | <a href="http://www.tevauk.com">www.tevauk.com</a>                                                                |
| UCB Pharma Ltd                                                                      | <a href="http://www.ucb.co.uk">www.ucb.co.uk</a>                                                                  |
| <b>Regional Neurological Alliances</b>                                              |                                                                                                                   |
| Black Country Neurological Alliance <sup>3</sup>                                    | <a href="http://www.blackcountryneuroalliance.org.uk">www.blackcountryneuroalliance.org.uk</a>                    |
| Bolton Neuro Voices                                                                 | <a href="http://www.boltoncvs.org.uk">www.boltoncvs.org.uk</a>                                                    |
| Greater Manchester Neurological Alliance <sup>3</sup>                               | <a href="http://www.gmna.co.uk">www.gmna.co.uk</a>                                                                |
| Hampshire Neurological Alliance                                                     | <a href="https://www.hampshireneural.org.uk/index.html">https://www.hampshireneural.org.uk/index.html</a>         |
| Lincolnshire Neurological Alliance <sup>3</sup>                                     | <a href="http://www.lincolnshire-neurological-alliance.org.uk">www.lincolnshire-neurological-alliance.org.uk</a>  |
| Merseyside and Cheshire Neurological Alliance                                       | <a href="http://www.neurosupport.org.uk">www.neurosupport.org.uk</a>                                              |
| Neuro Key (formerly Tees Valley, Durham, and North Yorkshire Neurological Alliance) | <a href="http://www.na-tvdny.org.uk">www.na-tvdny.org.uk</a>                                                      |
| West Berkshire Neurological Alliance                                                | <a href="http://www.wbna.org.uk">www.wbna.org.uk</a>                                                              |
| <b>Reciprocal members</b>                                                           |                                                                                                                   |
| Genetic Alliance UK <sup>1</sup>                                                    | <a href="https://geneticalliance.org.uk">https://geneticalliance.org.uk</a>                                       |
| National Voices                                                                     | <a href="https://www.nationalvoices.org.uk">https://www.nationalvoices.org.uk</a>                                 |
| Neurological Alliance of Ireland                                                    | <a href="http://www.nai.ie">www.nai.ie</a>                                                                        |
| Neurological Alliance of Scotland                                                   | <a href="http://www.scottishneurological.org.uk">www.scottishneurological.org.uk</a>                              |
| Neurological Alliance of Wales                                                      | <a href="http://www.walesneurologicalalliance.org.uk">www.walesneurologicalalliance.org.uk</a>                    |

|                                                                     |  |
|---------------------------------------------------------------------|--|
| Northern Ireland<br>Neurological Charities<br>Alliance <sup>1</sup> |  |
|---------------------------------------------------------------------|--|

<sup>1</sup>. New members in 2022-23

<sup>2</sup>. Ceased members in 2022-23

<sup>3</sup>. Organisation closed in 2022-23

### 3.2.3 The way we work

As a membership organisation, our whole ethos is to work in partnership. We work across the neurological community to identify common priorities for people affected by neurological conditions and then seek to influence, shape and support policy development to reduce inequalities, enhance their outcomes and, where possible, help them live for longer and in better health. Our activities are therefore based on a clear and shared sense of purpose. We work with the trustees, the Policy Group and Policy Steering group to determine our strategy and plans.

### 3.2.4 The Policy Group

Any member of the Alliance can take be part of the Policy Group. The group's purpose is to:

- Build collective ownership of the Alliance beyond staff and trustees and to promote team-working across the member organisations
- Provide a forum for policy, campaigns and public affairs staff of member organisations to share information and provide mutual support
- Feed into The Neurological Alliance policy development process
- More closely align member organisations' priorities with the collective needs of the Alliance; and
- Ensure that all member organisations, large and small, can contribute to the work of the Alliance.

### 3.2.5. Policy Group leads

|                  |                                                                                         |
|------------------|-----------------------------------------------------------------------------------------|
| Sam Carney       | Health Policy and Improvement Lead, Parkinson's UK, Co-Chair (May 2022 – May 2023)      |
| Charlotte Gerada | Policy and Public Affairs Manager, Huntington's Disease UK, Chair (June 2023 – present) |
| Dawn Golder      | Executive Director, FND Hope UK, Co-Chair (Feb 2022 – May 2023)                         |

### 3.3 Risk management

The trustees have assessed the major risks to which the charity is exposed and are satisfied that systems are in place to mitigate exposure to major risks. A risk management strategy, reviewed annually, is in place. We also have a risk-based reserves policy which mitigates one of our main financial risks in terms of having over three quarters of our income coming from just 13 funders (four charities, nine corporates).

### 4. Public benefit

Our work benefits people affected by a neurological condition and those who represent them. Sections 1 and 2 of this report set out our objectives, report on our activities and successes, and set out our plans for the current financial year.

The trustees consider that they have complied with their duty in s4 of the Charities Act 2011 to have due regard to the guidance on public benefit published by the Charity Commission. The trustees have considered this matter and concluded:

- That the aims of the organisation continue to be charitable
- That the aims and the work done give identifiable benefits to the charitable sector and both indirectly and directly to individuals in need
- That the benefits are for the public, are not unreasonably restricted in any way and certainly not by ability to pay
- That there is no detriment or harm arising from the aims or activities.

## **5. Reference and administrative details**

The Alliance is a registered charity (1039034) and company limited by guarantee (02939840) registered in England. The Alliance's registered office was, from 21<sup>st</sup> September 2019, The Junction, Station Road, Watford, WD17 1ET.

### **5.1 Trustees and the nominating organisation**

|                  |                                                         |
|------------------|---------------------------------------------------------|
| Alan Bowers      | Sue Ryder (Treasurer) (stepped down July 2023)          |
| Alison Fuller    | Epilepsy Action (elected Nov 2022)                      |
| Amanda Swain     | UK Acquired Brain Injury Forum (re-appointed Nov 2022)  |
| Angie Pullen     | Epilepsy Action (stepped down July 2022)                |
| Cath Stanley     | Huntington's Disease Association                        |
| Chris James      | Motor Neurone Disease Association                       |
| David Martin     | Multiple Sclerosis Trust (re-appointed Nov 2022, Chair) |
| Kripen Dhrona    | British Polio Fellowship                                |
| Marc Smith       | Brain and Spine Foundation (Vice-Chair)                 |
| Rob Music        | Migraine Trust (elected Nov 2022)                       |
| Sarah Rawlings   | MS Society                                              |
| Victoria Wareham | Dystonia UK (elected Nov 2022)                          |

During the year the Board, again, co-opted three independent trustees with the aim of achieving greater diversity on the Board in terms of the professional backgrounds of members. The co-opted trustees are:

|                    |                                                     |
|--------------------|-----------------------------------------------------|
| David Garmon-Jones | Appointed February 2018, re-appointed February 2021 |
| Ralph Gregory      | Appointed February 2018, re-appointed February 2021 |
| Arani Nitkunan     | Appointed July 2020, stepped down May 2023          |

### **5.2 Professional advisors**

|                       |                                                                                                                  |
|-----------------------|------------------------------------------------------------------------------------------------------------------|
| Bankers               | CAF Bank Ltd, PO Box 289, West Mallings, Kent, ME19 4TA<br>Metro Bank PLC, One Southampton Row, London, WC1B 5HA |
| Accountants           | Godfrey Wilson, 5th Floor, Mariner House, 62 Prince Street,<br>Bristol, BS1 4QD                                  |
| Independent Examiners | Goodman Jones LLP, 29-30 Fitzroy Square, London W1T 6LQ                                                          |

## **6. Finances**

### **6.1 Investment**

Article 5.1.23 empowers the Alliance, with advice from a financial expert, to invest the funds of the Alliance as it sees fit, with consideration of the the suitability of investments and the need for diversification.

### **6.2 Subscriptions**

Subscription rates are determined by the organisational income of each member and associate. Subscriptions for affiliate members are at a fixed rate.

### **6.3 Reserves policy**

A reserves policy was agreed by trustees during 2022. This policy is a risk-based policy, to reflect the reality that any reduction in income or increasing in costs would take place over a period of time.

Having considered the risks, trustees consider it prudent that reserves should be maintained in order to cover the loss of income from one third of the significant income sources. This equates to approximately £55,000.

At the end of the year reserves of £95,920 (2022: £58,036) were held, of which £4,241 (21/22: £5,234) were restricted. This is £36,679 above the level of reserves the trustees calculate are required.

### **6.4 Financial position**

Income from membership subscriptions increased by 2% in the year to £95,952 (21/22: £94,229). In parallel, unrestricted corporate funding has increased from £110,296 to £149,225. We also received charitable donations totalling £1,142.

We also received generous support from UCB to develop a new epilepsy Service Improvement Navigator tool, totalling £9,015.

Our Policy and External Affairs Manager, Sam Mountney, was seconded to National Voices between October 2022 and February 2023. We received £21,981 for this secondment.

Overall, there is a surplus of £38,877 (before transfers) on the unrestricted funds (21/22 deficit of £60,267) and a deficit of £993 (before transfers) on restricted funds (21/22: deficit of £19,632). This leaves an overall surplus of £37,884 (21/22 deficit of £64,198) for the year.

### **6.5 Trustees' responsibilities statement**

The trustees (who are also directors of The Neurological Alliance for the purposes of company law) are responsible for preparing the trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2015 (FRS 102);
- make judgements and estimates that are reasonable and prudent;

- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the trustees are aware:

- there is no relevant information of which the charitable company's independent examiner is unaware; and
- the trustees have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the independent examiner is aware of that information.

### **6.6 Independent examiners**

At the AGM in November 2023, members agreed to delegate responsibility for selecting The Neurological Alliance's Independent Examiners for the forthcoming year and 2022-2023 accounts to the Board of Trustees.

The Board decided to appoint Goodman Jones LLP to be our independent examiner for 2023/24.

### **6.7 Small company provisions**

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the Board of Trustees,

*Cath Stanley*

**Cath Stanley**

**Chair, Board of Trustees**

**Date:** 24-11-23

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**INDEPENDENT EXAMINER'S REPORT**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**Independent Examiner's Report to the Trustees of The Neurological Alliance ('the Charity')**

I report to the charity Trustees on my examination of the accounts of the Charity for the year ended 30 June 2023.

**Responsibilities and Basis of Report**

As the Trustees of the Charity (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

**Independent Examiner's Statement**

Since the Charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of (enter body here), which is one of the listed bodies.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Charity as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair' view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**INDEPENDENT EXAMINER'S REPORT (CONTINUED)**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

Signed: *Martin Bailey*

Dated: 24-11-23

Martin Bailey

FCA

**Martin Bailey FCA**  
Goodman Jones LLP  
29/30 Fitzroy Square  
London  
W1T 6LQ

**THE NEUROLOGICAL ALLIANCE**  
(A Company Limited by Guarantee)

**STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING INCOME AND EXPENDITURE ACCOUNT)  
FOR THE YEAR ENDED 30 JUNE 2023**

|                                    | Note | Unrestricted<br>funds<br>2023<br>£ | Restricted<br>funds<br>2023<br>£ | Total<br>funds<br>2023<br>£ | Total<br>funds<br>2022<br>£ |
|------------------------------------|------|------------------------------------|----------------------------------|-----------------------------|-----------------------------|
| <b>Income from:</b>                |      |                                    |                                  |                             |                             |
| Donations and legacies             | 4    | 1,166                              | -                                | 1,166                       | 5,768                       |
| Charitable activities              | 5    | 267,178                            | 35,545                           | 302,723                     | 211,854                     |
| Investments                        | 6    | 770                                | -                                | 770                         | 49                          |
| <b>Total income</b>                |      | <b>269,114</b>                     | <b>35,545</b>                    | <b>304,659</b>              | <b>217,671</b>              |
| <b>Expenditure on:</b>             |      |                                    |                                  |                             |                             |
| Charitable activities              | 7    | 230,237                            | 36,538                           | 266,775                     | 281,869                     |
| <b>Total expenditure</b>           |      | <b>230,237</b>                     | <b>36,538</b>                    | <b>266,775</b>              | <b>281,869</b>              |
| <b>Net movement in funds</b>       |      | <b>38,877</b>                      | <b>(993)</b>                     | <b>37,884</b>               | <b>(64,198)</b>             |
| <b>Reconciliation of funds:</b>    |      |                                    |                                  |                             |                             |
| Total funds brought forward        |      | 52,802                             | 5,234                            | 58,036                      | 122,234                     |
| Net movement in funds              |      | 38,877                             | (993)                            | 37,884                      | (64,198)                    |
| <b>Total funds carried forward</b> |      | <b>91,679</b>                      | <b>4,241</b>                     | <b>95,920</b>               | <b>58,036</b>               |

The Statement of Financial Activities includes all gains and losses recognised in the year.

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**  
**REGISTERED NUMBER: 02939840**

---

**BALANCE SHEET**  
**AS AT 30 JUNE 2023**

---

|                                                | Note | 2023<br>£   | 2022<br>£   |
|------------------------------------------------|------|-------------|-------------|
| <b>Fixed assets</b>                            |      |             |             |
| Tangible assets                                | 11   | -           | 304         |
|                                                |      | <hr/>       | <hr/>       |
|                                                |      | -           | 304         |
| <b>Current assets</b>                          |      |             |             |
| Debtors                                        | 12   | 27,040      | 13,605      |
| Cash at bank and in hand                       |      | 76,836      | 70,546      |
|                                                |      | <hr/>       | <hr/>       |
|                                                |      | 103,876     | 84,151      |
| Creditors: amounts falling due within one year | 13   | (7,956)     | (26,419)    |
|                                                |      | <hr/>       | <hr/>       |
| <b>Net current assets</b>                      |      | 95,920      | 57,732      |
|                                                |      | <hr/>       | <hr/>       |
| <b>Total net assets</b>                        |      | 95,920      | 58,036      |
|                                                |      | <hr/> <hr/> | <hr/> <hr/> |
| <b>Charity funds</b>                           |      |             |             |
| Restricted funds                               | 14   | 4,241       | 5,234       |
| Unrestricted funds                             | 14   | 91,679      | 52,802      |
|                                                |      | <hr/>       | <hr/>       |
| <b>Total funds</b>                             |      | 95,920      | 58,036      |
|                                                |      | <hr/> <hr/> | <hr/> <hr/> |

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006.

The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees and signed on their behalf by:

  
.....  
**Cath Stanley**  
Chair of Trustees

Date: 24-11-23

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**1. General information**

The Neurological Alliance is a registered charity and company limited by guarantee. Its charitable objects are set out in the Trustees' Report. Its registered office address is The Junction, Station Road, Watford, WD17 1EU.

**2. Accounting policies**

**2.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The financial statements are prepared on the going concern basis under the historical cost convention, modified to include certain items at fair value. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are presented in Sterling which is the functional currency of the Charity and monetary amounts are rounded to the nearest £.

The Neurological Alliance meets the definition of a public benefit entity under FRS 102.

**2.2 Company status**

The Charity is a company limited by guarantee. The members of the company are the Trustees named in the Trustee report section 5.1. In the event of the Charity being wound up, the liability in respect of the guarantee is limited to £10 per member of the Charity.

**2.3 Going concern**

The Trustees have assessed whether the use of the going concern assumption is appropriate in preparing these accounts and are of the opinion that the Charity will have sufficient resources to meet its liabilities as they fall due. The Trustees have made this assessment in respect of a period of one year from the date of approval of these accounts. The Trustees of the Charity have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the Charity to continue as a going concern.

**2.4 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**2. Accounting policies (continued)**

**2.5 Income**

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received, and the amount of income receivable can be measured reliably.

The following specific policies are applied to particular categories of income:

Subscription income is invoiced in line with the financial year and recognised in the period to which it relates.

Corporate support represents amounts invoiced in the year.

Donated services or facilities are recognised when the Charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the Charity of the item is probable and that economic benefit can be measured reliably. On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the Charity which is the amount the Charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

**2.6 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the Bank.

**2.7 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Support costs are those costs incurred directly in support of expenditure on the objects of the Charity. Governance costs are those incurred in connection with administration of the Charity and compliance with constitutional and statutory requirements.

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**2. Accounting policies (continued)**

**2.7 Expenditure (continued)**

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds. All expenditure is inclusive of irrecoverable VAT.

**2.8 Tangible fixed assets and depreciation**

Tangible fixed assets costing £NIL or more are capitalised and recognised when future economic benefits are probable and the cost or value of the asset can be measured reliably.

Tangible fixed assets are initially recognised at cost. After recognition, under the cost model, tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. All costs incurred to bring a tangible fixed asset into its intended working condition should be included in the measurement of cost.

Depreciation is charged so as to allocate the cost of tangible fixed assets less their residual value over their estimated useful lives, .

Depreciation is provided on the following basis:

|                  |                         |
|------------------|-------------------------|
| Office equipment | - 3 years straight line |
|------------------|-------------------------|

**2.9 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

**2.10 Cash at Bank and in hand**

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

**2.11 Liabilities and Provision**

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

**2.12 Operating Leases**

Rentals under operating leases are charged to the Statement of Financial Activities incorporating Income and Expenditure Account on a straight-line basis over the lease term.

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**2. Accounting policies (continued)**

**2.13 Pensions**

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

**3. Critical accounting estimates and areas of judgement**

In the application of the Charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

Critical accounting estimates and assumptions:

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

In the opinion of the Trustees, there are no significant areas of estimation, uncertainty and critical judgements in applying accounting policies that have significant effect on the amounts recognised in the financial statements.

**4. Income from donations and legacies**

|                   | <b>Unrestricted<br/>funds<br/>2023<br/>£</b> | <b>Total<br/>funds<br/>2023<br/>£</b> | <i>Total<br/>funds<br/>2022<br/>£</i> |
|-------------------|----------------------------------------------|---------------------------------------|---------------------------------------|
| Donations         | 1,166                                        | <b>1,166</b>                          | 5,215                                 |
| Legacies          | -                                            | -                                     | 553                                   |
|                   | <hr/> 1,166 <hr/>                            | <hr/> <b>1,166</b> <hr/>              | <hr/> 5,768 <hr/>                     |
| <i>Total 2022</i> | <hr/> 5,768 <hr/>                            | <hr/> 5,768 <hr/>                     |                                       |

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**5. Income from charitable activities**

|                   | <b>Unrestricted<br/>funds<br/>2023<br/>£</b> | <b>Restricted<br/>funds<br/>2023<br/>£</b> | <b>Total<br/>funds<br/>2023<br/>£</b> | <i>Total<br/>funds<br/>2022<br/>£</i> |
|-------------------|----------------------------------------------|--------------------------------------------|---------------------------------------|---------------------------------------|
| Corporate support | 171,226                                      | -                                          | <b>171,226</b>                        | 110,296                               |
| Subscriptions     | 95,952                                       | -                                          | <b>95,952</b>                         | 96,883                                |
| Projects          | -                                            | 35,545                                     | <b>35,545</b>                         | 4,675                                 |
|                   | <u>267,178</u>                               | <u>35,545</u>                              | <u><b>302,723</b></u>                 | <u>211,854</u>                        |
| <i>Total 2022</i> | <u>210,979</u>                               | <u>875</u>                                 | <u>211,854</u>                        |                                       |

**6. Investment income**

|                   | <b>Unrestricted<br/>funds<br/>2023<br/>£</b> | <b>Total<br/>funds<br/>2023<br/>£</b> | <i>Total<br/>funds<br/>2022<br/>£</i> |
|-------------------|----------------------------------------------|---------------------------------------|---------------------------------------|
| Interest income   | 770                                          | <b>770</b>                            | 49                                    |
|                   | <u>770</u>                                   | <u><b>770</b></u>                     | <u>49</u>                             |
| <i>Total 2022</i> | <u>49</u>                                    | <u>49</u>                             |                                       |

---

---

**THE NEUROLOGICAL ALLIANCE**  
(A Company Limited by Guarantee)

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**7. Analysis of expenditure on charitable activities**

**Summary by fund type**

|                    | <b>Unrestricted<br/>funds<br/>2023<br/>£</b> | <b>Restricted<br/>funds<br/>2023<br/>£</b> | <b>Total<br/>2023<br/>£</b> | <b>Total<br/>2022<br/>£</b> |
|--------------------|----------------------------------------------|--------------------------------------------|-----------------------------|-----------------------------|
| Policy Development | 65,768                                       | 12,510                                     | <b>78,278</b>               | 95,466                      |
| Members Activities | 164,469                                      | 24,028                                     | <b>188,497</b>              | 186,403                     |
|                    | <u>230,237</u>                               | <u>36,538</u>                              | <u><b>266,775</b></u>       | <u>281,869</u>              |
| <i>Total 2022</i>  | <u>268,691</u>                               | <u>13,178</u>                              | <u>281,869</u>              |                             |

**8. Analysis of expenditure by activities**

|                    | <b>Activities<br/>undertaken<br/>directly<br/>2023<br/>£</b> | <b>Support<br/>costs<br/>2023<br/>£</b> | <b>Total<br/>funds<br/>2023<br/>£</b> | <b>Total<br/>funds<br/>2022<br/>£</b> |
|--------------------|--------------------------------------------------------------|-----------------------------------------|---------------------------------------|---------------------------------------|
| Policy Development | 52,845                                                       | 25,433                                  | <b>78,278</b>                         | 95,466                                |
| Members Activities | 185,566                                                      | 2,931                                   | <b>188,497</b>                        | 186,403                               |
|                    | <u>238,411</u>                                               | <u>28,364</u>                           | <u><b>266,775</b></u>                 | <u>281,869</u>                        |
| <i>Total 2022</i>  | <u>257,581</u>                                               | <u>24,288</u>                           | <u>281,869</u>                        |                                       |

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**9. Staff costs**

|                                                      | <b>2023</b>    | <b>2022</b> |
|------------------------------------------------------|----------------|-------------|
|                                                      | <b>£</b>       | <b>£</b>    |
| Wages and salaries                                   | <b>156,847</b> | 130,233     |
| Social security costs                                | <b>10,725</b>  | 8,848       |
| Contribution to defined contribution pension schemes | <b>8,847</b>   | 7,706       |
|                                                      | <b>176,419</b> | 146,787     |

The average number of persons employed by the Charity during the year was as follows:

|           | <b>2023</b> | <b>2022</b> |
|-----------|-------------|-------------|
|           | <b>No.</b>  | <b>No.</b>  |
| Employees | <b>5</b>    | 4           |

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

|                               | <b>2023</b> | <b>2022</b> |
|-------------------------------|-------------|-------------|
|                               | <b>No.</b>  | <b>No.</b>  |
| In the band £60,001 - £70,000 | <b>1</b>    | -           |

Key management personnel remuneration, including employer's NIC and pension contributions, incurred by the Charity in the year totalled £77,193 (2022: £66,595).

**10. Trustees' remuneration and expenses**

During the year, no Trustees received any remuneration or other benefits (2022 - £NIL).

During the year ended 30 June 2023, expenses totalling £NIL were reimbursed or paid directly to Trustee (2022 - £172 to 2 Trustees).

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**11. Tangible fixed assets**

|                          | Office<br>equipment<br>£ |
|--------------------------|--------------------------|
| <b>Cost or valuation</b> |                          |
| At 1 July 2022           | 3,723                    |
| At 30 June 2023          | <u>3,723</u>             |
| <b>Depreciation</b>      |                          |
| At 1 July 2022           | 3,419                    |
| Charge for the year      | 304                      |
| At 30 June 2023          | <u>3,723</u>             |
| <b>Net book value</b>    |                          |
| At 30 June 2023          | <u>-</u>                 |
| At 30 June 2022          | <u>304</u>               |

**12. Debtors**

|                                | 2023<br>£     | 2022<br>£     |
|--------------------------------|---------------|---------------|
| <b>Due within one year</b>     |               |               |
| Other debtors                  | 11,661        | -             |
| Prepayments and accrued income | 15,379        | 13,605        |
|                                | <u>27,040</u> | <u>13,605</u> |

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**13. Creditors: Amounts falling due within one year**

|                              | <b>2023</b>  | <b>2022</b>   |
|------------------------------|--------------|---------------|
|                              | <b>£</b>     | <b>£</b>      |
| Trade creditors              | <b>3,430</b> | <b>21,785</b> |
| Other creditors              | <b>456</b>   | <b>1,118</b>  |
| Accruals and deferred income | <b>4,070</b> | <b>3,516</b>  |
|                              | <b>7,956</b> | <b>26,419</b> |

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**14. Statement of funds**

**Statement of funds - current year**

|                           | Balance at 1<br>July 2022<br>£ | Income<br>£    | Expenditure<br>£ | Balance at<br>30 June<br>2023<br>£ |
|---------------------------|--------------------------------|----------------|------------------|------------------------------------|
| <b>Unrestricted funds</b> |                                |                |                  |                                    |
| General Funds - all funds | <b>52,802</b>                  | <b>269,114</b> | <b>(230,237)</b> | <b>91,679</b>                      |
|                           |                                |                |                  |                                    |
| <b>Restricted funds</b>   |                                |                |                  |                                    |
| NNAG Pathways             | <b>5,234</b>                   | <b>-</b>       | <b>(4,515)</b>   | <b>719</b>                         |
| Epilepsy Tool             | <b>-</b>                       | <b>9,015</b>   | <b>(7,995)</b>   | <b>1,020</b>                       |
| Neurolifenow              | <b>-</b>                       | <b>12,500</b>  | <b>(10,000)</b>  | <b>2,500</b>                       |
| Outpatient Transformation | <b>-</b>                       | <b>14,030</b>  | <b>(14,028)</b>  | <b>2</b>                           |
|                           | <b>5,234</b>                   | <b>35,545</b>  | <b>(36,538)</b>  | <b>4,241</b>                       |
|                           |                                |                |                  |                                    |
| <b>Total funds</b>        | <b>58,036</b>                  | <b>304,659</b> | <b>(266,775)</b> | <b>95,920</b>                      |

---

---

**THE NEUROLOGICAL ALLIANCE**  
(A Company Limited by Guarantee)

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**14. Statement of funds (continued)**

**Statement of funds - prior year**

|                           | <i>Balance at<br/>1 July 2021<br/>£</i> | <i>Income<br/>£</i> | <i>Expenditure<br/>£</i> | <i>Transfers<br/>in/out<br/>£</i> | <i>Balance at<br/>30 June<br/>2022<br/>£</i> |
|---------------------------|-----------------------------------------|---------------------|--------------------------|-----------------------------------|----------------------------------------------|
| <b>Unrestricted funds</b> |                                         |                     |                          |                                   |                                              |
| General Funds - all funds | 113,069                                 | 216,796             | (261,362)                | (15,701)                          | 52,802                                       |
|                           | <hr/>                                   | <hr/>               | <hr/>                    | <hr/>                             | <hr/>                                        |
| <b>Restricted funds</b>   |                                         |                     |                          |                                   |                                              |
| NNAG Events               | 2,356                                   | -                   | (2,631)                  | 275                               | -                                            |
| NNAG Pathways             | 6,809                                   | -                   | (1,575)                  | -                                 | 5,234                                        |
| Epilepsy Tool             | -                                       | 875                 | (16,301)                 | 15,426                            | -                                            |
|                           | <hr/>                                   | <hr/>               | <hr/>                    | <hr/>                             | <hr/>                                        |
|                           | 9,165                                   | 875                 | (20,507)                 | 15,701                            | 5,234                                        |
|                           | <hr/>                                   | <hr/>               | <hr/>                    | <hr/>                             | <hr/>                                        |
| <b>Total funds</b>        | <hr/> 122,234                           | <hr/> 217,671       | <hr/> (281,869)          | <hr/> -                           | <hr/> 58,036                                 |

NNAG events - events and activities to support the development of an epilepsy pathway.

NNAG support - programme management support for The National Neuro Advisory Group, includes organising meetings, workstreams and events.

Neurolifenow - funds received for a real-time survey which aims to provide routine patient experience data to support service improvement and positive public policy change.

Epilepsy Navigator Tool - a tool developed to provide a range of resources to support service development.

Outpatient Transformation - funds to provide improvements to outpatient services and resources.

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**15. Analysis of net assets between funds**

**Analysis of net assets between funds - current year**

|                               | <b>Unrestricted<br/>funds<br/>2023<br/>£</b> | <b>Restricted<br/>funds<br/>2023<br/>£</b> | <b>Total<br/>funds<br/>2023<br/>£</b> |
|-------------------------------|----------------------------------------------|--------------------------------------------|---------------------------------------|
| Current assets                | 99,635                                       | 4,241                                      | <b>103,876</b>                        |
| Creditors due within one year | (7,956)                                      | -                                          | <b>(7,956)</b>                        |
| <b>Total</b>                  | <b>91,679</b>                                | <b>4,241</b>                               | <b>95,920</b>                         |

**Analysis of net assets between funds - prior year**

|                               | <i>Unrestricted<br/>funds<br/>2022<br/>£</i> | <i>Restricted<br/>funds<br/>2022<br/>£</i> | <i>Total<br/>funds<br/>2022<br/>£</i> |
|-------------------------------|----------------------------------------------|--------------------------------------------|---------------------------------------|
| Tangible fixed assets         | 304                                          | -                                          | 304                                   |
| Current assets                | 78,917                                       | 5,234                                      | 84,151                                |
| Creditors due within one year | (26,419)                                     | -                                          | (26,419)                              |
| <b>Total</b>                  | <b>77,668</b>                                | <b>(19,632)</b>                            | <b>58,036</b>                         |

**16. Pension commitments**

The Charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the Charity in an independently administered fund. The pension cost charge represents contributions payable by the Charity to the fund and amounted to £8,847 (2022 - £7,706).

Contributions totalling £456 (2022 - £1,118) were payable to the fund at the balance sheet date and are included in creditors.

---

---

**THE NEUROLOGICAL ALLIANCE**  
**(A Company Limited by Guarantee)**

---

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2023**

---

**17. Operating lease commitments**

At 30 June 2023 the Charity had commitments to make future minimum lease payments under non-cancellable operating leases as follows:

|                       | <b>2023</b>  | <b>2022</b>  |
|-----------------------|--------------|--------------|
|                       | <b>£</b>     | <b>£</b>     |
| Not later than 1 year | <b>9,000</b> | <b>9,000</b> |

**18. Related party transactions**

Other than disclosed elsewhere in these financial statements, there were no related party transactions requiring disclosure during the current or previous year

---

---

# Accounts

---

**COMPANY REGISTRATION NUMBER 02939840**



**THE NEUROLOGICAL ALLIANCE**

**(LIMITED BY GUARANTEE)**

**FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED**

**30 JUNE 2022**

**Charity Number 103903**

---

THE NEUROLOGICAL ALLIANCE  
TRUSTEE ANNUAL REPORT  
LETTER FROM THE CHAIR

As I write this, the neurological community, including people affected by neurological conditions, continue to face some of our most profound challenges ever – increases in cost of living are hitting people living with disabilities incredibly hard, the NHS is still reeling from the impacts of the COVID-19 pandemic, and the health service is going through major changes and Government structures are shifting. It can sometimes feel like we are just fighting fires, rather than being in a position to improve to treatment and support. There is more than ever for the Alliance to influence.

Here at the Alliance, we have been in a fortunate enough position to invest our resources and grow both our membership and our team. We invested in our My Neuro Survey, our fourth national patient experience survey and it was our biggest and most collaborative yet – together with Alliances across the UK, we delivered a survey accessible to all people with neurological conditions, no matter their age, and we delivered a united campaign too. The ‘Back the 1 in 6’ campaign continues to go from strength to strength – as I write this, more than 13,500 have supported the campaign, and we have exciting plans for the campaign as it evolves in 2022/23.

We also begun to develop our approach to co-production, with the establishment of our first ever co-production group of people affected by neurological conditions to steer the strategy of the ‘Back the 1 in 6 campaign’. Our new Co-Production Coordinator, Jess Mansel, has done a wonderful job of setting up the group, and I am confident they will go from strength to strength in the years to come.

Despite the very real challenges faced by both the voluntary sector and industry, our membership grew significantly in 21/22 too. This is a reflection of the excellent work undertaken by the team across the year, the difference we are making and the growing reach we are having. We hope the coming year will be another year of growth, enabling us to reach more people affected by neurological conditions and increase our influence even further.

It is in that context that we launched our new five-year strategy in September 2022, ‘Together for the 1 in 6’. In the strategy, we are committed to greater involvement of people affected by neurological conditions in all we do and growing our influence on public policy even more.

We do of course begin the strategy in challenging circumstances, but with some important opportunities ahead of us – new integrated structures within the NHS hold the promise of coordinated care, for the first time in eight years National Clinical Directors for neuroscience will be appointed by NHSE/I, and neuroscience transformation is a priority within the NHS in England. Perhaps most importantly, our collective movement is stronger than ever, with more organisations joining the Alliance by the month.

The next five years therefore represent unprecedented challenges and opportunities we must grasp as a community. We absolutely have to leverage the growing influence

the community holds at a national, regional and local level to ensure people affected by neurological conditions are heard and have real influence. We as a community have to collaborate in new and different ways too - we share many common challenges, which will only be addressed by working shoulder to shoulder and learning from one another. We are learning more about how to diagnose and treat many neurological conditions every day – it is now up to us to ensure we build a health and care system and workforce to ensure that innovation translates into improved quality of life no matter where you live.

I am hopeful of the positive change we can achieve over the next five years and beyond – quite frankly, we have never been in a better position, nor at a more critical moment, to back the 1 in 6 living with a neurological condition.

**David Martin, Chair, The Neurological Alliance**

**THE NEUROLOGICAL ALLIANCE**  
**ANNUAL REPORT AND ACCOUNTS**  
**YEAR ENDED JUNE 2022**

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Registered charity name**                      The Neurological Alliance

**Charity registration number**                1039034

**Company registration number**              02939840

**Registered office**                              The Junction  
Station Road  
Watford  
Hertfordshire  
WD17 1EU

**Independent Examiner**                      Martin Bailey FCA  
Goodman Jones LLP  
Chartered Accountants  
29-30 Fitzroy Square  
London  
W1T 6LQ

**Accountants**                                    Godfrey Wilson  
5th Floor, Mariner House  
62 Prince Street  
Bristol  
BS1 4QD

**Bankers**                                          CAF Bank Ltd  
25 Kings Hill Avenue  
Kings Hill  
West Malling  
Kent  
ME19 4JQ  
Metro Bank PLC  
One Southampton Row  
London  
WC1B 5HA

The Trustees present their report and independently examined financial statements for the Neurological Alliance for the year 1 July 2021 to 30 June 2022. The report and financial statements have been prepared in accordance with the Companies Act 2006 and the Charities Act 2011. The Trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) in preparing the report and financial statements. The report and financial statements will be laid before the members of the charity at the Annual General Meeting to be held on 15 November 2022. In preparation of this report, the Trustees had regard for the Charity Commission guidance on public benefit.

## **1. Our objects**

Our principal objectives, as derived from the objects set out in our Articles of Association, are to advance the education of the public in all matters concerning neurological disorders by carrying out research and investigation into preventative procedures, treatment and the needs and care of persons affected by neurological conditions, and publishing the useful results thereof, and the relief of those persons in the United Kingdom of Great Britain and Northern Ireland who are receiving or have received treatment for neurological conditions.

We are the only collective voice for over 80 national charities, professional bodies, regional organisations and corporate organisations working together to transform neurological treatment, care and support.

## **2. What we set out to do in 2021-22**

Our mission is to raise awareness and understanding of neurological conditions to ensure that every person diagnosed with a neurological condition has access to high quality, joined up services and information from their first symptoms, throughout their life.

Our strategic objectives, set at the Board away day in 2021, were to:

1. Increase the influence and involvement of people with neurological conditions
2. Increase and strengthen the collective voice of the neurological community
3. Increase and drive the national policy profile of neurology
4. Increase and support local action to improve neurological services
5. To build a sustainable organisation capable of bringing about change

The Annual Report of the Trustees for 2021/22 is set out under these strategic objectives.

## **Goal 1- Increase the influence and involvement of people with neurological conditions**

Over 8,500 people with neurological conditions shared their experiences as part of the latest iteration of our national neurological patient experience survey, My Neuro Survey. We worked closely with member organisations, healthcare professionals, Neurological Alliances across the UK and, most importantly, with people affected by neurological conditions to develop and promote the survey. Between the end of October and early February, over 100 organisations promoted the survey online and more than 30 services providing care and support to people with neurological conditions distributed physical copies, weblinks and a language line option.

The data and free text responses underpinned a set of policy reports, "Together for the 1 in 6", with both nation specific and a UK-wide versions. Importantly, we launched the #BackThe1in6 campaign calling on Governments across the UK to establish a Neuro Taskforce to provide political leadership, coordinate ongoing service improvement initiatives and promote collaboration in addressing common challenges including workforce shortages and waiting lists.

We launched the campaign at an event in Westminster alongside member organisations, clinical colleagues, a dozen MPs and Peers and people affected by neurological conditions. One of our supportive Peers, Lord Dubs, held a debate in the Lords following the launch, calling on Government to support our call for change. Peers from across the political spectrum showed their support for the campaign during the debate, and we hope to secure a similar debate in the Commons in 22/23.

More than 13,500 people have signed a petition supporting the campaign, which will be handed in to Government in early 2023.

Our campaign hashtag, #BackThe1in6 trended briefly on Twitter when the petition was launched on social media. In June we had 10.9 K profile visits on Twitter - the channel usually attracts between 2000 and 4000 profile visits per month. In June we had 556 mentions on Twitter (mentions in a month usually range between 70 and 120). Our posts and tweets have been widely shared and followers across Twitter, Instagram, Facebook and LinkedIn continue to increase.

The launch created 11 pieces of coverage in total in June, including television (Scotland – STV & BBC Breakfast) and radio and online press coverage in England. 12 people affected by neurological conditions volunteered to share their real-life stories in press, on our website and through newsletters, to support and promote the campaign and had their stories collected. More volunteers continue to come forward. Member organisations continue to back the campaign, sharing content on social media, and encouraging their communities to sign the petition and/or volunteer their stories.

In February 2022 Jessica Mansel joined the Alliance for one day a week to help set up a co-production group of people affected by neurological conditions to inform the Alliance's work, especially to develop the 'Back the 1 in 6 campaign'. 12 people were selected from over eighty people coming from England, Wales, Scotland and Northern Ireland. The volunteers live with different types of neurological conditions including rare conditions. During April and May the volunteers worked with the team on the key messages and the best ways to communicate about My Neuro Survey. Two of them, Debbie Williams and Rhys Holmes joined us at Westminster for the launch with Debbie giving a keynote speech in which she urged the Alliance to ensure that notice was taken of the MNS reports and that they were not simply filed away. You can read more from Jess [here](#) and from Rhys [here](#).

We would like to pay particular thanks to the Neurological Alliance of Scotland, Neurological Alliance Cymru and the Northern Ireland Neurological Charities Alliance (NINCA) for their contribution and tireless support to promote and develop the campaign. In addition, many thanks to the MS Society for unstintingly lending their time and resources to make this happen. We would also like to thank the Kinghorn family for their kind legacy donation, which provided much needed support to launch the reports and campaign.

Alongside My Neuro Survey, we have continued to partner with the Brain and Spine Foundation to deliver 'Neuro Life Now', a digital platform for people with neurological conditions to share their experiences. We worked with the Brain and Foundation to develop 6 new reports which include approximately 900 responses from people affected by neurological conditions about their experiences of care. The data has been used to inform debates in Parliament, call for support for women living with a neurological condition and to support work on the forthcoming UK Acquired Brain Injury Strategy. The platform itself is about to enter an exciting new phase of development, following generous support from the Sowerby Foundation and National Lottery.

Finally, we have been speaking up about the experience of people with neurological conditions throughout the pandemic. In particular, it is clear that the number of people waiting for specialist care is on the rise - the number of people waiting for an NHS neurology or neurosurgery appointment in June 2022 was 255,129 – an 85% rise since June 2020. We

have retained our position on the high level NHSE/I elective taskforce, Long COVID taskforce, and outpatient transformation working group for neurology. Our guidance on Patient Initiated Follow-Up has been published on the NHS Futures website to support outpatient transformation. We have been working with the high-level elective care recovery group to assess plans against the elective recovery fund.

Collectively, we have helped to ensure neurology and neurosurgery are very much part of wider strategic recovery planning at the highest levels of NHSE/I, although clearly there is much progress to be made.

Following reports from people affected by neurological conditions and healthcare professionals, we raised concerns with NHS England and NHS Improvement about the eligibility criteria for neutralising monoclonal antibodies (nMABs) for coronavirus and held a meeting together with a number of charities with the Shadow Health Minister on this topic.

## **Goal 2 - Increase and strengthen the collective voice of the neurological community**

We have continued to provide shared spaces for members to connect, including via our policy group, mental health group and rare conditions group.

We worked with members and specifically with our mental health subgroup to shape a detailed response to the consultation on a 10-year cross-government plan for mental health and wellbeing. Our response highlighted the specific mental health and wellbeing challenges facing people with neurological conditions including the complex and poorly understood interplay between the physical and psychiatric, emotional and cognitive impacts of such conditions. We highlighted concerns about the workforce, particularly chronic shortages and geographical imbalances of specialist mental health practitioners, alongside calls for a review of local Mental Health Commissioning Policies to ensure equitable access to mental health support for everyone with a neurological condition. Our response was underpinned by data from My Neuro Survey and included relevant recommendations from our recent "Together for the 1 in 6" England policy report.

We retained our co-opted membership of the Royal College of Psychiatry Neuropsychiatry Faculty executive for another year with the position currently held by our Policy and External Affairs Manager, Sam Mountney. We were delighted to have the support of the faculty for our national neurological patient experience survey, My Neuro Survey.

We also met with the Council of the Royal College of Psychiatry alongside Ben, a carer, to discuss his personal experiences supporting his wife who lived with Huntington's. A wide range of Faculties within the College expressed an interest in collaborating to develop improved support for people with neurological conditions and supporting the development of credentialling.

Our Rare Conditions Subgroup continues to meet quarterly providing a forum for members supporting those with rare neurological conditions to share intelligence and explore issues of mutual interest. The group has helped to shape responses to consultations including the recently enacted Innovative Medicines Fund and has helped to inform thinking and positioning on topics such as the UK Rare Diseases Framework and planned delegation of many specialised neuroscience from NHS England to Integrated Care Systems (ICSs). Sue Millman of Ataxia UK has provided the group with updates on the implementation of the UK Rare Diseases Framework. We have also strengthened our working relationship with Genetic Alliance UK, with reciprocal attendance of our Rare Conditions Subgroup and Genetic Alliances Patient Empowerment Group (PEG).

We completed work with RAND Europe to map out the feasibility of modelling specialist health workforce needs in the future in secondary and tertiary care. The work, which included data

kindly provided by members and associates from the Alliance, will soon be made available to our membership. The work concludes that it may be possible to map future workforce needs for medics and nurses, but it is unlikely this will be possible for allied healthcare professionals. On this basis, we will work with our associate members to map out the next stage of our work on the workforce, recognising this is an important priority for both people affected by neurological conditions and our membership. Our thanks to Merck, who provided funding to conduct the feasibility research.

We have also continued to support the roll out of the COVID Clinical Neuroscience Study (CNS), which is looking into the biological causes of neurological and neuropsychiatric impacts in people who have been hospitalised with COVID-19. The study, jointly conducted by Kings College London and the University of Liverpool, has already helped to enhance global understanding of these impacts, with more than 40 academic publications linked to the study since 2020. We have remained a committed member of the Patient and Public Involvement Panel, and also held a webinar with our members in January 2022 to heighten awareness of the study and initial findings.

### **Goal 3 – Increase and drive the national policy profile of neurology**

This year marked an important moment for neuroscience, as NHSE/I committed to the appointment of National Clinical Directors for both neurology and neurosurgery and spinal surgery. Our focus nationally therefore has been to continue to support the work of the National Neuroscience Advisory Group (NNAG), ensuring transformation work within the NHSE/I has the experiences of people affected by neurological conditions at its core, and providing critical input into new NHSE/I structures ahead of the NCDs being appointed.

These appointments follow strong pressure from our membership – more than 30 groups from across neuroscience wrote to the NHSE/I Medical Director Stephen Powis in November 2021, calling for the appointment of NCDs. These new NCD posts represent a new dawn of clinical leadership within the NHS, and we are committed to working closely with them to ensure people affected by neurological conditions and our members are central to their work.

In parallel, we have worked closely with NHSE/I specialised commissioning to develop their plans for the future commissioning models for neuroscience, as well as to map out the changing role of the NHSE/I neuroscience Clinical Reference Group (CRG). The CRG, which will in future be split into two (neurology and neurosurgery) and chaired by NCDs, are likely to take a broader, more integrated focus to planning. In addition, we have worked with our fellow Patient and Public Voice (PPV) CRG representative, Phillip Anderson (MS Society) to support people with neurological conditions to share their experiences directly with the neuroscience CRG. This is the first time an NHSE/I CRG has taken such an approach, and will urge our forthcoming NCDs to adopt a similar approach in future.

We have continued to provide secretariat support and to co-Chair NNAG and National Intelligence Collaborative (NIC), with a focus on developing optimum pathways of care and defining good outcomes associated with good care.

In September 2021, we worked with members of NNAG to host an outcomes event that sought to define good outcomes in neurology. More than 50 people attended the day, which included presentations from a range of leaders and people affected by neurological conditions, about their proposed approach to defining outcomes. Ahead of the event, we worked with the Association of British Neurologists Advisory Groups and Specialist Interest Groups to develop a 'long list' of proposed clinical and activity outcomes. Patient groups were also asked to submit patient experience measures and patient reported outcomes to aid the discussion. The [Defining outcomes in neurology report](#) was published on the NNAG website early in 2022, and we are working with the ABN Quality Committee to develop an approach to collecting common outcomes across neurology services.

In addition, we have worked with NNAG to develop 12 optimum care pathways across neuroscience. The integrated pathways have been developed with clinical leaders across a range of neurological conditions, and vital input from people affected by neurological conditions and patient groups. We would like to thank everyone involved for their commitment and input to this work.

Finally, NNAG and NIC have worked together to develop a vision for services for people affected by neurological conditions. The plan will serve as an important 'manifesto' for our incoming NCDs, as they begin to map out their priorities when in post.

Our influencing efforts around the Health and Care Bill (and subsequent Act) focussed on cross-sector calls for stronger workforce planning provisions and much-needed changes to the social care cap to provide better support to working age adults who require social care and less-well off older people. Our parliamentary engagement predominantly focussed on the House of Lords with amendments on both issues secured and passed by Peers, disappointingly neither amendment was accepted by Government. As part of the Care and Support Alliance (CSA) Working Age Disabled Adults (WADA) group, we met with Care Minister Gillian Keegan and Minister for Disabled People, Chloe Smith to discuss social care support. Engagement with the Royal College of Physicians, who led the workforce amendment coalition, has continued with the Alliance joining the Inequalities in Health Alliance.

Our guidance on patient-initiated follow-up (PIFU) in neurology was included on the NHS Futures outpatient transformation programme (OTP) workspace in April 2022. The platform has over 4600 members and the OTP workspace attracted over 125k views between July and September 2021. NHSE/I used its platforms to publicise the guidance and reach operational and transformation leads, regional leads, neurology clinicians and staff, through a variety of internal and external platforms including the Clinical Advisory Group, helping us to reach (and make ourselves known to) new key audiences. We also provided social media assets to facilitate the sharing of the guidance on the Outpatient Recovery & Transformation Programme LinkedIn page, which has 1000 followers. The guidance was also shared across our own platforms (members' newsletter, social media and website).

## **Goal 4 - Increase and support local action to improve neurological services**

This year, our work has increasingly focused on the local networks required to effectively engage with the right people within Integrated Care Systems, given their forthcoming responsibilities in the commissioning and provision of services for people with neurological conditions.

In particular, we held discussions with people affected by neurological conditions, our members, affiliates and healthcare professionals throughout the year about what they believe would constitute our shared aims and approach to engaging with ICS stakeholders. It is clear that collectively, the community would like to ensure people with neurological conditions have a voice within new structures, that we have common messaging and evidence across the Alliance, and that organisations are able to share their experiences of working with ICS stakeholders.

To this end, we will increase our focus on ICS engagement in this coming year and provide further opportunities for organisations across the Alliance to collaborate.

We have continued to hold regular meetings with members of the eight regional neurological alliance groups. These meetings provide the opportunity to provide updates on the work of the Alliance at national level and for regions to raise issues of concern. They report difficulties with funding and with other resources. Some Regional Alliance's have also cited a need for

additional support from the National Neurological Alliance, although the specifics of this need to be understood and mapped out further. This work will be undertaken in 2022 – 23.

Nonetheless, they continue to speak for the people in their areas and have been seeking to engage with the ICS structures as these are put into place.

## **Goal 5 - To build a sustainable organisation capable of bringing about change**

One of our key developments of the last year has been the establishment of a CEO forum for CEOs of our member charities, UK Neurological Alliances and Chairs of Regional Neurological Alliances. An initial meeting was held during NeuroFest November 2021, facilitated by Sarah Vibert of NCVO (National Council for Voluntary Organisations). This idea has proved to be popular with members with the two meetings in March and June 2022 (facilitated by Kripen Dhrona, British Polio Fellowship) being attended by twenty CEOs with lively and collaborative discussions. It was agreed that the group would continue to meet and to work on matters of common interest including local influencing and the impact of the cost of living crisis on people living with neurological conditions.

NeuroFest 2021 featured more than twenty speakers, including clinical directors, people affected by neurological conditions, representatives from NHSE/I and Trust Chief Executives. Needless to say we are hugely thankful to everyone who spoke at the festival and joined in the discussions.

We renewed our commitment to ensuring equity, diversity and inclusion are at the heart of what we do. We have worked closely with a small group of clinicians to develop a focussed literature review of evidence to suggest differences between sociodemographic groups in prevalence, incidence, access and experience of care amongst the ten most high prevalence neurological conditions. The evidence formed basis of ten academic posters at the Association of British Neurologist (ABN) conference in May 2022. Our particular thanks to our trustee Dr Arani Nitkunan, Dr James Mitchell, Dr Kit Wu and Micha Vidot, for their commitment and time dedicated to this project.

In addition, we conducted a light touch review of our recruitment processes, with a view to minimising risk of unconscious bias and to attract as a diverse a pool of candidates as possible. In 2022/23 We will continue to review our people policies with these aims in mind.

We conducted our annual survey of membership, and 34 members responded. Once again, the majority of members reported value for money of their membership, with 87% of respondents reporting this. Members felt we have a strong voice at a national level and provide a good space for collective action. Members did however report that people affected by neurological conditions could have a stronger voice in Alliance work, and do more to communicate changes in health policy. Our 2022/23 plans and new 5 year strategy have of course been strongly influenced by these results.

### **3. Our structure, governance and management**

#### **3.1 Trustees selection**

We are governed by a Board of Trustees, made up of a minimum of three and a maximum of 14 people. This includes up to three independent trustees and 11 elected trustees.

In advance of each Annual General Meeting (AGM), all members are invited to send in their nominations for the Board. Details of the Trustee candidates are then circulated to all members

and votes are made by ballot or poll at the AGM or sent in advance to the Chair using a proxy form; each member organisation is entitled to one vote, placed at the AGM.

After completing a three-year term, each Trustee will stand down from the Board. Trustees who have completed only one term may stand for re-election; those who have served two consecutive terms must stand down for one year before they may stand again for the Board.

On joining the Alliance Board, all new Trustees undertake a tailored induction programme. The Trustees, who are also directors for the purpose of the Companies Act, and who served during the year are listed in section 5.1.

### **3.2 Structure**

We are a company limited by guarantee (no 02939840) and a registered charity (no 1039034). We are governed by Articles of Association and Byelaws. Our main activity is to secure the highest standards of care and treatment for every person affected by a neurological condition.

Our Board of Trustees is responsible for our governance and strategy and meets every quarter. Our Chief Executive is responsible for implementing the strategy and reports on its progress at the Board meetings. The Chief Executive reports directly to and is supervised by the Chair. They speak and meet regularly to discuss Alliance business.

Communication, both formal and informal, between Trustees and staff is frequent and effective.

#### **3.2.1 Staff**

|                 |                                                                     |
|-----------------|---------------------------------------------------------------------|
| Georgina Carr   | Chief Executive and Company Secretary (from January 2020 – present) |
| Caroline Davies | Administration and Membership Officer (From October 2019 – present) |
| Miranda Lloyd   | Communications and External Affairs Officer (March 2021 – present)  |
| Jessica Mansel  | Co-production Co-ordinator (February 2022 – present)                |
| Sam Mountney    | Policy and External Affairs Manager (June 2021 – present)           |

#### **3.2.2 Members**

Full membership is open to national voluntary organisations who represent patients, service users, families and carers (non-statutory, non-profit) organisations, who, in addition to the full benefits of membership, will have a right to vote at the AGM, have the right to nominate a trustee and an opportunity to influence our strategic direction. Subscriptions are income assessed.

- Full affiliate membership is open to Regional Neurological Alliances operating on a non-statutory, non-profit basis. Affiliate members will pay a subscription rate which is not income assessed.
- Associate status is open to non-profit organisations, including professional associations and statutory authorities, who will play an active part in the Alliance but do not have the right to nominate a trustee or vote at the AGM. Subscriptions are income assessed.
- Regional Associations of Neurological Organisations are also associates. They are staff led groups and will pay a subscription rate which is not income assessed.
- Corporate supporter status is open to for-profit organisations, who cannot vote at the AGM or nominate a trustee.
- Reciprocal partners are normally umbrella organisations whose aims and objectives match well with those of the Alliance. They cannot vote or influence our strategic direction.

## Members 2021-2022

|                                                                             |                                                                                                 |
|-----------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
|                                                                             |                                                                                                 |
| Ataxia UK                                                                   | <a href="http://www.ataxia.org.uk">www.ataxia.org.uk</a>                                        |
| Autistica                                                                   | <a href="http://www.autistica.org.uk">www.autistica.org.uk</a>                                  |
| Batten Disease Family Association                                           | <a href="http://www.bdfa-uk.org.uk">www.bdfa-uk.org.uk</a>                                      |
| Brain and Spine Foundation                                                  | <a href="http://www.brainandspine.org.uk">www.brainandspine.org.uk</a>                          |
| Brain Research UK (formally Brain Research Trust)                           | <a href="http://www.brainresearchuk.org.uk/">www.brainresearchuk.org.uk/</a>                    |
| Brain Tumour Research                                                       | <a href="https://www.braintumourresearch.org/">https://www.braintumourresearch.org/</a>         |
| British Polio Fellowship                                                    | <a href="http://www.britishpolio.org.uk">www.britishpolio.org.uk</a>                            |
| Cavernoma Alliance UK                                                       | <a href="http://www.cavernoma.org.uk">www.cavernoma.org.uk</a>                                  |
| Childhood Tumour Trust <sup>1</sup>                                         | <a href="https://www.childhoodtumourtrust.org.uk/">https://www.childhoodtumourtrust.org.uk/</a> |
| Cure Parkinson's <sup>2</sup>                                               | <a href="https://cureparkinsons.org.uk/">https://cureparkinsons.org.uk/</a>                     |
| CMT United Kingdom                                                          | <a href="http://www.cmt.org.uk">www.cmt.org.uk</a>                                              |
| The Daisy Garland                                                           | <a href="http://www.thedaisygarland.org.uk">www.thedaisygarland.org.uk</a>                      |
| Different Strokes                                                           | <a href="http://www.differentstrokes.co.uk">www.differentstrokes.co.uk</a>                      |
| Downs Syndrome Research (DSRF)                                              | <a href="http://www.dsrf-uk.org">www.dsrf-uk.org</a>                                            |
| Dravet Syndrome UK                                                          | <a href="https://www.dravet.org.uk/">https://www.dravet.org.uk/</a>                             |
| Dystonia Society                                                            | <a href="http://www.dystonia.org.uk">www.dystonia.org.uk</a>                                    |
| Epilepsy Action                                                             | <a href="http://www.epilepsy.org.uk">www.epilepsy.org.uk</a>                                    |
| Epilepsy Research UK                                                        | <a href="http://www.epilepsyresearch.org.uk">www.epilepsyresearch.org.uk</a>                    |
| FD UK                                                                       | <a href="http://www.familialdysautonomia.co.uk">www.familialdysautonomia.co.uk</a>              |
| FND Action                                                                  | <a href="http://www.fndaction.org.uk">www.fndaction.org.uk</a>                                  |
| FND Hope                                                                    | <a href="http://www.fndhope.org">www.fndhope.org</a>                                            |
| GAIN (Guillain-Barré and Associated Inflammatory Neuropathies)              | <a href="http://www.gaincharity.org.uk">www.gaincharity.org.uk</a>                              |
| Glut 1 Deficiency UK <sup>1</sup>                                           | <a href="https://glut1deficiency.org.uk/">https://glut1deficiency.org.uk/</a>                   |
| Hereditary Spastic Paraplegia Support Group <sup>1</sup>                    | <a href="https://hspgroup.org/">https://hspgroup.org/</a>                                       |
| Huntington's Disease Association                                            | <a href="http://www.hda.org.uk">www.hda.org.uk</a>                                              |
| IIH UK                                                                      | <a href="https://www.iih.org.uk/">https://www.iih.org.uk/</a>                                   |
| Matthew's Friends                                                           | <a href="https://www.matthewsfriends.org/">https://www.matthewsfriends.org/</a>                 |
| Migraine Trust                                                              | <a href="http://www.migrainetrust.org">www.migrainetrust.org</a>                                |
| Motor Neurone Disease Association                                           | <a href="http://www.mndassociation.org">www.mndassociation.org</a>                              |
| Multiple Sclerosis National Therapy Centres                                 | <a href="http://www.msntc.org.uk">www.msntc.org.uk</a>                                          |
| Multiple Sclerosis Society                                                  | <a href="http://www.mssociety.org.uk">www.mssociety.org.uk</a>                                  |
| Multiple Sclerosis Trust                                                    | <a href="http://www.mstrust.org.uk">www.mstrust.org.uk</a>                                      |
| Multiple System Atrophy Trust                                               | <a href="http://www.msatrust.org.uk">www.msatrust.org.uk</a>                                    |
| Myaware                                                                     | <a href="http://www.myaware.org">www.myaware.org</a>                                            |
| Myelopathy.org                                                              | <a href="https://myelopathy.org/">https://myelopathy.org/</a>                                   |
| Narcolepsy UK                                                               | <a href="http://www.narcolepsy.org.uk">www.narcolepsy.org.uk</a>                                |
| The National Hospital for Neurology And Neurosurgery Development Foundation | <a href="http://www.nationalbrainappeal.org">www.nationalbrainappeal.org</a>                    |
| National Tremor Foundation                                                  | <a href="http://www.tremor.org.uk">www.tremor.org.uk</a>                                        |
| Nerve Tumours UK <sup>1</sup>                                               | <a href="http://nervetumours.org.uk">nervetumours.org.uk</a>                                    |
| Overcoming MS                                                               | <a href="http://www.overcomingMS.org">www.overcomingMS.org</a>                                  |
| Parkinson's UK                                                              | <a href="http://www.parkinsons.org.uk">www.parkinsons.org.uk</a>                                |

**Members (continued)**

|                                                                           |                                                                                        |
|---------------------------------------------------------------------------|----------------------------------------------------------------------------------------|
| Polio Survivors Network                                                   | <a href="http://www.poliosurvivorsnetwork.org.uk">www.poliosurvivorsnetwork.org.uk</a> |
| Polio Warriors (The World-Wide Fellowship of Polio Warriors) <sup>1</sup> | <a href="http://www.poliowarriors.org">www.poliowarriors.org</a>                       |
| PSP Association                                                           | <a href="http://www.pspeur.org">www.pspeur.org</a>                                     |
| Ring 20 Research and Support UK CIO                                       | <a href="http://ring20researchsupport.co.uk/">ring20researchsupport.co.uk/</a>         |
| Spinal Muscular Atrophy Support UK                                        | <a href="http://smauk.org.uk/">smauk.org.uk/</a>                                       |
| Spotlight YOPD                                                            | <a href="http://spotlightyopd.org/">spotlightyopd.org/</a>                             |
| SUDEP Action                                                              | <a href="http://www.sudep.org">www.sudep.org</a>                                       |
| Sue Ryder                                                                 | <a href="http://www.sueryder.org">www.sueryder.org</a>                                 |
| Tourettes Action                                                          | <a href="http://www.tourettes-action.org.uk">www.tourettes-action.org.uk</a>           |
| Transverse Myelitis Society                                               | <a href="http://www.myelitis.org.uk">www.myelitis.org.uk</a>                           |
| Trigeminal Neuralgia Association UK                                       | <a href="http://www.tna.org.uk">www.tna.org.uk</a>                                     |
| UK Acquired Brain Injury Forum                                            | <a href="http://www.ukabif.org.uk">www.ukabif.org.uk</a>                               |

**Associates**

|                                                                                                               |                                                                                                                                                                                          |
|---------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Association of British Neurologists                                                                           | <a href="http://www.theabn.org">www.theabn.org</a>                                                                                                                                       |
| Association of Chartered Physiotherapists in Neurology (ACPIN)                                                | <a href="http://www.acpin.org.uk">www.acpin.org.uk</a>                                                                                                                                   |
| British Association of Stroke Physicians (Now British and Irish association of Stoke Physicians) <sup>1</sup> | <a href="http://www.biasp.org">www.biasp.org</a>                                                                                                                                         |
| British Paediatric Neurology Association                                                                      | <a href="http://www.bpna.org.uk">www.bpna.org.uk</a>                                                                                                                                     |
| Division of Neuropsychology (British Psychological Society)                                                   | <a href="http://www.bps.org.uk/networks-and-communities/member-microsite/division-neuropsychology">www.bps.org.uk/networks-and-communities/member-microsite/division-neuropsychology</a> |
| British Society of Rehabilitation Medicine <sup>1</sup>                                                       | <a href="https://www.bsrn.org.uk/">https://www.bsrn.org.uk/</a>                                                                                                                          |
| The Independent Neurorehabilitation Providers Alliance <sup>1</sup>                                           | <a href="https://in-pa.org.uk/">https://in-pa.org.uk/</a>                                                                                                                                |
| The Neurology Academy                                                                                         | <a href="https://neurologyacademy.org/">https://neurologyacademy.org/</a>                                                                                                                |

**Associate Regional Groups**

|                                                                    |                                                        |
|--------------------------------------------------------------------|--------------------------------------------------------|
| East Midlands Association of Neurological Organisations            |                                                        |
| South West Alliance of Neurological Organisations                  | <a href="http://www.swano.org">www.swano.org</a>       |
| Yorkshire and Humberside Association of Neurological Organisations | <a href="http://www.yhano.org.uk">www.yhano.org.uk</a> |

**Corporate supporters**

|                       |                                                                                 |
|-----------------------|---------------------------------------------------------------------------------|
| AbbVie Allergan       | <a href="http://www.abbvie.co.uk">www.abbvie.co.uk</a>                          |
| Biogen                | <a href="http://www.biogen.uk.com">www.biogen.uk.com</a>                        |
| Boston Scientific     | <a href="https://www.bostonscientific.com">https://www.bostonscientific.com</a> |
| Genzyme               | <a href="http://www.genzyme.co.uk">www.genzyme.co.uk</a>                        |
| Lundbeck <sup>1</sup> | <a href="https://www.lundbeck.com/uk">https://www.lundbeck.com/uk</a>           |
| Merck Serono          | <a href="http://www.merckserono.co.uk">www.merckserono.co.uk</a>                |
| Novartis              | <a href="http://www.novartis.co.uk">www.novartis.co.uk</a>                      |
| Teva UK Limited       | <a href="http://www.tevauk.com">www.tevauk.com</a>                              |
| Roche                 | <a href="https://www.roche.com/">https://www.roche.com/</a>                     |
| UCB Pharma Ltd        | <a href="http://www.ucb.co.uk">www.ucb.co.uk</a>                                |

### Regional Neurological Alliances

|                                                                                     |                                                                                                                  |
|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| Black Country Neurological Alliance                                                 | <a href="http://www.blackcountryneuroalliance.org.uk">www.blackcountryneuroalliance.org.uk</a>                   |
| Bolton Neuro Voices                                                                 | <a href="http://www.boltoncvcs.org.uk">www.boltoncvcs.org.uk</a>                                                 |
| Greater Manchester Neurological Alliance                                            | <a href="http://www.gmna.co.uk/">www.gmna.co.uk/</a>                                                             |
| Hampshire Neurological Alliance                                                     | <a href="http://www.hantsneuroalliance.hampshire.org.uk">www.hantsneuroalliance.hampshire.org.uk</a>             |
| Lincolnshire Neurological Alliance                                                  | <a href="http://www.lincolnshire-neurological-alliance.org.uk">www.lincolnshire-neurological-alliance.org.uk</a> |
| Merseyside and Cheshire Neurological Alliance                                       | <a href="http://www.neurosupport.org.uk">www.neurosupport.org.uk</a>                                             |
| Neuro Key (formerly Tees Valley, Durham, and North Yorkshire Neurological Alliance) | <a href="http://www.na-tvdny.org.uk">www.na-tvdny.org.uk</a>                                                     |
| West Berkshire Neurological Alliance                                                | <a href="http://www.wbna.org.uk">www.wbna.org.uk</a>                                                             |

### Reciprocal members

|                                   |                                                                                                |
|-----------------------------------|------------------------------------------------------------------------------------------------|
| National Voices                   | <a href="https://www.nationalvoices.org.uk/">https://www.nationalvoices.org.uk/</a>            |
| Neurological Alliance of Ireland  | <a href="http://www.nai.ie">www.nai.ie</a>                                                     |
| Neurological Alliance of Scotland | <a href="http://www.scottishneurological.org.uk">www.scottishneurological.org.uk</a>           |
| Neurological Alliance of Wales    | <a href="http://www.walesneurologicalalliance.org.uk">www.walesneurologicalalliance.org.uk</a> |

<sup>1</sup>. New members in 2021-22

<sup>2</sup>. Ceased members in 2021-22

<sup>3</sup>. Organisation closed in 2021-22

### 3.2.3 The way we work

As a membership organisation, our whole ethos is to work in partnership. We work across the neurological community to identify common priorities for people affected by a condition and then seek to influence, shape and support policy development to reduce inequalities, enhance their outcomes and, where possible, help them live for longer and in better health. Our activities are therefore based on a clear and shared sense of purpose. We work with the Trustees, the Policy Group and Policy Steering group to determine our strategy and plans.

#### 3.2.3a The Policy Group

Any member of the Alliance can take part of the Policy Group. The Group's purpose is to:

- Make recommendations to Alliance Trustees on Alliance policy and activity, ensuring that these reflect the needs and objectives of its member organisations
- Build collective ownership of the Alliance beyond staff and Trustees and to promote team-working across the member organisations
- Provide a forum for policy and campaigns staff of member organisations to share information and provide mutual support
- More closely align member organisations' priorities with the collective needs of the Alliance
- Ensure that all member organisations, large and small, can contribute to the work of the Alliance.

### **3.2.3.1ai Policy Group leads**

Sam Carney Health Policy and Improvement Lead, Parkinson's UK, Co-Chair (appointed May 2021)

Dawn Golder Executive Director, FND Hope UK, Co-Chair (appointed Feb 2021)

### **3.3 Risk management**

The Trustees have assessed the major risks to which the charity is exposed and are satisfied that systems are in place to mitigate exposure to major risks. A risk management strategy, reviewed annually, is in place. We also have a risk-based reserves policy which mitigates one of our main financial risks, in terms of having over three quarters of our income coming from just 13 funders (four charities, ten corporates).

### **4. Public benefit**

Our work benefits people affected by a neurological condition and those who represent them. Sections 1 and 2 of this report set out our objectives, report on our activities and successes, and set out our plans for the current financial year.

The Trustees consider that they have complied with their duty in s4 of the Charities Act 2011 to have due regard to the guidance on public benefit published by the Charity Commission. The Trustees have considered this matter and concluded:

- That the aims of the organisation continue to be charitable
- That the aims and the work done give identifiable benefits to the charitable sector and both indirectly and directly to individuals in need
- That the benefits are for the public, are not unreasonably restricted in any way and certainly not by ability to pay
- That there is no detriment or harm arising from the aims or activities.

### **5. Reference and administrative details**

The Alliance is a registered charity (1039034) and company limited by guarantee (02939840) registered in England. The Alliance's registered office was, from 21<sup>st</sup> September 2019, The Junction, Station Road, Watford, WD17 1ET.

### **5.1 Trustees and the nominating organisation**

|                    |                                                                     |
|--------------------|---------------------------------------------------------------------|
| Katharine Crawford | Parkinson's UK                                                      |
| Kripen Dhrona      | British Polio Fellowship (appointed Nov 2021)                       |
| Marc Smith         | Brain and Spine Foundation (Vice-Chair)                             |
| Chris James        | Motor Neurone Disease Association                                   |
| Alan Bowers        | Sue Ryder (appointed Nov 2021)                                      |
| David Martin       | Multiple Sclerosis Trust (re-appointed Nov 2021, Chair)             |
| Caroline Morrice   | Guillain-Barre and Associated Inflammatory Neuropathies (Treasurer) |
| Sarah Rawlings     | MS Society                                                          |
| Cath Stanley       | Huntington's Disease Association                                    |
| Amanda Swain       | UK Acquired Brain Injury Forum (re-appointed Nov 2021)              |
| Angie Pullen       | Epilepsy Action (stepped down July 2022)                            |

During the year the Board, again, co-opted three independent Trustees with the aim of achieving greater diversity on the board in terms of the professional backgrounds of members. The three co-opted trustees are:

|                    |                                                    |
|--------------------|----------------------------------------------------|
| David Garmon-Jones | appointed February 2018, reappointed February 2021 |
| Ralph Gregory      | appointed February 2018, reappointed February 2021 |
| Arani Nitkunan     | Appointed July 2020                                |
| Alison Fuller      | Appointed August 2022                              |

## 5.2 Professional advisors

|                       |                                                                                                                 |
|-----------------------|-----------------------------------------------------------------------------------------------------------------|
| Bankers               | CAF Bank Ltd, PO Box 289, West Malling, Kent, ME19 4TA<br>Metro Bank PLC, One Southampton Row, London, WC1B 5HA |
| Accountants           | Godfrey Wilson, 5th Floor, Mariner House<br>62 Prince Street<br>Bristol<br>BS1 4QD                              |
| Independent Examiners | Goodman Jones LLP, 29-30 Fitzroy Square, London W1T 6LQ                                                         |

## 6. Finances

### 6.1 Investment

Article 5.1.23 empowers the Alliance, with advice from a financial expert, to invest the funds of the Alliance as it sees fit, with consideration of the the suitability of investments and the need for diversification.

### 6.2 Subscriptions

Subscription rates are determined by the organisational income of each member and associate. Subscriptions for affiliate members are at a fixed rate.

### 6.3 Reserves policy

A reserves policy was agreed by Trustees during 2021. This policy is a risk-based policy, to reflect the reality that any reduction in income or increasing in costs would take place over a period of time.

Having considered the risks, Trustees consider it prudent that reserves should be maintained in order to cover the loss of income from one third of the significant income sources. This equates to approximately £55,000.

At the end of the year reserves of £58,306 were held, of which £5,234 (2021: £9,165) was held in restricted funds.

### 6.4 Financial position

Income from membership subscriptions increased slightly to £96,883 (2020/21: £96,652). In parallel, the corporate funding has increased from £109,180 to £110,296. We also received charitable donations totalling £5,200.

We also received generous support from Merck to develop a new report on modelling future health and care workforce needs, totalling £2,000.

Overall, there is a deficit of £60,267 (before transfers) on the unrestricted funds (2020/21 surplus of £41,646) and a deficit of £19,632 (before transfers) on restricted funds (2020/21: deficit of £11,238). This leaves an overall deficit of £64,198 (2020/21 surplus of £30,408) for the year.

### 6.5 Trustees' responsibilities statement

The Trustees (who are also directors of The Neurological Alliance for the purposes of company law) are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2019;
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

- there is no relevant information of which the charitable company's independent examiner is unaware; and
- the Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the independent examiner is aware of that information.

## **6.6 Independent Examiners**

At the AGM in November 2021, members agreed to delegate responsibility for selecting the Neurological Alliance's Independent Examiners for the forthcoming year and 2021-2022 accounts to the Board of trustees.

The Board decided to appoint Goodman Jones LLP to be our independent examiner for 2021/22.

## **6.7 Small company provisions**

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the Board of Trustees

*David Martin*

**David Martin**

**Chair, Board of Trustees**

**Date:** 18-11-22

**INDEPENDENT EXAMINER'S REPORT**  
**TO THE TRUSTEES OF THE NEUROLOGICAL ALLIANCE (the 'Charity')**  
**YEAR ENDED 30 JUNE 2022**

I report to the charity Trustees on my examination of the accounts of the Neurological Alliance for the year ended 30 June 2022.

**Responsibilities and basis of report**

As the Trustees of the Charity (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

**Independent examiner's statement**

I have completed my examination. I can confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

**Martin Bailey, FCA**  
**Goodman Jones LLP**  
Chartered Accountants  
29-30 Fitzroy Square  
London W1T 6LQ

*Martin Bailey*

Dated: 18-11-22

# THE NEUROLOGICAL ALLIANCE

## STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING THE INCOME AND EXPENDITURE ACCOUNT)

YEAR ENDED 30 JUNE 2022

|                                             | Note | Unrestricted<br>Funds<br>£ | Restricted<br>Funds<br>£ | Total Funds<br>2022<br>£ | Total Funds<br>2021<br>£ |
|---------------------------------------------|------|----------------------------|--------------------------|--------------------------|--------------------------|
| <b>INCOME AND<br/>ENDOWMENTS FROM:</b>      |      |                            |                          |                          |                          |
| Donations and legacies                      | 3    | 5,768                      | -                        | 5,768                    | 500                      |
| Charitable activities                       | 4    | 210,979                    | 875                      | 211,854                  | 223,332                  |
| Investments                                 | 5    | 49                         | -                        | 49                       | 7                        |
| <b>TOTAL</b>                                |      | <b>216,796</b>             | <b>875</b>               | <b>217,671</b>           | <b>223,839</b>           |
| <b>EXPENDITURE ON:</b>                      |      |                            |                          |                          |                          |
| Raising funds                               |      | 5,901                      | -                        | 5,901                    | 5,857                    |
| Charitable activities                       |      | 255,461                    | 20,507                   | 275,968                  | 187,574                  |
| <b>TOTAL</b>                                | 6    | <b>261,362</b>             | <b>20,507</b>            | <b>281,869</b>           | <b>193,431</b>           |
| <b>NET EXPENDITURE<br/>BEFORE TRANSFERS</b> |      |                            |                          |                          |                          |
| Transfers between Funds                     | 14   | (44,566)<br>(15,701)       | (19,632)<br>15,701       | (64,198)<br>-            | 30,408<br>-              |
| <b>NET MOVEMENT IN<br/>FUNDS</b>            |      | <b>(60,267)</b>            | <b>(3,931)</b>           | <b>(64,198)</b>          | <b>30,408</b>            |
| <b>RECONCILIATION OF<br/>FUNDS:</b>         |      |                            |                          |                          |                          |
| Total funds brought forward                 |      | 113,069                    | 9,165                    | 122,234                  | 91,826                   |
| Net movement in funds                       |      | (60,267)                   | (3,931)                  | (64,198)                 | 30,408                   |
| <b>TOTAL FUNDS<br/>CARRIED FORWARD</b>      |      | <b>52,802</b>              | <b>5,234</b>             | <b>58,036</b>            | <b>122,234</b>           |

The Statement of Financial Activities includes all gains and losses recognised in the year.

All income and expenditure derives from continuing activities.

The notes below part of these financial statements.

# THE NEUROLOGICAL ALLIANCE

## BALANCE SHEET

30 JUNE 2022

|                                                       | Note | 2022<br>£            | 2021<br>£             |
|-------------------------------------------------------|------|----------------------|-----------------------|
| <b>FIXED ASSETS</b>                                   |      |                      |                       |
| Tangible assets                                       | 12   | 304                  | 999                   |
| <b>CURRENT ASSETS</b>                                 |      |                      |                       |
| Debtors                                               | 13   | 13,605               | 56,265                |
| Cash at bank and in hand                              |      | 70,546               | 80,405                |
|                                                       |      | <u>83,373</u>        | <u>136,670</u>        |
| <b>CREDITORS: Amounts falling due within one year</b> | 14   | <u>(26,419)</u>      | <u>(15,435)</u>       |
| <b>NET CURRENT ASSETS</b>                             |      | <b>57,732</b>        | <b>121,235</b>        |
| <b>NET ASSETS</b>                                     |      | <u><b>58,036</b></u> | <u><b>122,234</b></u> |
| <b>CHARITY FUNDS</b>                                  |      |                      |                       |
| Restricted income funds                               | 15   | 5,234                | 9,165                 |
| Unrestricted income funds                             | 15   | 52,802               | 113,069               |
| <b>TOTAL FUNDS</b>                                    |      | <u><b>58,036</b></u> | <u><b>122,234</b></u> |

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006. The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees on and signed on their behalf, by:

*David Martin*

**David Martin**  
**Chair, Board of Trustees**

**Date:** 18-11-22

Company Registration Number: 02939840

**The notes below part of these financial statements.**

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2022**

**1. GENERAL INFORMATION**

The Neurological Alliance is a registered charity and company limited by guarantee. Its charitable objects are set out in the Trustees' Report. Its registered office address is The Junction, Station Road, Watford, WD17 1EU

**2. ACCOUNTING POLICIES**

**2.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The financial statements are prepared on the going concern basis under the historical cost convention, modified to include certain items at fair value. The financial statements are presented in sterling which is the functional currency of the charitable company and rounded to the nearest £. The Neurological Alliance meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

**2.2 Company status**

The Charity is a company limited by guarantee. The members of the company are the Trustees named in the Trustee report section 5.1. In the event of the Charity being wound up, the liability in respect of the guarantee is limited to £10 per member of the Charity.

**2.3 Going concern**

The Trustees have assessed whether the use of the going concern assumption is appropriate in preparing these accounts and are of the opinion that the Charity will have sufficient resources to meet its liabilities as they fall due. The Trustees have made this assessment in respect of a period of one year from the date of approval of these accounts. The Trustees of the Charity have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the Charity to continue as a going concern.

**2.4 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2022**

**2. ACCOUNTING POLICIES** *(continued)*

**2.5 Income**

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received, and the amount of income receivable can be measured reliably.

The following specific policies are applied to particular categories of income:

Subscription income is invoiced in line with the financial year and recognised in the period to which it relates.

Corporate support represents amounts invoiced in the year.

Donated services or facilities are recognised when the Charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the Charity of the item is probable and that economic benefit can be measured reliably. On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the Charity which is the amount the Charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

**2.6 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the Bank.

**2.7 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Support costs are those costs incurred directly in support of expenditure on the objects of the Charity. Governance costs are those incurred in connection with administration of the Charity and compliance with constitutional and statutory requirements.

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2022**

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds. All expenditure is inclusive of irrecoverable VAT.

## **2.8 Operating leases**

Rentals under operating leases are charged to the Statement of Financial Activities incorporating Income and Expenditure Account on a straight-line basis over the lease term.

## **2.9 Tangible fixed assets and depreciation**

A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate that the carrying value of any fixed asset may not be recoverable. Shortfalls between the carrying value of fixed assets and their recoverable amounts are recognised as impairments. Impairment losses are recognised in the Statement of Financial Activities incorporating Income and Expenditure Account.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Office equipment        -        3 years straight line

## **2.10 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

## **2.11 Cash at Bank and in hand**

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

## **2.12 Liabilities and provisions**

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

## **2.13 Financial instruments**

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2022**

**2. ACCOUNTING POLICIES** *(continued)*

**2.14 Pensions**

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

**2.15 Critical accounting estimates and areas of judgement**

In the application of the Charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

In the opinion of the Trustees, there are no significant areas of estimation, uncertainty and critical judgements in applying accounting policies that have significant effect on the amounts recognised in the financial statements.

**3. INCOME FROM DONATIONS AND LEGACIES**

|                   | <b>Unrestricted<br/>Funds<br/>£</b> | <b>Restricted<br/>Funds<br/>£</b> | <b>Total Funds<br/>2022<br/>£</b> | <b>Total Funds<br/>2021<br/>£</b> |
|-------------------|-------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Donations         | 5,215                               | -                                 | 5,215                             | 500                               |
| Legacies          | 553                                 | -                                 | 553                               | -                                 |
|                   | <b>5,768</b>                        | <b>-</b>                          | <b>5,768</b>                      | <b>500</b>                        |
| <i>Total 2021</i> | <i>500</i>                          | <i>-</i>                          | <i>500</i>                        |                                   |

**4. INCOME FROM CHARITABLE ACTIVITIES**

|                   | <b>Unrestricted<br/>Funds<br/>£</b> | <b>Restricted<br/>Funds<br/>£</b> | <b>Total Funds<br/>2022<br/>£</b> | <b>Total Funds<br/>2021<br/>£</b> |
|-------------------|-------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Corporate Support | 110,296                             | -                                 | 110,296                           | 109,180                           |
| Subscriptions     | 96,883                              | -                                 | 96,883                            | 96,652                            |
| Projects          | 3,800                               | 875                               | 4,675                             | 17,500                            |
|                   | <b>210,979</b>                      | <b>875</b>                        | <b>211,854</b>                    | <b>223,332</b>                    |
| <i>Total 2021</i> | <i>210,832</i>                      | <i>12,500</i>                     | <i>223,332</i>                    |                                   |

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2022**

**5. INVESTMENT INCOME**

|                   | Unrestricted Funds<br>£ | Restricted Funds<br>£ | Total Funds<br>2022<br>£ | Total Funds<br>2021<br>£ |
|-------------------|-------------------------|-----------------------|--------------------------|--------------------------|
| Interest income   | 49                      | -                     | 49                       | 7                        |
|                   | <u>49</u>               | <u>-</u>              | <u>49</u>                | <u>7</u>                 |
| <i>Total 2021</i> | <u>7</u>                | <u>-</u>              | <u>7</u>                 |                          |

**6. ANALYSIS OF EXPENDITURE BY EXPENDITURE TYPE**

|                                         | Staff Costs<br>£ | Depreciation<br>£ | Other costs<br>£ | Total Funds<br>2022<br>£ | Total Funds<br>2021<br>£ |
|-----------------------------------------|------------------|-------------------|------------------|--------------------------|--------------------------|
| Expenditure on raising voluntary income | 4,404            | 69                | 1,428            | 5,901                    | 5,857                    |
| <b>Costs of raising funds</b>           | <b>4,404</b>     | <b>69</b>         | <b>1,428</b>     | <b>5,901</b>             | <b>5,857</b>             |
| Policy Development                      | 54,312           | 278               | 83,327           | 137,917                  | 91,921                   |
| Members' Activities                     | 36,697           | -                 | 31,365           | 68,062                   | 40,935                   |
| Support costs                           | 33,761           | 208               | 8,939            | 42,908                   | 39,359                   |
| <b>Charitable activities</b>            | <b>129,174</b>   | <b>556</b>        | <b>125,059</b>   | <b>254,788</b>           | <b>172,215</b>           |
| <b>Expenditure on governance</b>        | <b>17,613</b>    | <b>140</b>        | <b>9,328</b>     | <b>27,081</b>            | <b>15,359</b>            |
|                                         | <b>146,787</b>   | <b>695</b>        | <b>134,387</b>   | <b>281,869</b>           | <b>193,431</b>           |
| <i>Total 2020</i>                       | <i>134,944</i>   | <i>695</i>        | <i>57,792</i>    | <i>193,431</i>           |                          |

Expenditure on charitable activities attributable to unrestricted funds was £254,987 (2021: £166,693) and £26,882 (2021: £23,738) was attributable to restricted funds. All expenditure on raising funds was attributable to unrestricted funds in both the current and prior years.

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2022**

**7. DIRECT COSTS**

|                           | Policy Development<br>£ | Members Activities<br>£ | Total 2022<br>£ | Total 2021<br>£ |
|---------------------------|-------------------------|-------------------------|-----------------|-----------------|
| Project costs             | 77,676                  | 25,981                  | 103,657         | 39,494          |
| Meeting costs             | 1,229                   | 743                     | 1,972           | (400)           |
| Office and property costs | 1,367                   | 164                     | 1,533           | 1,271           |
| Legal & professional      | 2,775                   | 1,223                   | 3,998           | 7,199           |
| Wages and salaries        | 48,186                  | 32,559                  | 80,745          | 74,994          |
| National insurance        | 3,274                   | 2,212                   | 5,486           | 5,294           |
| Pension cost              | 2,851                   | 1,927                   | 4,778           | 4,726           |
| Depreciation              | 278                     | -                       | 278             | 278             |
| Software                  | 281                     | 94                      | 374             | -               |
| Bad debts written off     | -                       | 3,159                   | 3,159           | -               |
| <b>Total 2022</b>         | <b>137,917</b>          | <b>68,062</b>           | <b>205,980</b>  | <b>132,856</b>  |
| <i>Total 2021</i>         | <i>91,922</i>           | <i>40,934</i>           | <i>132,856</i>  |                 |

**8. SUPPORT COSTS**

|                               | Fundraising costs<br>£ | Governance<br>£ | Policy and Members Activities<br>£ | Total 2022<br>£ | Total 2021<br>£ |
|-------------------------------|------------------------|-----------------|------------------------------------|-----------------|-----------------|
| Project costs                 | -                      | -               | 1,273                              | 1,273           | 1,945           |
| Subscriptions                 | 257                    | 257             | 257                                | 771             | 1,406           |
| Post, printing and stationery | -                      | -               | 166                                | 166             | 148             |
| Property costs                | 36                     | 71              | 107                                | 214             | 234             |
| Bank charges                  | 10                     | 21              | 31                                 | 62              | 47              |
| Insurance                     | 143                    | 287             | 430                                | 860             | 833             |
| Recruitment and training      | 306                    | 1,528           | 1,528                              | 3,362           | 376             |
| Meeting costs                 | 243                    | 243             | 486                                | 972             | -               |
| Trustee meetings and AGM      | -                      | 3,056           | -                                  | 3,056           | 47              |
| Accountancy and payroll       |                        |                 | 3,360                              | 3,360           | 2,587           |
| Legal Fees                    |                        | 3,000           |                                    | 3,000           | 175             |
| Marketing                     | 339                    | 679             | 1,018                              | 2,036           | 2,431           |
| Software                      | 93                     | 187             | 281                                | 561             | -               |
| Wages and salaries            | 4,404                  | 17,613          | 33,761                             | 55,780          | 49,929          |
| Depreciation                  | 70                     | 169             | 208                                | 417             | 417             |
| <b>Total 2022</b>             | <b>5,901</b>           | <b>27,081</b>   | <b>42,908</b>                      | <b>75,890</b>   | <b>93,117</b>   |
| <i>Total 2021</i>             | <i>5,857</i>           | <i>15,359</i>   | <i>39,359</i>                      | <i>60,575</i>   |                 |

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2022**

**9. GOVERNANCE COSTS**

|                            | Unrestricted Funds | Restricted Funds | Total Funds 2022 | Total Funds 2021 |
|----------------------------|--------------------|------------------|------------------|------------------|
|                            | £                  | £                | £                | £                |
| Support costs - Governance | 9,328              | -                | 9,328            | 3,073            |
| Wages and salaries         | 17,613             | -                | 17,613           | 12,146           |
| Depreciation               | 140                | -                | 140              | 140              |
|                            | <u>27,081</u>      | <u>-</u>         | <u>27,081</u>    | <u>15,359</u>    |

**10. NET INCOME/(EXPENDITURE)**

This is stated after charging:

|                                        | 2022<br>£    | 2021<br>£    |
|----------------------------------------|--------------|--------------|
| Depreciation of tangible fixed assets: |              |              |
| - owned by the charity                 | 695          | 695          |
| Independent examination fee            | <u>1,800</u> | <u>1,800</u> |

During the year, no Trustees received any remuneration (2021 - £NIL).

During the year, no Trustees received any benefits in kind (2021 - £NIL).

During the year, 2 Trustees received £172 reimbursement of travel expenses (2021 – £NIL).

**11. STAFF COSTS**

**Staff costs were as follows:**

|                       | 2022<br>£      | 2021<br>£      |
|-----------------------|----------------|----------------|
| Wages and salaries    | 130,233        | 119,039        |
| Social security costs | 8,848          | 8,403          |
| Other pension costs   | 7,706          | 7,502          |
|                       | <u>146,787</u> | <u>134,944</u> |

The average number of persons employed by the Charity during the year was as follows:

|           | 2022<br>No. | 2021<br>No. |
|-----------|-------------|-------------|
| Employees | 4           | 4           |

No employee received remuneration amounting to more than £60,000 in either year. Key management personnel remuneration, including employer's NIC and pension, incurred by the charity in the 2021/22 year amounted to £66,595. This compared to £66,042 during 2020/21.

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2022**

**12. TANGIBLE FIXED ASSETS**

|                        | Office<br>Equipment<br>£ |
|------------------------|--------------------------|
| <b>COST</b>            |                          |
| At 1 July 2021         | 3,821                    |
| Additions in the year  | -                        |
| Disposals in the year  | (98)                     |
|                        | <hr/> 3,723 <hr/>        |
| <b>At 30 June 2022</b> | <b>3,723</b>             |
| <b>DEPRECIATION</b>    |                          |
| At 1 July 2021         | 2,822                    |
| Charge for the year    | 695                      |
| Disposal for the year  | (98)                     |
|                        | <hr/> 3,419 <hr/>        |
| <b>At 30 June 2022</b> | <b>3,419</b>             |
| <b>NET BOOK VALUE</b>  |                          |
| <b>At 30 June 2022</b> | <b>304</b>               |
|                        | <hr/> <hr/>              |
| At 30 June 2021        | 999                      |
|                        | <hr/> <hr/>              |

**13. DEBTORS**

|                                | 2022<br>£          | 2021<br>£          |
|--------------------------------|--------------------|--------------------|
| Trade debtors                  | -                  | 11,660             |
| Prepayments and accrued income | 13,605             | 44,605             |
|                                | <hr/> 13,605 <hr/> | <hr/> 56,265 <hr/> |

**14. CREDITORS: Amounts falling due within one year**

|                                    | 2022<br>£          | 2021<br>£          |
|------------------------------------|--------------------|--------------------|
| Trade creditors                    | 21,785             | 4,685              |
| Other creditors                    | 1,118              | 2,245              |
| Other taxation and social security | -                  | 5,265              |
| Accruals and deferred income       | 3,516              | 3,240              |
|                                    | <hr/> 26,419 <hr/> | <hr/> 15,435 <hr/> |

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2022**

**15. STATEMENT OF FUNDS**

**STATEMENT OF FUNDS – CURRENT YEAR**

|                           | Balance at<br>1 July 2021<br>£ | Income<br>£ | Expenditure<br>£ | Transfers<br>in/out<br>£ | Balance at<br>30 June<br>2021<br>£ |
|---------------------------|--------------------------------|-------------|------------------|--------------------------|------------------------------------|
| <b>Unrestricted funds</b> |                                |             |                  |                          |                                    |
| General Funds             | 113,069                        | 216,796     | (261,362)        | (15,701)                 | 52,802                             |
| <b>Restricted funds</b>   |                                |             |                  |                          |                                    |
| NNAG Events               | 2,356                          | -           | (2,631)          | 275                      | -                                  |
| NNAG Pathways             | 6,809                          | -           | (1,575)          | -                        | 5,234                              |
| NNAG                      | -                              | 875         | (16,301)         | 15,426                   | -                                  |
|                           | 9,165                          | 875         | (20,507)         | 15,701                   | 5,234                              |
| Total of funds            | 122,234                        | 217,671     | (281,869)        | -                        | 58,036                             |

NNAG events - events and activities to support the development of an epilepsy pathway

NNAG support - programme management support for The National Neuro Advisory Group, includes organising meetings, workstreams and events.

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2022**

**15. STATEMENT OF FUNDS (continued)**

**STATEMENT OF FUNDS – PRIOR YEAR**

|                           | <i>Balance at<br/>1 July 2020<br/>£</i> | <i>Income<br/>£</i> | <i>Expenditure<br/>£</i> | <i>Transfers<br/>in/out<br/>£</i> | <i>Balance at<br/>30 June<br/>2021<br/>£</i> |
|---------------------------|-----------------------------------------|---------------------|--------------------------|-----------------------------------|----------------------------------------------|
| <b>Unrestricted funds</b> |                                         |                     |                          |                                   |                                              |
| <i>General Funds</i>      | 88,186                                  | 211,339             | (169,693)                | (16,763)                          | 113,069                                      |
| <b>Restricted funds</b>   |                                         |                     |                          |                                   |                                              |
| NNAG Events               | 2,356                                   | -                   | -                        | -                                 | 2,356                                        |
| NNAG Pathways             | 4,284                                   | 5,000               | (2,475)                  | -                                 | 6,809                                        |
| NNAG                      | (3,000)                                 | 7,500               | (21,263)                 | 16,763                            | -                                            |
|                           | 3,640                                   | 17,500              | (23,738)                 | -                                 | 9,165                                        |
| <i>Total of funds</i>     | 91,826                                  | 223,839             | (193,431)                | -                                 | 122,234                                      |

**16. ANALYSIS OF NET ASSETS BETWEEN FUNDS**

**ANALYSIS OF NET ASSETS BETWEEN FUNDS – current year**

|                               | <b>Unrestricted<br/>funds<br/>£</b> | <b>Restricted<br/>funds<br/>£</b> | <b>Total<br/>funds<br/>2022<br/>£</b> |
|-------------------------------|-------------------------------------|-----------------------------------|---------------------------------------|
| Tangible fixed assets         | 304                                 | -                                 | 304                                   |
| Current assets                | 78,917                              | 5,234                             | 84,151                                |
| Creditors due within one year | (26,419)                            | -                                 | (26,419)                              |
|                               | 52,802                              | 5,234                             | 58,036                                |

**ANALYSIS OF NET ASSETS BETWEEN FUNDS – prior year**

|                                      | <i>Unrestricted<br/>funds<br/>£</i> | <i>Restricted<br/>funds<br/>£</i> | <i>Total<br/>funds<br/>2021<br/>£</i> |
|--------------------------------------|-------------------------------------|-----------------------------------|---------------------------------------|
| <i>Tangible fixed assets</i>         | 999                                 | -                                 | 999                                   |
| <i>Current assets</i>                | 127,506                             | 9,165                             | 136,670                               |
| <i>Creditors due within one year</i> | (15,435)                            | -                                 | (15,435)                              |
|                                      | 113,069                             | 9,165                             | 122,234                               |

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2022**

**17. PENSION COMMITMENTS**

The Charity operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Charity in an independently administered fund. The pension cost charge represents contributions payable by the Charity to the fund and amounted to £7,706 (2021 - £7,502).

Contributions totalling £1,118 (2021 - £2,245) were payable to the fund at the balance sheet date and are included in creditors.

**18. OPERATING LEASE COMMITMENTS**

At 30 June 2022 the total of the Charity's future minimum lease payments under non-cancellable operating leases was:

|                       | <b>2022</b>  | 2021        |
|-----------------------|--------------|-------------|
|                       | <b>£</b>     | £           |
| Amounts payable:      |              |             |
| Within 1 year         | <b>9,000</b> | 9,000       |
| Between 1 and 5 years | -            | -           |
|                       | <hr/>        | <hr/>       |
| Total                 | <b>9,000</b> | 9,000       |
|                       | <hr/> <hr/>  | <hr/> <hr/> |

**19. RELATED PARTY TRANSACTIONS**

Other than disclosed elsewhere in these financial statements, there were no related party transactions requiring disclosure during the current or previous year.

---

# Accounts

---

**COMPANY REGISTRATION NUMBER 02939840**



**THE NEUROLOGICAL ALLIANCE  
(LIMITED BY GUARANTEE)  
FINANCIAL STATEMENTS  
FOR THE YEAR ENDED  
30 JUNE 2021**

**Charity Number 103903**

---

## THE NEUROLOGICAL ALLIANCE

### Dedication

We dedicate our annual report to our former Chair, colleague and friend, Suzanne Dobson, who passed away in July 2021, to our great sadness. Suzanne was Chair of the Alliance from 2016 – 2020, bringing energy and enthusiasm to the role, and enabling the organisation to go from strength to strength. Suzanne was passionate about ensuring all of our members, regardless of size or scale, were listened to and represented at all levels of Government. Suzanne has had a hugely positive impact on the Alliance, much of which is reflected in this report. We will miss her deeply, and our thoughts are very much with her friends and family.



## **TRUSTEE ANNUAL REPORT**

### **LETTER FROM THE CHAIR**

I am pleased to introduce The Neurological Alliance Annual Report for 2020-21. This year has of course been extremely turbulent, and with the Covid-19 pandemic continuing to so deeply impact all of our lives, we have redoubled our efforts to mitigate the impacts of the crisis on people with neurological conditions and our members. At such a critical time, I was honoured to take up the role of Chair in November 2020.

Despite these challenges, the Alliance has continued to go from strength to strength, growing our membership and influence.

Together, we were successful in our campaigns to ensure that the impact of the pandemic on people with neurological conditions and services was recognised in Government efforts to restart health services. This included two reports. The first, in July 2020, detailed the immediate impact of the pandemic. The second report, published by the National Neuroscience Advisory Group (NNAG) in June 2021, collated experiences and evidence from across the neurological community to set out the impact of the pandemic across services. This has undoubtedly contributed to decision making by NHS England and the NHS Improvement specialised commissioning team to prioritise neurology and neurosurgery as part of their plans to support recovery of elective care. Importantly, this means that Integrated Care Systems should have all developed plans to support recovery, which provides an important basis for our community's future engagement with these new bodies.

We welcomed four new members and affiliates to the Alliance, along with two new corporate supporters. Every single one of our national members renewed with us in 2020/21, demonstrating the importance of us, the neurological community, sticking together during these challenging times. We were also pleased to welcome new trustees to the Board: Dr Arani Nitkunan (Consultant Neurologist), Cath Stanley (Huntington's Disease Association) and Sarah Rawlings (MS Society). Alan Bowers (Sue Ryder) also kindly stepped in following the departure of Pamela Mackenzie from Sue Ryder. Their enthusiasm and expertise have already made a positive difference to our work, and I look forward to continuing to work with trustees to enable the Board to be as effective as it can be.

We have also worked closely with the Brain and Spine Foundation, our fellow pan-neurological organisation, to develop NeuroLifeNow, a new app to collect the experiences of people with neurological conditions. The app also enables people with neurological conditions to access information and news. The evidence gathered up via the app has been vital in our efforts to influence the restart of services later on .

The first ever NeuroFest was held in November 2020 – a brand new event to bring together members, associates and individuals interested in improving neurological

treatment, care and support. The event attracted more than 200 attendees, and we received hugely positive feedback.

Working together, we have also ensured that people with neurological conditions and their experiences were amplified in Westminster. We supported the All Party Parliamentary Groups (APPG) for multiple sclerosis (MS), Parkinson's, traumatic brain injury (TBI) and motor neurone disease (MND) to host a joint meeting to discuss the impact of the pandemic on people with neurological conditions. In addition, APPG Chairs and our Chief Executive met with the Minister for Health Edward Argar MP in early 2021 to urge him to support a recovery plan for services for people with neurological conditions. This group of Parliamentarians also worked together to secure a debate in the House of Lords on services for people with neurological conditions, which had excellent attendance from a range of parties, and resulted in a number of important commitments to prioritise neurology in NHS recovery efforts.

Outside policy related to COVID-19, we worked with our rare condition sub group to develop an extensive report on the realities of life with a rare neurological condition, recognising that access to treatment and care can be even more challenging when living with a condition that is less prevalent. The report 'Out of the Shadows' received positive feedback from policy-makers, and many of its recommendations chimed with the UK Government Rare Disease Framework, which was published in January 2021. We, together with our members, are now working closely with NHS England and NHS Improvement and the Department for Health and Social Care to develop an implementation plan that can deliver real change for people with neurological conditions.

These are just some of the highlights of the year, and much more of the Alliance's work, and the difference we have made, is detailed in the pages that follow. You will also find some information about our plans for the coming year, as the NHS continues to try and bring waiting lists down and embed new models of care.

I would like to take this opportunity to thank the Board, the team and every one of our members and supporters for their continued support – we are, I believe, stronger than ever, and are in fantastic position to continue to improve access to treatment, care and support for the one in six of us who live with a neurological condition.

**David Martin, Chair, The Neurological Alliance**

**THE NEUROLOGICAL ALLIANCE**  
**ANNUAL REPORT AND ACCOUNTS**  
**YEAR ENDED JUNE 2021**

**REFERENCE AND ADMINISTRATIVE DETAILS**

**Registered charity name**            The Neurological Alliance

**Charity registration number**    1039034

**Company registration number** 02939840

**Registered office**                    The Junction  
Station Road  
Watford  
Hertfordshire  
WD17 1EU

**Independent Examiner**            Martin Bailey FCA  
Goodman Jones LLP  
Chartered Accountants  
29-30 Fitzroy Square  
London  
W1T 6LQ

**Accountants**                        Godfrey Wilson  
5th Floor, Mariner House  
62 Prince Street  
Bristol  
BS1 4QD

**Bankers**                                CAF Bank Ltd  
25 Kings Hill Avenue  
Kings Hill  
West Malling  
Kent  
ME19 4JQ

                                                Metro Bank PLC  
One Southampton Row  
London  
WC1B 5HA

---

The Trustees present their report and independently examined financial statements for The Neurological Alliance for the year 1 July 2020 to 30 June 2021. The report and financial statements have been prepared in accordance with the Companies Act 2006 and the Charities Act 2011. The Trustees have adopted the provisions of the Statement of Recommended Practice (SORP) "Accounting and Reporting by Charities" (FRS 102) in preparing the report and financial statements. The report and financial statements will be laid before the members of the charity at the Annual General Meeting to be held on 17 November 2021. In preparation of this report, the Trustees had regard for the Charity Commission guidance on public benefit.

## **1. Our objects**

Our principal objectives, as derived from the objects set out in our Articles of Association, are to advance the education of the public in all matters concerning neurological disorders by carrying out research and investigation into preventative procedures, treatment and the needs and care of persons affected by neurological conditions, and publishing the useful results thereof, and the relief of those persons in the United Kingdom of Great Britain and Northern Ireland who are receiving or have received treatment for neurological conditions.

We are the only collective voice for over 70 national charities, professional bodies, regional organisations and corporate organisations working together to transform neurological treatment, care and support.

## **2. What we set out to do in 2020-21**

Our mission is to raise awareness and understanding of neurological conditions to ensure that every person diagnosed with a neurological condition has access to high quality, joined up services and information from their first symptoms, throughout their life.

Our strategic objectives, set at the Board away day in 2020, were to:

1. Increase the influence and involvement of people with neurological conditions
2. Increase and strengthen the collective voice of the neurological community
3. Increase and drive the national policy profile of neurology
4. Increase and support local action to improve neurological services
5. To build a sustainable organisation capable of bringing about change

The Annual Report of the Trustees for 2020/21 is set out under these strategic objectives.

1. Increase the influence and involvement of people with neurological conditions

***"The Neurological Alliance plays an important role in leading the sector's engagement with UK Government and Parliament.***

***"Over the last year this has included bringing together a range of different neurological charities and representative bodies in one unified voice in response to Covid-19, including communicating a vision to politicians for how neurological services should resume in the wake of the pandemic.***

***“The Neurological Alliance is a trusted voice for its knowledge and the expertise of its members and the challenges that people with neurological conditions face, and we’re proud to be a member.” – Joseph Brunwin, MS Society***

Ensuring the impacts of the Covid-19 pandemic on people with neurological conditions are heard by policy-makers has been central to much of our work this year.

In July 2020, we published the results of our survey of more than 1,600 people with neurological conditions, with over 7 in 10 respondents reporting delays to their medical appointments as a result of COVID-19. 1,672 people took part in the survey, and we found that:

- 72% of respondents reported having had their NHS appointments delayed – 4 in 10 people didn’t know when until.
- Almost 4 in 10 people (39%) due to see a neurologist were not given a future date for their delayed appointment, leaving them in complete limbo.
- 19% of respondents felt lonely, 1 in 10 felt hopeless.

The report launched successfully and included a letter from 41 neurological organisations to Simon Stevens, former Chief Executive of NHS England and NHS Improvement (NHSE/I) calling on NHSE/I to set out their plans to restart neurological services. A similar letter, in support of this call, has been co-signed by Neurological All Party Parliamentary Group (APPG) Chairs to the then Secretary of State for Health and Care, Matt Hancock.

We also obtained coverage in the Health Service Journal PharmaForum, Nursing Times and Charity News Today. Our report was also circulated to more than 50 Parliamentarians and policy-makers across Westminster and Whitehall, including Health Education England, the CQC and NHS Digital.

We have worked closely with the Brain and Spine Foundation to launch NeuroLifeNow, a new app for people with neurological conditions to share their experiences of care. The app, which was launched in January 2021, includes a bi-monthly survey – more than 800 survey responses were collected before the end of July 2021, and five reports of the results have been published, providing invaluable real-time evidence of the impact of the pandemic on people with neurological conditions.

We also worked with Wilmington Healthcare and a volunteer data analyst to develop a briefing that brings together Hospital Episode Statistics and GP Prescribing datasets to look at how NHS activity changed over the first lockdown. We published the national analysis of this data on our website and have provided condition specific data to our members.

As a result of this evidence and engagement, we were able to highlight the impacts of the pandemic on people and services. This included working with the MS Society, UKABIF, MNDA, Epilepsy Action and Parkinson’s UK to organise and present at a joint meeting of the All Party Parliamentary Groups (APPGs) for motor neuron disease

(MND), multiple sclerosis (MS), epilepsy, Traumatic Brain Injury (TBI) and Parkinson's in December 2020. This meeting focussed in on the impacts of the pandemic on rehabilitation in particular.

The Chairs of these Groups, together with our Chief Executive, met with the Minister for Health, Edward Argar MP, early in 2021.

As a result of the community's tireless campaigning, we were pleased to see neurology and neurosurgery prioritised as part of NHSE/I recovery strategy. NHSE/I published the 2021/22 Priorities and Operational Planning Guidance for Integrated Care Systems (ICSs) in March 2021, setting out the priorities for the year ahead including restoration of services and reducing the elective care backlogs that have built up as a result of the pandemic. As part of the implementation guidance ICSs were asked to submit a national template summarising their recovery plans for all elective activity including a breakdown of particular specialties including neurology and neurosurgery. These plans are now being used by ICSs to monitor restoration of elective activity at a local level.

Finally, we have been developing the next iteration of the Patient Experience Survey, now entitled 'My Neuro Survey'. In 2020/21, we worked with members and people with neurological conditions to revise and test the survey, and recruit two clinics to pilot the survey. For the first time ever, we will be launching a survey for children and young people with a neurological condition, as well as adults, and are gathering up responses from across the UK. We are working closely with a number of organisations, including Stonewall and Healthwatch, to ensure we are reaching as many people as possible through the survey too.

We would like to thank everyone who has been involved in developing the survey so far – your input has been invaluable, and we very much look forward to launching the results in 2022.

## 2. Increase and strengthen the collective voice of the neurological community

***"We were proud to be part of work to develop the 'Out of the Shadows' report, alongside fellow members of the Alliance. The report allowed us to bring an important and much needed focus on the experiences of people living with r20 and other rare epilepsies. Being part of the campaign meant that we were able to amplify our voice, and our families, right when public policymakers needed to hear it most."***

***Quote from Allison Watson, member of the rare conditions group, Ring20 Support***

Through our policy group and interest groups on mental health, rare conditions, regional work and research, we have been able to support members to share and develop evidence on common areas of interest.

In particular, we published our rare condition report, 'Out of the Shadows' in November 2020. It is available [here](#). The report, which was featured in Rare Revolution magazine, was developed following a short survey of our membership, a deep dive into public policy related to rare conditions, engagement with Genetic Alliance UK and additional analysis of the 2018/19 Patient Experience Survey. The recommendations of the report fed into our engagement with the Department of Health and Social Care ahead of the publication of the UK Framework for Rare Diseases in January 2021.

As a result of this engagement, we were invited to join the UK Government Rare Diseases Forum, which has been set up to support the development of the forthcoming Framework Implementation Plans and ongoing engagement with Government throughout the lifetime of the Framework. Our Trustee, Sue Millman, sits on this group as a representative for the Alliance.

Our new Research Interest Group has met twice this year, and has provided a new opportunity for charitable members who fund research to share experiences and collaborate. Thus far, the group has been working on gathering evidence to examine the investment into neurological research, which will be published in 2021/22.

We have continued to work tirelessly to highlight the importance of mental health support for people with neurological conditions. This has included working with members via our Mental Health Interest Group to develop a refreshed plan for our work together, and providing input into the forthcoming National Neuroscience Advisory Group (NNAG) pathway on mental health services for people with neurological conditions. We were also pleased to join the Royal College of Psychiatry Faculty of NeuroPsychiatry Executive Committee, to provide another important opportunity to influence professional practice. A particular highlight was working with NHSE/I to deliver a webinar on mental health and neurological conditions to IAPT conditions in the Autumn, where practitioners heard first-hand from Phil and Mandy, who live with neurological conditions, about the importance of support for their mental wellbeing. We also worked with members to develop a response to the Government Consultation on the reform of the Mental Health Act in May 2021.

Our Policy Group worked to share experiences of the pandemic and connect to policy-makers and influencers about key public policy topics of interest. Most recently, the group worked together to develop guidelines on Patient Initiated Follow-Up (PIFU) – these guidelines are already being used to input into the NHSE/I outpatient transformation programme.

We were very pleased to welcome Dawn Golder, Chief Executive of FND Hope UK as Vice-Chair of the group. A huge thank you to our Policy Group Officers for their tireless commitment, enthusiasm and leadership, ensuring the group reflects the needs and priorities of our membership. A special thank you to Sammy Ashby, Deputy Chief Executive of SUDEP Action, who stepped down as Chair of the Policy Group this year.

### 3. Increase and drive the national policy profile of neurology

***NNAG and in particular the Patients Forum is vital in driving better services for people with neurological conditions. It ensures we have a collective voice in presenting our case to decision makers***

***Quote from Chris James, trustee and co-chair of the NNAG patient forum, member of NNAG, Motor Neurone Disease Association***

The National Neuroscience Advisory Group (NNAG) published its report, Lessons Learnt From The COVID-19 Pandemic, on the impact of COVID-19 on neuroscience services in April 2021. The report, which was developed using evidence collected from patient groups, NHS England and NHS Improvement key datasets, professional bodies and services, highlights:

- An estimated backlog of more than 225,000 neurology appointments and 58,000 neurosurgery appointments at the end of 2020 – the winter surge of COVID cases is likely to have increased these figures further.
- A growing number of long-COVID patients who now require neurological, neurorehabilitation and neuro-psychiatric and/or neuro-psychological care to manage their symptoms and functioning – this will too increase demand for neuroscience services.
- A slow-down in referrals more generally. For example, specialist centres for MND have experienced an estimated 30-50% drop in referrals, leading to delays in diagnosis and support.
- There was already a significant shortage of specialist neuroscience professionals across the country prior to the pandemic. Redeployment to COVID-19 wards and increased pressure to reduce waiting lists are having a significant impact on the mental health of health and care professionals, and without the right support and planning, we risk losing much needed specialist expertise after COVID-19.
- The COVID-19 pandemic has magnified the challenges facing rehabilitation services in particular. NHS data shows there were 20,000 fewer outpatient appointments with a rehab consultant across all neurological conditions between March and June 2020 compared with the same period last year.
- New models of care, particularly remote consultations, must be rolled out carefully – evidence received from across the neurological sector suggests mixed patient experience with remote consultations, and clear concerns about the possible exacerbation of health inequalities should they become common place.

The report was developed following a call for evidence from NNAG member organisations, including the Alliance, and outlines a series of short- and long-term recommendations for the future. These recommendations were discussed in detail with the Medical Director for NHSE/I, Professor Stephen Powis, and have resulted in representatives from the neurological community now sitting on key strategic groups at a national level. These include the NHSE/I Long COVID taskforce and elective recovery taskforce.

NNAG optimum clinical pathways continue to be developed, with seven pathways out for consultation during the course of the year. More than 100 individuals and organisations have responded to these pathways during consultation.

In addition, we have partnered with the Migraine Trust, FND Hope UK and UKABIF to host focus groups with more than 35 people with neurological conditions to review the Functional Neurological Disorder, Headache and Migraine, and Traumatic Brain Injury pathways. The findings from these focus groups are being collated and have fed directly into the revision of these pathways.

The final Quality Standards for suspected neurological conditions were published in January. The Alliance has fed into this work throughout the development of the Quality Standards, submitting a response to the consultation and providing input as a lay member of the Quality Standard Committee. We were pleased to see considerable improvement to the Standards following consultation, in particular of Standards on Functional Neurological Disorder and patient experience. We hope to use the results of My Neuro Survey to shed light on the implementation of the Standards in practice.

We have of course been engaging very closely with NHS reform in England. This has included working with other key infrastructure organisations, such as National Voices and the Specialised HealthCare Alliance (SCHA) to shape our national policy positioning on the reforms, and supporting the Health Foundation to engage with our membership on the reforms. Through the national NHSE/I Specialised Commissioning Forum and the Neuroscience Transformation Programme, we have also sought to influence the future model of commissioning for neuroscience services, work which will continue in 2021/2022.

#### 4. Increase and support local action to improve neurological services

***“As the northern-most Regional Neurological Alliance, we have found it difficult influencing neuro-disability policy outside of London. Although we are a charity in our own right, The Neurological Alliance has offered a platform for discussion and inclusion in the past 12 months which has increased the volume of and validated our beneficiaries lived experience and contribution to strategic thinking.” Jo Cole, Neurokey***

We have continued to work closely with our Regional Alliances, who have been working closely with local policy-makers, clinicians and services to shape COVID-19 recovery strategy.

We have hosted meetings of our Regional Alliances every 6-8 weeks, and have focussed on sharing experiences of engagement with Integrated Care Systems (ICSs), and, of course, what people with neurological conditions have been sharing with at a regional level. Many of our members have also developed new information resources for people with neurological conditions.

As NHS reform develops, it is clear that Integrated Care Systems (ICSs) are likely to play an increased role in the commissioning of services for people with neurological conditions. The neurological community's ability to engage and influence these systems is therefore paramount. That's why this year we have been working with

members across the Alliance to understand levels of engagement with ICSs thus far and map ICS priorities where possible.

We also held two events specifically looking at our local influencing strategy – a Chatham House discussion with policy makers, clinicians and patient groups debating the question “Will ICSs improve treatment, care and support for people with neurological conditions?”, and a panel discussion with more than 20 people during NeuroFest 2020.

We have also had the pleasure of continuing to be closely involved in the South London Neuroscience Operational Delivery Network, sitting on their Programme Board and having the opportunity to observe the patient network. Understandably, much of the work this network has undertaken has been to support the coordination of delivery of services during surges of COVID-19.

5. To build a sustainable organisation capable of bringing about change

***‘I am really proud of the way we have continued to develop and improve virtual events with diverse, insightful content, great speakers and high levels of participation from member organisations.’ Angie Pullen, trustee and Neurofest task and finish group, Epilepsy Action***

The Alliance has gone from strength to strength this year. We were pleased to welcome six new members and corporate supporters in 2020/2021, and every single national member of the Alliance renewed their membership with us despite the multiple challenges brought about by COVID-19.

We also held our first NeuroFest, an opportunity for the neurological community to come together to share their experiences and debate key topics of interest. More than 200 attendees took part in the online series of workshops and panel debates, with people with neurological conditions on every panel session held. Of those who responded to our feedback survey, every attendee said they would attend the event again. The event culminated with our AGM, which included Professor Stephen Powis, Medical Director NHSE/I, as keynote speaker.

Our annual membership survey yielded hugely positive findings, with 49 members responding to the survey. 95% of members agreed that the Alliance was a strong national voice for the neurological community, and 8 of 10 said that our priorities work for them as an organisation. Every single respondent said their membership was value for money. Some respondents highlighted that we could improve how we communicate, and also felt they would like to be more engaged with the Alliance’s activities.

Our online presence has also continued to grow this year. We have recently launched our refreshed website, and our Twitter followers have grown to more 6000.

## What next?

The Trustees have developed a refreshed annual plan for the Alliance. We have developed the plan using input from across the sector, and importantly, from our membership. 49 member organisations covering a range of neurological conditions responded to our membership survey. They told us these topics should be top of our list:

1. Disruption of neurological services due to COVID
2. Accessing the right health specialist
3. Accessing effective treatment
4. Support for mental wellbeing
5. Health inequalities
6. Information and support at diagnosis
7. Rehabilitation

We're also focusing on understanding the continuing impact of COVID-19 on people with neurological conditions, and calling for much needed support for services to recover.

### **- Increase the influence and involvement of people with neurological conditions**

We will continue to work closely with the Brain and Spine Foundation to refresh and improve NeuroLifeNow, ensuring the experiences shared influence positive change at every level of Government.

We will launch the results from our flagship project, My Neuro Survey. The survey will provide an important opportunity to understand how the pandemic has impacted people, and what's needed now.

We have redoubled our efforts to ensure equity, diversity and inclusion are at the heart of everything we do. This year, that means ensuring My Neuro Survey reaches as many people as possible, and we also intend to publish a literature review, developed with Dr Kit Wu and Dr Arani Nitkunan, looking at how experience and outcomes of care may differ according to sociodemographic characteristics.

### **- Increase and strengthen the collective voice of the neurological community**

We will continue to provide a space for our members to meet and network via our Policy Group and mental health, research and rare conditions interest groups.

The Mental Health Group will work together to develop a new report looking at what services need to be in place now as we rebuild from the COVID-19 pandemic.

We will work with ACPIN to develop new evidence looking at access to and experience of rehabilitation services, particularly amongst seldom heard groups.

We have also commissioned RAND Europe to undertake an analysis of the current number of health and care professionals in secondary and tertiary neurology, dementia and stroke care. We hope that this work will enable us to conduct a more in-depth

analysis of the workforce needs of the future, particularly in light of expanding treatment options.

- **Increase and drive the national policy profile of neurology**

The NHS in England is undergoing some of its most significant reform in nearly a decade – this is likely to have profound impacts on the way in which services for people with neurological conditions are funded and provided across the country.

We will therefore continue to work with partners across the sector to ensure the Health and Care Bill brings about structural change which aids the improvement of treatment, care and support for people with neurological conditions.

We also look forward to continuing to take on the role of Patient and Public Voice (PPV) representative on the NHSE/I neuroscience Clinical Reference Group (CRG), particularly as the future commissioning model for neuroscience services is further refined.

The National Neuroscience Advisory Group (NNAG) will continue to meet, with a particular focus on defining the outcomes associated with good care, and supporting members to engage with ICSs. The finalised optimum pathways will be published, providing an important suite of evidence for the neurological community to use when engaging with NHS systems.

- **Increase and support local action to improve neurological services**

We will work with members to refine our collective local influencing strategy, which will include an in-depth mapping of ICS priorities, and the extent to which they are involving people with long term conditions in their work.

We will also use the results of My Neuro Survey to further understand unwarranted geographical variation.

- **Build a sustainable organisation capable of bringing about change**

We hope to continue to grow our membership, despite the challenges so many organisations face at present.

We will also review our internal processes and policies, ensuring that they reaffirm our commitment to equity, diversity and inclusion. This will include, for example, reviewing our recruitment practices to ensure they are as equitable and fair as possible.

### **3. Our structure, governance and management**

#### **3.1 Trustees selection**

We are governed by a Board of Trustees, made up of a minimum of three and a maximum of 13 people nominated by our members, recommended by our Trustees and then elected by our members.

In advance of each Annual General Meeting (AGM), all members are invited to send in their nominations for the Board. Details of the Trustee candidates are then circulated to all members and votes are made by ballot at the AGM or sent in advance to the

Chair using a proxy form; each member organisation is entitled to one vote, placed at the AGM.

After completing a three-year term, each Trustee will stand down from the Board. Trustees who have completed only one term may stand for re-election; those who have served two consecutive terms must stand down for one year before they may stand again for the Board.

On joining the Alliance Board, all new Trustees undertake a tailored induction programme. The Trustees, who are also directors for the purpose of the Companies Act, and who served during the year, are listed in section 5.1.

### **3.2 Structure**

We are a company limited by guarantee (no 02939840) and a registered charity (no 1039034). We are governed by Articles of Association and Byelaws. Our main activity is to secure the highest standards of care and treatment for every person affected by a neurological condition.

Our Board of Trustees is responsible for our governance and strategy and meets every quarter. Our Chief Executive is responsible for implementing the strategy and reports on its progress at the Board meetings. The Chief Executive reports directly to and is supervised by the Chair. They speak and meet regularly to discuss Alliance business.

Communication, both formal and informal, between Trustees and staff is frequent and effective.

#### **3.2.1 Staff**

|                    |                                                                                                                                                                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Georgina Carr      | Chief Executive and Company Secretary (from January 2020 – present)                                                                                                               |
| Katharine McIntosh | Senior Policy and Campaigns Advisor (from January 2018 – July 2019), Policy and External Affairs Manager (July 2019 – June 2021) (Maternity leave from April 2020 – January 2021) |
| Judith Abel        | Policy and External Affairs Manager (April 2020 – December 2020) (Maternity cover)                                                                                                |
| Samuel Mountney    | Policy and External Affairs Manager (June 2021 – present)                                                                                                                         |
| Caroline Davies    | Administrator and Membership Assistant (From October 2019 – present)                                                                                                              |
| Miranda Lloyd      | Communications and External Affairs Officer (March 2021 – present)                                                                                                                |

### **3.2.2 Members**

Full membership is open to national voluntary organisations who represent patients, service users, families and carers (non-statutory, non-profit) organisations, who, in addition to the full benefits of membership, will have a right to vote at the AGM, have the right to nominate a trustee and an opportunity to influence our strategic direction. Subscriptions are income assessed.

- Full affiliate membership is open to Regional Neurological Alliances operating on a non-statutory, non-profit basis. Affiliate members will pay a subscription rate which is not income assessed.
  - Associate status is open to non-profit organisations, including professional associations and statutory authorities, who will play an active part in the Alliance but do not have the right to nominate a trustee or vote at the AGM. Subscriptions are income assessed.
  - Regional Associations of Neurological Organisations are also associates. They are staff led groups and will pay a subscription rate which is not income assessed.
  - Corporate supporter status is open to for-profit organisations, who cannot vote at the AGM or nominate a trustee.
  - Reciprocal partners are normally umbrella organisations whose aims and objectives match well with those of the Alliance. They cannot vote or influence our strategic direction.
-

## Members 2020-2021

|                                                                             |                                                                                    |
|-----------------------------------------------------------------------------|------------------------------------------------------------------------------------|
|                                                                             |                                                                                    |
| Ataxia UK                                                                   | <a href="http://www.ataxia.org.uk">www.ataxia.org.uk</a>                           |
| Autistica                                                                   | <a href="http://www.autistica.org.uk">www.autistica.org.uk</a>                     |
| Batten Disease Family Association                                           | <a href="http://www.bdfa-uk.org.uk">www.bdfa-uk.org.uk</a>                         |
| Brain and Spine Foundation                                                  | <a href="http://www.brainandspine.org.uk">www.brainandspine.org.uk</a>             |
| Brain And Spinal Injury Centre (BASIC)                                      | <a href="http://www.basiccharity.org.uk">www.basiccharity.org.uk</a>               |
| Brain Research UK (formally Brain Research Trust)                           | <a href="http://www.brainresearchuk.org.uk">www.brainresearchuk.org.uk</a>         |
| Brain Tumour Research <sup>1</sup>                                          | <a href="http://www.braintumourresearch.org">www.braintumourresearch.org</a>       |
| British Polio Fellowship                                                    | <a href="http://www.britishpolio.org.uk">www.britishpolio.org.uk</a>               |
| Cavernoma Alliance UK                                                       | <a href="http://www.cavernoma.org.uk">www.cavernoma.org.uk</a>                     |
| CMT United Kingdom                                                          | <a href="http://www.cmt.org.uk">www.cmt.org.uk</a>                                 |
| Cure Parkinson's Trust                                                      | <a href="http://www.cureparkinsons.org.uk">www.cureparkinsons.org.uk</a>           |
| The Daisy Garland                                                           | <a href="http://www.thedaisygarland.org.uk">www.thedaisygarland.org.uk</a>         |
| Different Strokes                                                           | <a href="http://www.differentstrokes.co.uk">www.differentstrokes.co.uk</a>         |
| Downs Syndrome Research (DSRF)                                              | <a href="http://www.dsrf-uk.org">www.dsrf-uk.org</a>                               |
| Dravet Syndrome UK                                                          | <a href="https://www.dravet.org.uk/">https://www.dravet.org.uk/</a>                |
| Dystonia Society                                                            | <a href="http://www.dystonia.org.uk">www.dystonia.org.uk</a>                       |
| Epilepsy Action                                                             | <a href="http://www.epilepsy.org.uk">www.epilepsy.org.uk</a>                       |
| Epilepsy Research UK                                                        | <a href="http://www.epilepsyresearch.org.uk">www.epilepsyresearch.org.uk</a>       |
| FD UK                                                                       | <a href="http://www.familialdysautonomia.co.uk">www.familialdysautonomia.co.uk</a> |
| FND Action                                                                  | <a href="http://www.fndaction.org.uk">www.fndaction.org.uk</a>                     |
| FND Hope                                                                    | <a href="http://www.fndhope.org">www.fndhope.org</a>                               |
| GAIN (Guillain-Barré and Associated Inflammatory Neuropathies)              | <a href="http://www.gaincharity.org.uk">www.gaincharity.org.uk</a>                 |
| Huntington's Disease Association                                            | <a href="http://www.hda.org.uk">www.hda.org.uk</a>                                 |
| IIH UK                                                                      | <a href="https://www.iih.org.uk/">https://www.iih.org.uk/</a>                      |
| Matthew's Friends                                                           | <a href="https://www.matthewsfriends.org/">https://www.matthewsfriends.org/</a>    |
| Migraine Trust                                                              | <a href="http://www.migrainetrust.org">www.migrainetrust.org</a>                   |
| Motor Neurone Disease Association                                           | <a href="http://www.mndassociation.org">www.mndassociation.org</a>                 |
| Multiple Sclerosis National Therapy Centres                                 | <a href="http://www.msntc.org.uk">www.msntc.org.uk</a>                             |
| Multiple Sclerosis Society                                                  | <a href="http://www.mssociety.org.uk">www.mssociety.org.uk</a>                     |
| Multiple Sclerosis Trust                                                    | <a href="http://www.mstrust.org.uk">www.mstrust.org.uk</a>                         |
| Multiple System Atrophy Trust                                               | <a href="http://www.msatrust.org.uk">www.msatrust.org.uk</a>                       |
| Myaware                                                                     | <a href="http://www.myaware.org">www.myaware.org</a>                               |
| Myelopathy.org                                                              | <a href="https://myelopathy.org/">https://myelopathy.org/</a>                      |
| Narcolepsy UK                                                               | <a href="http://www.narcolepsy.org.uk">www.narcolepsy.org.uk</a>                   |
| The National Hospital for Neurology And Neurosurgery Development Foundation | <a href="http://www.nationalbrainappeal.org">www.nationalbrainappeal.org</a>       |
| National Tremor Foundation                                                  | <a href="http://www.tremor.org.uk">www.tremor.org.uk</a>                           |
| Overcoming MS <sup>1</sup>                                                  | <a href="http://www.overcomingms.org">www.overcomingms.org</a>                     |
| Parkinson's UK                                                              | <a href="http://www.parkinsons.org.uk">www.parkinsons.org.uk</a>                   |

**Members (continued)**

|                                     |                                                                                        |
|-------------------------------------|----------------------------------------------------------------------------------------|
| Polio Survivors Network             | <a href="http://www.poliosurvivorsnetwork.org.uk">www.poliosurvivorsnetwork.org.uk</a> |
| PSP Association                     | <a href="http://www.pspeur.org">www.pspeur.org</a>                                     |
| Ring 20 Research and Support UK CIO | <a href="http://ring20researchsupport.co.uk/">ring20researchsupport.co.uk/</a>         |
| Spinal Muscular Atrophy Support UK  | <a href="http://smauk.org.uk/">smauk.org.uk/</a>                                       |
| Spotlight YOPD                      | <a href="http://spotlightyopd.org/">spotlightyopd.org/</a>                             |
| SUDEP Action                        | <a href="http://www.sudep.org">www.sudep.org</a>                                       |
| Sue Ryder                           | <a href="http://www.sueryder.org">www.sueryder.org</a>                                 |
| Tourettes Action                    | <a href="http://www.tourettes-action.org.uk">www.tourettes-action.org.uk</a>           |
| Transverse Myelitis Society         | <a href="http://www.myelitis.org.uk">www.myelitis.org.uk</a>                           |
| Trigeminal Neuralgia Association UK | <a href="http://www.tna.org.uk">www.tna.org.uk</a>                                     |
| UK Acquired Brain Injury Forum      | <a href="http://www.ukabif.org.uk">www.ukabif.org.uk</a>                               |

**Associates**

|                                                                     |                                                                                                                                                                                          |
|---------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Association of British Neurologists                                 | <a href="http://www.theabn.org">www.theabn.org</a>                                                                                                                                       |
| Association of Chartered Physiotherapists in Neurology <sup>1</sup> | <a href="http://www.acpin.net">www.acpin.net</a>                                                                                                                                         |
| British Paediatric Neurology Association                            | <a href="http://www.bpna.org.uk">www.bpna.org.uk</a>                                                                                                                                     |
| Division of Neuropsychology (British Psychological Society)         | <a href="http://www.bps.org.uk/networks-and-communities/member-microsite/division-neuropsychology">www.bps.org.uk/networks-and-communities/member-microsite/division-neuropsychology</a> |
| Neurology Academy <sup>1</sup>                                      | <a href="http://www.neurologyacademy.org">www.neurologyacademy.org</a>                                                                                                                   |

**Associate Regional Groups**

|                                                                    |                                                        |
|--------------------------------------------------------------------|--------------------------------------------------------|
| South West Alliance of Neurological Organisations                  | <a href="http://www.swano.org">www.swano.org</a>       |
| Yorkshire and Humberside Association of Neurological Organisations | <a href="http://www.yhano.org.uk">www.yhano.org.uk</a> |

**Corporate supporters**

|                                |                                                                        |
|--------------------------------|------------------------------------------------------------------------|
| AbbVie                         | <a href="http://www.abbvie.co.uk">www.abbvie.co.uk</a>                 |
| Allergan Limited               | <a href="http://www.allergan.co.uk">www.allergan.co.uk</a>             |
| Biogen                         | <a href="http://www.biogen.uk.com">www.biogen.uk.com</a>               |
| Boston Scientific <sup>1</sup> | <a href="http://www.bostonscientific.com">www.bostonscientific.com</a> |
| Kyowa Kirin <sup>1</sup>       | <a href="http://www.kyowakirin.com">www.kyowakirin.com</a>             |
| Merck Serono                   | <a href="http://www.merckserono.co.uk">www.merckserono.co.uk</a>       |
| Novartis                       | <a href="http://www.novartis.co.uk">www.novartis.co.uk</a>             |
| Sanofi Genzyme                 | <a href="http://www.genzyme.co.uk">www.genzyme.co.uk</a>               |
| Teva UK Limited                | <a href="http://www.tevauk.com">www.tevauk.com</a>                     |
| Roche                          | <a href="https://www.roche.com/">https://www.roche.com/</a>            |
| UCB Pharma Ltd                 | <a href="http://www.ucb.co.uk">www.ucb.co.uk</a>                       |

## Regional Neurological Alliances

|                                                                                     |                                                                                                                  |
|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------|
| Black Country Neurological Alliance                                                 | <a href="http://www.blackcountryneuroalliance.org.uk">www.blackcountryneuroalliance.org.uk</a>                   |
| Bolton Neuro Voices                                                                 | <a href="http://www.boltoncvs.org.uk">www.boltoncvs.org.uk</a>                                                   |
| Cumbria Neurological Alliance <sup>2</sup>                                          | <a href="http://www.cumbrianeurologicalalliance.wordpress.com">www.cumbrianeurologicalalliance.wordpress.com</a> |
| Greater Manchester Neurological Alliance                                            | <a href="http://www.gmna.co.uk/">www.gmna.co.uk/</a>                                                             |
| Hampshire Neurological Alliance                                                     | <a href="http://www.hantsneuroalliance.hampshire.org.uk">www.hantsneuroalliance.hampshire.org.uk</a>             |
| Lincolnshire Neurological Alliance                                                  | <a href="http://www.lincolnshire-neurological-alliance.org.uk">www.lincolnshire-neurological-alliance.org.uk</a> |
| Merseyside and Cheshire Neurological Alliance                                       | <a href="http://www.neurosupport.org.uk">www.neurosupport.org.uk</a>                                             |
| Neuro Key (formerly Tees Valley, Durham, and North Yorkshire Neurological Alliance) | <a href="http://www.na-tvdny.org.uk">www.na-tvdny.org.uk</a>                                                     |
| West Berkshire Neurological Alliance                                                | <a href="http://www.wbna.org.uk">www.wbna.org.uk</a>                                                             |

## Reciprocal members

|                                   |                                                                                                |
|-----------------------------------|------------------------------------------------------------------------------------------------|
| National Voices                   | <a href="http://www.nationalvoices.org">www.nationalvoices.org</a>                             |
| Neurological Alliance of Ireland  | <a href="http://www.nai.ie">www.nai.ie</a>                                                     |
| Neurological Alliance of Scotland | <a href="http://www.scottishneurological.org.uk">www.scottishneurological.org.uk</a>           |
| Neurological Alliance of Wales    | <a href="http://www.walesneurologicalalliance.org.uk">www.walesneurologicalalliance.org.uk</a> |

<sup>1</sup>. New members in 2020-21

<sup>2</sup>. Ceased members in 2020-21

<sup>3</sup>. Organisation closed in 2020-21

### 3.2.3 The way we work

As a membership organisation, our whole ethos is to work in partnership. We work across the neurological community to identify common priorities for people affected by a condition and then seek to influence, shape and support policy development to reduce inequalities, enhance their outcomes and, where possible, help them live for longer and in better health. Our activities are therefore based on a clear and shared sense of purpose. We work with the Trustees, the Policy Group and Policy Steering group to determine our strategy and plans.

#### 3.2.3a The Policy Group

Any member of the Alliance can take part of the Policy Group. The Group's purpose is to:

- Make recommendations to Alliance Trustees on Alliance policy and activity, ensuring that these reflect the needs and objectives of its member organisations
- Build collective ownership of the Alliance beyond staff and Trustees and to promote team-working across the member organisations
- Provide a forum for policy and campaigns staff of member organisations to share information and provide mutual support
- More closely align member organisations' priorities with the collective needs of the Alliance
- Ensure that all member organisations, large and small, can contribute to the work of the Alliance.

### **3.2.3.1ai Policy Group leads**

|              |                                                                                                                                               |
|--------------|-----------------------------------------------------------------------------------------------------------------------------------------------|
| Sammy Ashby  | Deputy Chief Executive, SUDEP Action, Co-Vice Chair (from June 2018) Co-Chair (from October 2018 – January 2021)                              |
| Sam Mountney | Senior Policy and Campaigns Officer, Epilepsy Action, Co-Vice Chair (from November 2019 – March 2020 ) Co-Chair (from April 2020 – June 2021) |
| Dawn Golder  | Chief Executive, FND Hope UK, Co-Chair (from February 2021 - present)                                                                         |

### **3.3 Risk management**

The Trustees have assessed the major risks to which the charity is exposed and are satisfied that systems are in place to mitigate exposure to major risks. A risk management strategy, reviewed annually, is in place. We also have a risk-based reserves policy which mitigates one of our main financial risks in terms of having over three quarters of our income coming from just 13 funders (four charities, nine corporates).

### **4. Public benefit**

Our work benefits people affected by a neurological condition and those who represent them. Sections 1 and 2 of this report set out our objectives, reports on our activities and successes, and set out our plans for the current financial year.

The Trustees consider that they have complied with their duty in s4 of the Charities Act 2011 to have due regard to the guidance on public benefit published by the Charity Commission. The Trustees have considered this matter and concluded:

- That the aims of the organisation continue to be charitable.
- That the aims and the work done give identifiable benefits to the charitable sector and both indirectly and directly to individuals in need.
- That the benefits are for the public, are not unreasonably restricted in any way and certainly not by ability to pay.
- That there is no detriment or harm arising from the aims or activities.

### **5. Reference and administrative details**

The Alliance is a registered charity (1039034) and company limited by guarantee (02939840) registered in England. The Alliance's registered office was, from 21 September 2019, The Junction, Station Road, Watford, WD17 1ET.

#### **5.1 Trustees and the nominating organisation**

|                    |                                         |
|--------------------|-----------------------------------------|
| Katharine Crawford | Parkinson's UK                          |
| Marc Smith         | Brain and Spine Foundation (Vice Chair) |
| Sarah Rawlings     | MS Society (Appointed November 2020)    |
| Chris James        | Motor Neurone Disease Association       |
| Pamela Mackenzie   | Sue Ryder (resigned August 2021)        |

|                  |                                                                     |
|------------------|---------------------------------------------------------------------|
| David Martin     | Multiple Sclerosis Trust (Chair)                                    |
| Sue Millman      | Ataxia UK                                                           |
| Caroline Morrice | Guillain-Barre and Associated Inflammatory Neuropathies (Treasurer) |
| Cath Stanley     | Huntington's Disease Association (Appointed November 2020)          |
| Amanda Swain     | UK Acquired Brain Injury Forum                                      |
| Angie Pullen     | Epilepsy Action                                                     |

During the year the Board, again, co-opted three independent Trustees with the aim of achieving greater diversity on the board in terms of the professional backgrounds of members. The co-opted trustees are:

|                    |                                                    |
|--------------------|----------------------------------------------------|
| David Garmon-Jones | appointed February 2018, reappointed February 2021 |
| Ralph Gregory      | appointed February 2018, reappointed February 2021 |
| Arani Nitkunan     | Appointed July 2020                                |

## 5.2 Professional advisors

|                       |                                                                                                                 |
|-----------------------|-----------------------------------------------------------------------------------------------------------------|
| Bankers               | CAF Bank Ltd, PO Box 289, West Malling, Kent, ME19 4TA<br>Metro Bank PLC, One Southampton Row, London, WC1B 5HA |
| Accountants           | Godfrey Wilson, 5th Floor, Mariner House, 62 Prince Street<br>Bristol, BS1 4QD                                  |
| Independent Examiners | Goodman Jones LLP, 29-30 Fitzroy Square, London W1T 6LQ                                                         |

## 6. Finances

### 6.1 Investment

Article 5.1.23 empowers the Alliance, with advice from a financial expert, to invest the funds of the Alliance as it sees fit, with consideration of the the suitability of investments and the need for diversification.

### 6.2 Subscriptions

Subscription rates are determined by the organisational income of each member and associate. Subscriptions for affiliate members are at a fixed rate.

### 6.3 Reserves policy

A reserves policy was agreed by Trustees during 2020/21. This new policy is a risk-based policy, to reflect the reality that any reduction in income or increasing in costs would take place over a period of time.

Having considered the risks, Trustees consider it prudent that reserves should be maintained in order to cover the loss of income from one third of the significant income sources. In 2020/21, this equates to approximately £59,000.

At the end of the year cash reserves of £125,222 were held. This is £66,585 above the level of reserves the trustees calculate are required. Total unrestricted funds totalled £88,486.

#### **6.4 Financial position**

Income from membership subscriptions decreased by 0.7% in the year to £96,652 (20/20: £96,945). In parallel, the corporate funding has increased from £96,732 to £109,180. We also received charitable donations totalling £2,000. Given the unprecedented impact of the COVID-19 pandemic on voluntary sector income, the Trustees decided to lift the 50% cap on income from corporate membership for three years (until 2023/24).

We received restricted donations from the University Hospital Birmingham Charity to support the NNAG work. Unrestricted funds have however been used to support this work also. We would like to thank the charity for their significant support this year.

We also received generous support from the Brain and Spine Foundation to develop the NeuroLifeNow application. This totalled £5,000.

Overall, there is a surplus of £41,646 (before transfers) on the unrestricted funds (2019/2020 surplus of £9,434) and a deficit of £11,238 (before transfers) on restricted funds (2019/2020: deficit of £7,948). This leaves an overall surplus of £30,408 (2019/2020: surplus of £1486) for the year.

#### **6.5 Trustees' responsibilities statement**

The Trustees (who are also directors of The Neurological Alliance for the purposes of company law) are responsible for preparing the Trustees' Annual Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period. In preparing these financial statements, the Trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities SORP 2015 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The Trustees are responsible for keeping adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable

company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as the Trustees are aware:

- there is no relevant information of which the charitable company's independent examiner is unaware; and
- the Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant information and to establish that the independent examiner is aware of that information.

### **6.6 Independent Examiners**

At the AGM in November 2020, members agreed to delegate responsibility for selecting The Neurological Alliance's Independent Examiners for the forthcoming year and 2020-2021 accounts to the Board of Trustees.

The Board decided to appoint Goodman Jones LLP to be our independent examiner for 2020/21.

### **6.7 Small company provisions**

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies exemption.

On behalf of the Board of Trustees

*David Martin*

**David Martin**

**Chair, Board of Trustees Date:** 23-11-21

**INDEPENDENT EXAMINER'S REPORT**  
**TO THE TRUSTEES OF THE NEUROLOGICAL ALLIANCE (the 'Charity')**  
**YEAR ENDED 30 JUNE 2021**

I report to the charity Trustees on my examination of the accounts of the Neurological Alliance for the year ended 30 June 2021.

**Responsibilities and basis of report**

As the Trustees of the Charity (and its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Charity are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of the Charity's accounts carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

**Independent examiner's statement**

I have completed my examination. I can confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a 'true and fair view' which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities [applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)].

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

This report is made solely to the Charity's Trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. My work has been undertaken so that I might state to the Charity's Trustees those matters I am required to state to them in an Independent Examiner's Report and for no other purpose. To the fullest extent permitted by law, I do not accept or assume responsibility to anyone other than the Charity and the Charity's Trustees as a body, for my work or for this report.

**Martin Bailey, FCA**  
**Goodman Jones LLP**  
Chartered Accountants  
29-30 Fitzroy Square  
London W1T 6LQ

*Martin Bailey*

Dated: 23-11-21

# THE NEUROLOGICAL ALLIANCE

## STATEMENT OF FINANCIAL ACTIVITIES (INCORPORATING THE INCOME AND EXPENDITURE ACCOUNT)

YEAR ENDED 30 JUNE 2021

|                                         | Note | Unrestricted<br>Funds<br>£ | Restricted<br>Funds<br>£ | Total Funds<br>2021<br>£ | Total Funds<br>2020<br>£ |
|-----------------------------------------|------|----------------------------|--------------------------|--------------------------|--------------------------|
| <b>INCOME AND ENDOWMENTS FROM:</b>      |      |                            |                          |                          |                          |
| Donations and legacies                  | 3    | 500                        | -                        | 500                      | 2,000                    |
| Charitable activities                   | 4    | 210,832                    | 12,500                   | 223,332                  | 218,677                  |
| Investments                             | 5    | 7                          | -                        | 7                        | 536                      |
| <b>TOTAL</b>                            |      | <b>211,339</b>             | <b>12,500</b>            | <b>223,839</b>           | <b>221,213</b>           |
| <b>EXPENDITURE ON:</b>                  |      |                            |                          |                          |                          |
| Raising funds                           |      | 5,857                      | -                        | 5,857                    | 8,962                    |
| Charitable activities                   |      | 163,836                    | 23,738                   | 187,574                  | 210,765                  |
| <b>TOTAL</b>                            | 6    | <b>169,693</b>             | <b>23,738</b>            | <b>193,431</b>           | <b>219,727</b>           |
| <b>NET EXPENDITURE BEFORE TRANSFERS</b> |      |                            |                          |                          |                          |
| Transfers between Funds                 | 14   | 41,646<br>(16,763)         | (11,238)<br>16,763       | 30,408<br>-              | 1,486<br>-               |
| <b>NET MOVEMENT IN FUNDS</b>            |      | <b>24,883</b>              | <b>5,525</b>             | <b>30,408</b>            | <b>1,486</b>             |
| <b>RECONCILIATION OF FUNDS:</b>         |      |                            |                          |                          |                          |
| Total funds brought forward             |      | 88,186                     | 3,640                    | 91,826                   | 90,340                   |
| Net movement in funds                   |      | 24,883                     | 5,525                    | 30,408                   | 1,486                    |
| <b>TOTAL FUNDS CARRIED FORWARD</b>      |      | <b>113,069</b>             | <b>9,165</b>             | <b>122,234</b>           | <b>91,826</b>            |

The Statement of Financial Activities includes all gains and losses recognised in the year.

All income and expenditure derives from continuing activities.

The notes below part of these financial statements.

# THE NEUROLOGICAL ALLIANCE

## BALANCE SHEET

30 JUNE 2021

|                                                       | Note | 2021<br>£       | 2020<br>£      |
|-------------------------------------------------------|------|-----------------|----------------|
| <b>FIXED ASSETS</b>                                   |      |                 |                |
| Tangible assets                                       | 11   | 999             | 1,694          |
| <b>CURRENT ASSETS</b>                                 |      |                 |                |
| Debtors                                               | 12   | 56,265          | 36,394         |
| Cash at bank and in hand                              |      | 80,405          | 60,824         |
|                                                       |      | <b>136,670</b>  | <b>97,218</b>  |
| <b>CREDITORS: Amounts falling due within one year</b> | 13   | <b>(15,435)</b> | <b>(7,086)</b> |
| <b>NET CURRENT ASSETS</b>                             |      | <b>121,235</b>  | <b>90,132</b>  |
| <b>NET ASSETS</b>                                     |      | <b>122,234</b>  | <b>91,826</b>  |
| <b>CHARITY FUNDS</b>                                  |      |                 |                |
| Restricted income funds                               | 14   | 9,165           | 3,640          |
| Unrestricted income funds                             | 14   | 113,069         | 88,186         |
| <b>TOTAL FUNDS</b>                                    |      | <b>122,234</b>  | <b>91,826</b>  |

The Charity was entitled to exemption from audit under section 477 of the Companies Act 2006. The members have not required the company to obtain an audit for the year in question in accordance with section 476 of Companies Act 2006.

The Trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to entities subject to the small companies regime.

The financial statements were approved and authorised for issue by the Trustees on and signed on their behalf, by:

*David Martin*

**David Martin**  
**Chair, Board of Trustees**

**Date:** 23-11-21

Company Registration Number: 02939840

**The notes below part of these financial statements.**

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2021**

**1. GENERAL INFORMATION**

The Neurological Alliance is a registered charity and company limited by guarantee. Its charitable objects are set out in the Trustees' Report. Its registered office address is The Junction, Station Road, Watford, WD17 1EU

**2. ACCOUNTING POLICIES**

**2.1 Basis of preparation of financial statements**

The financial statements have been prepared in accordance with the Charities SORP (FRS 102) - Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

The financial statements are prepared on the going concern basis under the historical cost convention, modified to include certain items at fair value. The financial statements are presented in sterling which is the functional currency of the charitable company and rounded to the nearest £.

The Neurological Alliance meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

**2.2 Company status**

The Charity is a company limited by guarantee. The members of the company are the Trustees named on page 1. In the event of the Charity being wound up, the liability in respect of the guarantee is limited to £10 per member of the Charity.

**2.3 Going concern**

The Trustees have assessed whether the use of the going concern assumption is appropriate in preparing these accounts and are of the opinion that the Charity will have sufficient resources to meet its liabilities as they fall due. The Trustees have made this assessment in respect of a period of one year from the date of approval of these accounts. The Trustees of the Charity have concluded that there are no material uncertainties related to events or conditions that may cast significant doubt on the ability of the Charity to continue as a going concern.

**2.4 Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the Charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2021**

**2. ACCOUNTING POLICIES** *(continued)*

**2.5 Income**

All income is recognised once the Charity has entitlement to the income, it is probable that the income will be received, and the amount of income receivable can be measured reliably.

The following specific policies are applied to particular categories of income:

Subscription income is invoiced in line with the financial year and recognised in the period to which it relates.

Corporate support represents amounts invoiced in the year.

Donated services or facilities are recognised when the Charity has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use of the Charity of the item is probable and that economic benefit can be measured reliably.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the Charity which is the amount the Charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

**2.6 Interest receivable**

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the Charity; this is normally upon notification of the interest paid or payable by the Bank.

**2.7 Expenditure**

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is classified by activity. The costs of each activity are made up of the total of direct costs and shared costs, including support costs involved in undertaking each activity. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs which contribute to more than one activity and support costs which are not attributable to a single activity are apportioned between those activities on a basis consistent with the use of resources. Central staff costs are allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset's use.

Support costs are those costs incurred directly in support of expenditure on the objects of the Charity. Governance costs are those incurred in connection with administration of the Charity and compliance with constitutional and statutory requirements.

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2021**

Costs of generating funds are costs incurred in attracting voluntary income, and those incurred in trading activities that raise funds. All expenditure is inclusive of irrecoverable VAT.

## **2.8 Operating leases**

Rentals under operating leases are charged to the Statement of Financial Activities incorporating Income and Expenditure Account on a straight-line basis over the lease term.

## **2.9 Tangible fixed assets and depreciation**

A review for impairment of a fixed asset is carried out if events or changes in circumstances indicate that the carrying value of any fixed asset may not be recoverable. Shortfalls between the carrying value of fixed assets and their recoverable amounts are recognised as impairments. Impairment losses are recognised in the Statement of Financial Activities incorporating Income and Expenditure Account.

Tangible fixed assets are carried at cost, net of depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Office equipment        -        3 years straight line

## **2.10 Debtors**

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

## **2.11 Cash at Bank and in hand**

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

## **2.12 Liabilities and provisions**

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the Charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

## **2.13 Financial instruments**

The Charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2021**

**2. ACCOUNTING POLICIES** *(continued)*

**2.14 Pensions**

The Charity operates a defined contribution pension scheme and the pension charge represents the amounts payable by the Charity to the fund in respect of the year.

**2.15 Critical accounting estimates and areas of judgement**

In the application of the Charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

In the opinion of the Trustees, there are no significant areas of estimation, uncertainty and critical judgements in applying accounting policies that have significant effect on the amounts recognised in the financial statements.

**3. INCOME FROM DONATIONS AND LEGACIES**

|                   | <b>Unrestricted<br/>Funds<br/>£</b> | <b>Restricted<br/>Funds<br/>£</b> | <b>Total Funds<br/>2021<br/>£</b> | <b>Total Funds<br/>2020<br/>£</b> |
|-------------------|-------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Donations         | <b>500</b>                          | -                                 | <b>500</b>                        | 2,000                             |
|                   | <b>500</b>                          | -                                 | <b>500</b>                        | 2,000                             |
| <i>Total 2020</i> | <i>2,000</i>                        | -                                 | <i>2,000</i>                      |                                   |

**4. INCOME FROM CHARITABLE ACTIVITIES**

|                   | <b>Unrestricted<br/>Funds<br/>£</b> | <b>Restricted<br/>Funds<br/>£</b> | <b>Total Funds<br/>2021<br/>£</b> | <b>Total Funds<br/>2020<br/>£</b> |
|-------------------|-------------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|
| Corporate Support | <b>109,180</b>                      | -                                 | <b>109,180</b>                    | 96,732                            |
| Subscriptions     | <b>96,652</b>                       | -                                 | <b>96,652</b>                     | 96,945                            |
| Projects          | <b>5,000</b>                        | <b>12,500</b>                     | <b>17,500</b>                     | 25,000                            |
|                   | <b>210,832</b>                      | <b>12,500</b>                     | <b>223,332</b>                    | 218,677                           |
| <i>Total 2020</i> | <i>193,677</i>                      | <i>25,000</i>                     | <i>218,677</i>                    |                                   |

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2021**

**5. INVESTMENT INCOME**

|                 | Unrestricted<br>Funds<br>£ | Restricted<br>Funds<br>£ | Total Funds<br>2021<br>£ | Total Funds<br>2020<br>£ |
|-----------------|----------------------------|--------------------------|--------------------------|--------------------------|
| Interest income | 7                          | -                        | 7                        | 536                      |

**6. ANALYSIS OF EXPENDITURE BY EXPENDITURE TYPE**

|                                            | Staff Costs<br>£ | Depreciation<br>£ | Other<br>costs<br>£ | Total Funds<br>2021<br>£ | Total Funds<br>2020<br>£ |
|--------------------------------------------|------------------|-------------------|---------------------|--------------------------|--------------------------|
| Expenditure on raising<br>voluntary income | 4,048            | 69                | 1,740               | 5,857                    | 8,962                    |
| <b>Costs of raising<br/>funds</b>          | <b>4,048</b>     | <b>69</b>         | <b>1,740</b>        | <b>5,857</b>             | <b>8,962</b>             |
| Policy Development                         | 48,579           | 278               | 43,064              | 91,921                   | 89,871                   |
| Members' Activities                        | 36,435           | -                 | 4,500               | 40,935                   | 36,738                   |
| Support costs                              | 33,736           | 208               | 5,415               | 39,359                   | 53,469                   |
| <b>Charitable activities</b>               | <b>118,750</b>   | <b>486</b>        | <b>52,979</b>       | <b>172,215</b>           | <b>180,078</b>           |
| <b>Expenditure on<br/>governance</b>       | <b>12,146</b>    | <b>140</b>        | <b>3,073</b>        | <b>15,359</b>            | <b>30,687</b>            |
|                                            | <b>134,944</b>   | <b>695</b>        | <b>57,792</b>       | <b>193,431</b>           | <b>219,727</b>           |
| <i>Total 2020</i>                          | <i>137,610</i>   | <i>800</i>        | <i>81,317</i>       | <i>219,727</i>           |                          |

Expenditure on charitable activities attributable to unrestricted funds was £166,693 (2020: £184,304) and £23,738 (2020: £32,948) was attributable to restricted funds. All expenditure on raising funds was attributable to unrestricted funds in both the current and prior years.

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2021**

**7. DIRECT COSTS**

|                           | Policy Development<br>£ | Members Activities<br>£ | Total 2021<br>£ | Total 2020<br>£ |
|---------------------------|-------------------------|-------------------------|-----------------|-----------------|
| Project costs             | 37,538                  | 1,956                   | 39,494          | 37,621          |
| Meeting costs             | (200)                   | (200)                   | (400)           | 3,670           |
| Office and property costs | 1,271                   | -                       | 1,271           | -               |
| Legal & professional      | 4,455                   | 2,744                   | 7,199           | -               |
| Wages and salaries        | 42,854                  | 32,140                  | 74,994          | 75,325          |
| National insurance        | 3,025                   | 2,269                   | 5,294           | 5,486           |
| Pension cost              | 2,701                   | 2,025                   | 4,726           | 4,507           |
| Depreciation              | 278                     | -                       | 278             | -               |
| <b>Total 2021</b>         | <b>91,922</b>           | <b>40,934</b>           | <b>132,856</b>  | 126,609         |
| <i>Total 2020</i>         | <i>89,871</i>           | <i>36,738</i>           | <i>126,609</i>  |                 |

**8. SUPPORT COSTS**

|                               | Fundraising costs<br>£ | Governance<br>£ | Policy and Members Activities<br>£ | Total 2021<br>£ | Total 2020<br>£ |
|-------------------------------|------------------------|-----------------|------------------------------------|-----------------|-----------------|
| Project costs                 | 278                    | 555             | 1,112                              | 1,945           | 574             |
| Subscriptions                 | 422                    | 422             | 562                                | 1,406           | 274             |
| Post, printing and stationery | 25                     | 49              | 74                                 | 148             | 206             |
| Property costs                | 39                     | 78              | 117                                | 234             | 8,396           |
| Bank charges                  | 8                      | 16              | 23                                 | 47              | 61              |
| Insurance                     | 139                    | 278             | 416                                | 833             | 1,260           |
| Recruitment and training      | 30                     | 29              | 317                                | 376             | 7,361           |
| ICO registration              | -                      | -               | -                                  | -               | 40              |
| Trustee meetings and AGM      | -                      | 47              | -                                  | 47              | 5,502           |
| Accountancy and payroll       | 370                    | 739             | 1478                               | 2,587           | 5,480           |
| Legal Fees                    | 25                     | 50              | 100                                | 175             | 4,210           |
| Marketing                     | 405                    | 810             | 1,216                              | 2,431           | 4,187           |
| Fundraising expenses          | -                      | -               | -                                  | -               | 2,475           |
| Wages and salaries            | 4,048                  | 12,146          | 33,735                             | 49,929          | 52,291          |
| Depreciation                  | 68                     | 140             | 209                                | 417             | 800             |
| <b>Total 2021</b>             | <b>5,857</b>           | <b>15,359</b>   | <b>39,359</b>                      | <b>60,575</b>   | 93,117          |
| <i>Total 2020</i>             | <i>8,962</i>           | <i>30,687</i>   | <i>53,469</i>                      | <i>93,117</i>   |                 |

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2021**

**9. GOVERNANCE COSTS**

|                            | Unrestricted Funds | Restricted Funds | Total Funds 2021 | Total Funds 2020 |
|----------------------------|--------------------|------------------|------------------|------------------|
|                            | £                  | £                | £                | £                |
| Support costs - Governance | 3,073              | -                | 3,073            | 14,014           |
| Wages and salaries         | 12,146             | -                | 12,146           | 16,513           |
| Depreciation               | 140                | -                | 140              | 160              |
|                            | <u>15,359</u>      | <u>-</u>         | <u>15,359</u>    | <u>30,687</u>    |

**10. NET INCOME/(EXPENDITURE)**

This is stated after charging:

|                                        | 2021<br>£    | 2020<br>£    |
|----------------------------------------|--------------|--------------|
| Depreciation of tangible fixed assets: |              |              |
| - owned by the charity                 | 695          | 800          |
| Independent examination fee            | <u>1,800</u> | <u>1,800</u> |

During the year, no Trustees received any remuneration (2020 - £NIL).

During the year, no Trustees received any benefits in kind (2020 - £NIL).

During the year, no Trustees received any reimbursement of expenses (2020 - £NIL).

**11. STAFF COSTS**

**Staff costs were as follows:**

|                       | 2021<br>£      | 2020<br>£      |
|-----------------------|----------------|----------------|
| Wages and salaries    | 119,039        | 121,492        |
| Social security costs | 8,403          | 8,849          |
| Other pension costs   | 7,502          | 7,269          |
|                       | <u>134,944</u> | <u>137,610</u> |

The average number of persons employed by the Charity during the year was as follows:

|           | 2021<br>No. | 2020<br>No. |
|-----------|-------------|-------------|
| Employees | 4           | 4           |

No employee received remuneration amounting to more than £60,000 in either year. Key management personnel remuneration, including employer's NIC and pension, incurred by the charity in the 2020/21 year amounted to £66,042. This compared to £54,746 during 2019/20.

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2021**

**12. TANGIBLE FIXED ASSETS**

|                        | Office<br>Equipment<br>£ |
|------------------------|--------------------------|
| <b>COST</b>            |                          |
| At 1 July 2020         | 3,821                    |
| Additions in the year  | -                        |
| <b>At 30 June 2021</b> | <u>3,821</u>             |
| <b>DEPRECIATION</b>    |                          |
| At 1 July 2020         | 2,127                    |
| Charge for the year    | 695                      |
| <b>At 30 June 2021</b> | <u>2,822</u>             |
| <b>NET BOOK VALUE</b>  |                          |
| <b>At 30 June 2021</b> | <u><u>999</u></u>        |
| At 30 June 2020        | <u><u>1,694</u></u>      |

**13. DEBTORS**

|                                | 2021<br>£     | 2020<br>£     |
|--------------------------------|---------------|---------------|
| Trade debtors                  | 11,660        | 13,748        |
| Prepayments and accrued income | 44,605        | 22,646        |
|                                | <u>36,394</u> | <u>36,394</u> |

**14. CREDITORS: Amounts falling due within one year**

|                                    | 2021<br>£     | 2020<br>£    |
|------------------------------------|---------------|--------------|
| Trade creditors                    | 4,685         | 60           |
| Other creditors                    | 2,245         | 2,776        |
| Other taxation and social security | 5,265         | -            |
| Accruals and deferred income       | 3,240         | 4,250        |
|                                    | <u>15,435</u> | <u>7,086</u> |

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2021**

**15. STATEMENT OF FUNDS**

**STATEMENT OF FUNDS – CURRENT YEAR**

|                           | Balance at<br>1 July 2021<br>£ | Income<br>£ | Expenditure<br>£ | Transfers<br>in/out<br>£ | Balance at<br>30 June<br>2021<br>£ |
|---------------------------|--------------------------------|-------------|------------------|--------------------------|------------------------------------|
| <b>Unrestricted funds</b> |                                |             |                  |                          |                                    |
| General Funds             | 88,186                         | 211,339     | (169,693)        | (16,763)                 | 113,069                            |
| <b>Restricted funds</b>   |                                |             |                  |                          |                                    |
| NNAG Events               | 2,356                          | -           | -                | -                        | 2,356                              |
| NNAG Pathways             | 4,284                          | 5,000       | (2,475)          | -                        | 6,809                              |
| NNAG                      | (3,000)                        | 7,500       | (21,263)         | 16,763                   | -                                  |
|                           | 3,640                          | 17,500      | (23,738)         | 16,763                   | 9,165                              |
| Total of funds            | 91,826                         | 223,839     | (193,431)        | -                        | 123,234                            |

NNAG events - events and activities to support the development of an epilepsy pathway

NNAG support - programme management support for The National Neuro Advisory Group, includes organising meetings, workstreams and events.

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2021**

**15. STATEMENT OF FUNDS (continued)**

**STATEMENT OF FUNDS – PRIOR YEAR**

|                                  | <i>Balance at<br/>1 July 2019<br/>£</i> | <i>Income<br/>£</i> | <i>Expenditure<br/>£</i> | <i>Transfers<br/>in/out<br/>£</i> | <i>Balance at<br/>30 June<br/>2020<br/>£</i> |
|----------------------------------|-----------------------------------------|---------------------|--------------------------|-----------------------------------|----------------------------------------------|
| <b><i>Unrestricted funds</i></b> |                                         |                     |                          |                                   |                                              |
| <i>General Funds</i>             | 87,584                                  | 196,213             | (186,779)                | (8,832)                           | 88,186                                       |
| <b><i>Restricted funds</i></b>   |                                         |                     |                          |                                   |                                              |
| NNAG Events                      | 2,756                                   | 2,500               | (2,900)                  | -                                 | 2,356                                        |
| NNAG Pathways                    | -                                       | 15,000              | (10,716)                 | -                                 | 4,284                                        |
| NNAG                             | -                                       | 7,500               | (19,332)                 | 8,832                             | (3,000)                                      |
|                                  | 2,756                                   | 25,000              | (32,948)                 | -                                 | 3,640                                        |
| <i>Total of funds</i>            | 90,340                                  | 221,213             | (219,727)                | -                                 | 91,826                                       |

**16. ANALYSIS OF NET ASSETS BETWEEN FUNDS**

**ANALYSIS OF NET ASSETS BETWEEN FUNDS – current year**

|                               | <b>Unrestricted<br/>funds<br/>£</b> | <b>Restricted<br/>funds<br/>£</b> | <b>Total<br/>funds<br/>2021<br/>£</b> |
|-------------------------------|-------------------------------------|-----------------------------------|---------------------------------------|
| Tangible fixed assets         | 999                                 | -                                 | 999                                   |
| Current assets                | 127,506                             | 9,165                             | 136,670                               |
| Creditors due within one year | (15,435)                            | -                                 | (15,435)                              |
|                               | 113,069                             | 9,165                             | 122,234                               |

**ANALYSIS OF NET ASSETS BETWEEN FUNDS – prior year**

|                                      | <i>Unrestricted<br/>funds<br/>£</i> | <i>Restricted<br/>funds<br/>£</i> | <i>Total<br/>funds<br/>2020<br/>£</i> |
|--------------------------------------|-------------------------------------|-----------------------------------|---------------------------------------|
| <i>Tangible fixed assets</i>         | 1,694                               | -                                 | 1,694                                 |
| <i>Current assets</i>                | 93,578                              | 3,640                             | 97,218                                |
| <i>Creditors due within one year</i> | (7,086)                             | -                                 | (7,086)                               |
|                                      | 88,186                              | 3,640                             | 91,826                                |

**THE NEUROLOGICAL ALLIANCE**  
**NOTES TO THE FINANCIAL STATEMENTS**  
**YEAR ENDED 30 JUNE 2021**

**17. PENSION COMMITMENTS**

The Charity operates a defined contributions pension scheme. The assets of the scheme are held separately from those of the Charity in an independently administered fund. The pension cost charge represents contributions payable by the Charity to the fund and amounted to £7,502 (2020 - £7,269).

Contributions totalling £2,245 (2020 - £1,158) were payable to the fund at the balance sheet date and are included in creditors.

**18. OPERATING LEASE COMMITMENTS**

At 30 June 2021 the total of the Charity's future minimum lease payments under non-cancellable operating leases was:

|                       | <b>2021</b>  | 2020        |
|-----------------------|--------------|-------------|
|                       | <b>£</b>     | £           |
| Amounts payable:      |              |             |
| Within 1 year         | <b>9,000</b> | 9,000       |
| Between 1 and 5 years | -            | -           |
|                       | <hr/>        | <hr/>       |
| Total                 | <b>9,000</b> | 9,000       |
|                       | <hr/> <hr/>  | <hr/> <hr/> |

**19. RELATED PARTY TRANSACTIONS**

Other than disclosed elsewhere in these financial statements, there were no related party transactions requiring disclosure during the current or previous year.